Transgenic microorganisms and synthesis of piperazic acid, piperazic acid containing products, and derivatives thereof

ABSTRACT

Among the various aspects of the present disclosure is the provision of a biological and biochemical production of piperazic acid derived from the newly discovered production pathway for L-piperazic acid. One aspect of the present disclosure includes a transgenic microorganism (e.g., bacteria) engineered to accumulate piperazic acid and derivatives thereof, including a piperazic acid (Piz)-containing product. Another aspect of the present disclosure includes biochemical and biological methods for producing piperazic acid and derivatives thereof, including a piperazic acid (Piz)-containing product. Another aspect of the present disclosure includes compositions and methods of using isotopically labeled piperazic acid and derivatives thereof, including a piperazic acid (Piz)-containing product.

CROSS-REFERENCE TO RELATED APPLICATIONS

This application claims priority from U.S. Provisional Application Ser. No. 62/527,586 filed on 30 Jun. 2017, which is incorporated herein by reference in its entirety.

STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH OR DEVELOPMENT

Not Applicable.

MATERIAL INCORPORATED-BY-REFERENCE

The Sequence Listing, which is a part of the present disclosure, includes a computer readable form comprising nucleotide and/or amino acid sequences of the present invention. The subject matter of the Sequence Listing is incorporated herein by reference in its entirety.

FIELD OF THE INVENTION

The present disclosure generally relates to the synthesis of piperazic acid.

BACKGROUND OF THE INVENTION

Piperazic acid (Piz) is a nonproteinogenic amino acid that contains a characteristic and biochemically unusual N—N bond. Piz is a proline structural mimic, and Piz-containing compounds are of significant interest for drug discovery. Piz itself is not bioactive, but peptidic compounds incorporating Piz as a building block include antibacterial, antiviral, immunomodulatory, and anticancer drug leads. Intriguingly, all naturally-occurring Piz containing compounds discovered thus far have been bioactive.

SUMMARY OF THE INVENTION

Among the various aspects of the present disclosure is the provision of a biological and biochemical production of enantiopure piperazic acid derived from the newly discovered production pathway for L-piperazic acid. For example, the present disclosure provides for a transgenic microorganism for the synthesis of L-piperazic acid and derivatives thereof and additional biosynthetic processes for the production of L-piperazic acid and derivatives thereof.

Briefly, therefore, the present disclosure is directed to methods of producing piperazic acid, especially L-piperazic acid and derivatives thereof. Synthesis of enantiopure L-Piz has been elusive and expensive. The methods and transgenic organisms as described herein have overcome many of the challenges currently faced regarding the synthesis of enantiopure L-Piz. L-Piz and derivatives thereof can be used as a starting material for a large range of bioactive molecules, including many currently known therapeutics and can be isotopically labeled for use in drug discovery analyses and imaging modalities. The new synthetic routes can give access to isotope (e.g., ¹⁵N, ¹³C, ²H) or radioisotopically-labeled piperazic acid for which no synthetic pathways are currently reported.

One aspect of the present disclosure includes transgenic microorganisms (e.g., bacteria) engineered to accumulate piperazic acid and derivatives thereof, including a piperazic acid (Piz)-containing product.

Another aspect of the present disclosure includes biochemical and biological methods for producing piperazic acid and derivatives thereof, including a piperazic acid (Piz)-containing product.

Another aspect of the present disclosure includes compositions and methods of using isotopically labeled piperazic acid and derivatives thereof, including a piperazic acid (Piz)-containing product.

Another aspect of the present disclosure provides for a method for preparing a piperazic acid (Piz)-containing product. In some embodiments, the method comprises: (i) providing N⁵—OH-Ornithine or derivative thereof; (ii) providing a suitable enzyme comprising a N⁵—OH Ornithine cyclase/dehydratase; or (iii) optionally, buffer salts, a NADPH cofactor, Fe⁺² salts, and a catalytic Flavin Adenine Dinucleotide (FAD) cofactor.

In some embodiments, the method further comprises: (i) providing an ornithine or a derivative thereof; or (ii) providing a suitable enzyme comprising an ornithine N⁵ hydroxylase.

In some embodiments, the (i) the N⁵—OH-Ornithine or derivative thereof is an enantiopure L-Ornithine or derivative thereof; (ii) the enzyme comprising N⁵—OH Ornithine cyclase/dehydratase is a L-N⁵—OH Ornithine cyclase/dehydratase or a PzbB enzyme; or (iii) the enzyme comprising ornithine N⁵ hydroxylase is an L-ornithine N⁵—OHase or a PzbA enzyme.

In some embodiments, the method is carried out in the absence of O₂, substantially no O₂, or in the presence of low O₂.

In some embodiments, the method comprises a coupled enzyme assay.

In some embodiments, the piperazic acid (Piz)-containing product comprises a compound of formula:

where R⁵ is a hydrogen, an alkyl, a piperazic acid, an acetyl, or a carboxyl protecting group; each R¹ and R² are independently selected from hydrogen or an amino protecting group, wherein R¹ and R² may be taken together to form a fused bicyclic or tricyclic amino protecting group; or each R³ and R⁴ are independently selected from a hydrogen, a halo (e.g., a chloro, a fluoro, a bromo, a iodo), or a hydroxyl. In some embodiments, R¹ and R² are not simultaneously hydrogen.

In some embodiments, the piperazic acid (Piz)-containing product is used as a starting material in a synthetic method of making a bioactive Piz-containing composition selected from the group consisting of: (i) an antibacterial agent, an antibiotic agent, an antitumor agent, an antiviral agent, an immunomodulatory agent, or an anti-inflammatory agent; (ii) a molecular probe, anticancer drug, or drug lead; (ii) a metalloprotease inhibitor, a caspase inhibitor, an angiotensin converting enzyme (ACE) inhibitor, an inflammatory peptide C5a antagonist, an oxytocin receptor antagonist, or a matylastin type-IV collagenase inhibitor; (iii) a dehydropiperazic acid; a chloropiperazic acid; a hydroxypiperazic acid; a monamycin, an aurantimycin, an antrimycin, an azinothricin, a luzopeptin, a kettapeptin, a quinoxapeptin, a lydiamycin, a piperazimycin, or a sangamide; or (iv) sanglifehrin A, pandanamide A, azinothricin, Sch392583, luzopeptin A, kutzernide 2, piperazic acid, L-piperazic acid, antrimycin, kettapeptin, GE3, A83586C, chloptosin, himastatin, luzopeptin, quinoxapeptin, lydiamycin, piperazimycin, sanglifehrin, sangamide NVP018, sangamide NVP019, sanglifehrin, Sch 382583; chloptosin, himastatin, verucopeptin, luzopeptin A, L-156,602, aurantimycin A, or L-156,373.

Another aspect of the present disclosure provides for a transgenic microorganism comprising an artificial DNA construct. In some embodiments, the transgenic microorganism comprises, as operably associated components in the 5′ to 3′ direction of transcription: (I)(a) a promoter functional in the microorganism; (b)(i) a first polynucleotide comprising a nucleotide sequence encoding a first polypeptide having a L-Ornithine N⁵ hydroxylase activity; (ii) a second polynucleotide comprising a nucleotide sequence encoding a second polypeptide having a L-Ornithine N⁵ cyclase activity or L-Ornithine N⁵ dehydratase activity; or (iii) a third polynucleotide comprising a nucleotide sequence encoding a third polypeptide having a L-Ornithine N⁵ hydroxylase activity and a L-Ornithine N⁵ cyclase activity or L-Ornithine N⁵ dehydratase activity; or (c) a transcriptional termination sequence; or (II)(a) a promoter functional in the microorganism; (b)(i) a first polynucleotide comprising a nucleotide sequence encoding a first polypeptide having PzbA activity; (ii) a second polynucleotide comprising a nucleotide sequence encoding a second polypeptide having PzbB activity; or (iii) a third polynucleotide comprising a nucleotide sequence encoding a first polypeptide having PzbA activity and PzbB activity; or (c) a transcriptional termination sequence. In some embodiments, the transgenic microorganism accumulates increased levels of a piperazic acid (Piz)-containing product, optionally L-Piz, compared to a microorganism not comprising the DNA construct.

In some embodiments, the microorganism comprises (a)(i) a nucleotide sequence encoding a polypeptide selected from SEQ ID NO: 1-SEQ ID NO: 81 or SEQ ID NO: 167-SEQ ID NO: 176 or a sequence at least 25% identical thereto having L-Ornithine N⁵ hydroxylase activity; or (ii) a nucleotide sequence encoding a polypeptide selected from SEQ ID NO: 82-SEQ ID NO: 166 or SEQ ID NO: 167-SEQ ID NO: 176 or a sequence at least 25% identical thereto having L-Ornithine N⁵ cyclase activity and L-Ornithine N⁵ dehydratase activity; or (b) a nucleotide sequence encoding a polypeptide selected from SEQ ID NO: 167-SEQ ID NO: 176 or a sequence at least 25% identical thereto having L-Ornithine N⁵ hydroxylase activity, L-Ornithine N⁵ cyclase activity, and L-Ornithine N⁵ dehydratase activity.

In some embodiments, the microorganism comprises: (i) a PzbA ortholog with at least about 25% identity to SEQ ID NO: 1-SEQ ID NO: 81 or SEQ ID NO: 167-SEQ ID NO: 176 and has PzbA activity to produce a piperazic acid (Piz)-containing product; (ii) a PzbB ortholog with at least about 25% identity to SEQ ID NO: 82-SEQ ID NO: 166 or SEQ ID NO: 167-SEQ ID NO: 176 and has PzbB activity to produce a piperazic acid (Piz)-containing product; or (iii) a PzbAB ortholog with at least about 25% identity to or SEQ ID NO: 167-SEQ ID NO: 176 and has PzbA and PzbB activity to produce a piperazic acid (Piz)-containing product.

In some embodiments, the microorganism is an Actinobacteria selected from the group consisting of Streptomyces, Corynebacterium, Kutzneria, and Actinomadura; is a heterologous population of microorganisms; is an Actinobacteria (optionally, an actinomycete); or is selected from the group consisting of Streptomyces lividans or Corynebacterium glutamicum, optionally carrying one or more copies of a native or non-native pzbA and optionally carrying one or more copies of pzbB.

In some embodiments, the transgenic microorganism overproduces L-Ornithine; the pzbA or the pzbB are cloned from a sanglifehrin biosynthetic locus of Streptomyces flaveolus; or a piperazic acid (Piz)-containing product accumulates within the microorganism.

Another aspect of the present disclosure provides for a method for producing a piperazic acid (Piz)-containing product. In some embodiments, the method comprises: (i) providing a transgenic microorganism capable of accumulating a piperazic acid (Piz)-containing product; (ii) cultivating the microorganism; or (iii) isolating accumulated piperazic acid (Piz)-containing product.

In some embodiments, the method comprises providing a transgenic microorganism and providing a feedstock, wherein the transgenic microorganism comprises at least one copy of pzbA and at least one copy of pzbB under a constitutive promoter; or the at least one pzbA is optionally a native copy.

In some embodiments, the transgenic microorganism is (i) a heterologous population of microorganisms; (ii) an Actinobacteria (optionally, an actinomycete); or (ii) selected from the group consisting of Streptomyces lividans or Corynebacterium glutamicum, optionally carrying one or more copies of a native or non-native pzbA and optionally carrying one or more copies of pzbB.

In some embodiments, the pzbA or pzbB are cloned from a sanglifehrin biosynthetic locus of Streptomyces flaveolus; or a piperazic acid (Piz)-containing product accumulates within the microorganism.

In some embodiments, the method is carried out in the absence of O₂, substantially no O₂, or in the presence of low O₂.

In some embodiments, the piperazic acid (Piz)-containing product comprises a compound of formula:

where: R⁵ is a hydrogen, an alkyl, a piperazic acid, an acetyl, or a carboxyl protecting group; each R¹ and R² are independently selected from hydrogen or an amino protecting group, wherein R¹ and R² may be taken together to form a fused bicyclic or tricyclic amino protecting group; or each R³ and R⁴ are independently selected from a hydrogen, a halo (e.g., a chloro, a fluoro, a bromo, a iodo), or hydroxyl. In some embodiments, R¹ and R² are not simultaneously hydrogen.

In some embodiments, the piperazic acid (Piz)-containing product is used as a starting material in the synthesis of a bioactive Piz-containing composition selected from the group consisting of: (i) an antibacterial agent, an antibiotic agent, an antitumor agent, an antiviral agent, an immunomodulatory agent, or an anti-inflammatory agent; (ii) a molecular probe, anticancer drug, or drug lead; (iii) a metalloprotease inhibitor, a caspase inhibitor, an angiotensin converting enzyme (ACE) inhibitor, an inflammatory peptide C5a antagonist, an oxytocin receptor antagonist, or a matylastin type-IV collagenase inhibitor; (iv) a dehydropiperazic acid; a chloropiperazic acid; a hydroxypiperazic acid; a monamycin, an aurantimycin, an antrimycin, an azinothricin, a luzopeptin, a kettapeptin, a quinoxapeptin, a lydiamycin, a piperazimycin, or a sangamide; or (v) sanglifehrin A, pandanamide A, azinothricin, Sch392583, luzopeptin A, kutzernide 2, piperazic acid, L-piperazic acid, antrimycin, kettapeptin, GE3, A83586C, chloptosin, himastatin, luzopeptin, quinoxapeptin, lydiamycin, piperazimycin, sanglifehrin, sangamide NVP018, sangamide NVP019, sanglifehrin, Sch 382583; chloptosin, himastatin, verucopeptin, luzopeptin A, L-156,602, aurantimycin A, or L-156,373.

Another aspect of the present disclosure provides for a composition comprising a radiolabeled piperazic acid-containing product or a pharmaceutically acceptable salt, solvate, or polymorph thereof, including all tautomers and stereoisomers thereof, optionally in combination with one or more pharmaceutically acceptable excipients.

Another aspect of the present disclosure provides for a method comprising a process for preparation of a radiolabeled piperazic acid-containing product comprising: (i) providing a radiolabeled N⁵—OH-Ornithine or derivative thereof; (ii) providing a suitable N⁵—OH Ornithine cyclase/dehydratase; or (iii) optionally, buffer salts, a NADPH cofactor, Fe⁺² salts, and a catalytic Flavin Adenine Dinucleotide (FAD) cofactor.

In some embodiments, the method comprises: (i) providing a radiolabeled ornithine or a derivative thereof; or (ii) providing a suitable ornithine N⁵ hydroxylase.

In some embodiments, (i) the radiolabeled N⁵—OH-Ornithine or derivative thereof is an enantiopure radiolabeled L-Ornithine or derivative thereof; (ii) the enzyme comprising N⁵—OH Ornithine cyclase/dehydratase is L-N⁵—OH Ornithine cyclase/dehydratase or the enzyme PzbB, or (iii) the enzyme comprising ornithine N⁵ hydroxylase is a L-ornithine N⁵—OHase or the enzyme PzbA.

In some embodiments, the method comprises a coupled enzyme assay.

Another aspect of the present disclosure provides for a method of detecting radiolabeled piperazic acid-containing product. In some embodiments, the method comprises: (i) providing a microorganism; (ii) contacting the microorganism with a radiolabeled piperazic acid-containing product; or (iii) detecting a radiolabeled natural product, a radiolabeled biocatalysis product, or a radiolabeled metabolite.

Another aspect of the present disclosure provides for a the radiolabeled piperazic acid-containing product is: (i) labeled for use as a biologically active molecular probe as a drug discovery agent; or (ii) labeled for use in detecting a natural product drug lead compound.

Another aspect of the present disclosure provides for a piperazic acid (Piz)-containing product comprises: (i) a single radiolabel; (ii) a radiolabel selected from the group consisting of ²H (D or deuterium), ³H (T or tritium), ¹¹C, ¹³C, ¹⁴C, ¹³N, ¹⁵N, ¹⁵O, ¹⁷O, ¹⁸O, ¹⁸F, ³⁵S, ³⁶Cl, ⁸²Br, ⁷⁵Br, ⁷⁶Br, ⁷⁷Br, ¹²³I, ¹²⁴I, ¹²⁵I, and ¹³¹I; (iii) a radiolabel selected from the group consisting of ¹⁵N, ¹³C, and ²H; or (iv) a radiolabeled L-Piz or L-Piz derivative.

In some embodiments, the composition can be used in mass spectrometry, gamma imaging, magnetic resonance imaging, magnetic resonance spectroscopy, or fluorescence spectroscopy.

Other objects and features will be in part apparent and in part pointed out hereinafter.

DESCRIPTION OF THE DRAWINGS

Those of skill in the art will understand that the drawings, described below, are for illustrative purposes only. The drawings are not intended to limit the scope of the present teachings in any way.

FIG. 1 is a series of chemical structures showing examples of piperazic acid (Piz) family natural products. Piz and modified Piz (dehydropiperazic, chloropiperazic and hydroxypiperazic acid) molecular components are shown in red. All of these molecules are bioactive, with sanglifehrin (top left) under consideration as an immunosuppressant and Hepatitis-C antiviral. The small molecule in the center (Sch 382583) is a member of an emerging group of Piz containing metalloprotease inhibitors with clinical relevance as metastatic cancer and antibacterial antibiotic leads. All of these molecules are currently thought to be exclusively produced by actinobacteria. Piz and modified Piz (dehydropiperazic, chloropiperazic and hydroxypiperazic acid) molecular components are shown in red.

FIG. 2 shows orthologs of both PzbA (yellow) and PzbB (red) are found within biosynthetic gene clusters for known Piz-containing antibiotics. As these clusters encode molecules that are structurally dissimilar except for the incorporation of Piz, parsimony suggests both pzbA and pzbB (previously unrecognized) are involved in Piz biosynthesis.

FIG. 3 shows HPLC-ESI-MS detection of products and substrates with assay time points at time 0 min, 15 min, and 30 min showing the consumption of L-Orn, accumulation of the known intermediate N⁵—OH-Orn, and the concomitant formation of Piz. In vitro reconstitution of L-Piz production from L-Orn in a coupled enzymatic reaction containing purified PzbA, PzbB buffer salts, NADPH cofactor, Fe⁺² salts, and catalytic FAD (Flavin Adenine Dinucleotide) cofactor according to Scheme 2. Not shown: In the same assay lacking PzbB, the enzyme product is N⁵—OH-Orn and no Piz is formed.

FIG. 4 is a series of LC/MS spectra of biosynthetic Piz compared against an authentic L-Piz standard (top row) showing in vivo production of L-Piz in a heterologous bacterial host, Streptomyces lividans. S. lividans (WT parent, no Piz production) is compared against S. lividans harboring a single copy of pzbA (sfaB) alone, pzbB (sfaC) alone, or co-expressing pzbA and pzbB (sfaBC) cloned from the sanglifehrin biosynthetic locus of Streptomyces flaveolus. LC/MS detection of biosynthetic Piz was compared against an authentic L-Piz standard (top row). In contrast with the in vitro data above, pzbA is dispensable in the heterologous system because S. lividans encodes a native copy of the gene as part of a siderophore biosynthetic pathway unrelated to Piz production. Thus, pzbA remains required for Piz production, but its role in bacteria is not limited to Piz anabolism. In contrast, it is currently thought that pzbB is only found associated with Piz production.

FIG. 5 is a series of LC/MS spectra showing the detection of sanglifehrin, a Piz-containing compound produced by Streptomyces flaveolus. Four major isobaric isomers of sanglifehrin A detected in WT S. flaveolus fermentation extracts. As expected from the results above, an unmarked gene deletion of pzbB (sfaC) from S. flaveolus abrogates sanglifehrin production. Genetic complementation of this mutant with an additional copy of pzbB, or exogenously supplied 50 μM authentic L-Piz (top), restored the production of the four sanglifehrin A isobars. L-Piz is therefore cell penetrant and qualitatively nontoxic. These data additionally link pzbB function with Piz production in vivo, which agrees with the in vitro assay data.

FIG. 6 is a Marfey's derivatization analysis of the product of PzbB in an assay with L-N5 hydroxy Ornithine substrate (the product of PzbA) showing that the synthesized compound is enantiopure L-Piz.

FIG. 7 is a graph showing L-Piz production from various Streptomyces strains. Randomly selected environmental Streptomyces isolates were transformed with pYH015 via intergeneric conjugation as described for S. lividans.

DETAILED DESCRIPTION OF THE INVENTION

The present disclosure is based, at least in part, on the discovery of a complete biosynthetic pathway to L-Piz from the central metabolite L-Orn (the complete biosynthetic pathway not previously known). As shown herein, the present disclosure provides for biological and biochemical production of enantiopure L-piperazic acid. For example, the present disclosure provides for in vitro coupled enzyme assay furnished L-Piz or d₇-L-Piz. As another example, the present disclosure provides for in vivo L-Piz production using genetically engineered S. lividans (natively containing pzbA-gene, pzbB engineered), and data indicating incorporation of L-Piz in L-Piz containing sanglifehrin.

Advantages of the methods as described herein include a more cost-effective method of producing L-Piz; the methods as described herein avoid the multi-step synthetic processes currently known in the art; the enzyme catalysts are typically stereospecific providing enantiopure products.

One aspect of the present disclosure provides for green biocatalysis of L-Piz in vitro, where no organic solvents and fewer reagents are used (see e.g., Example 2). Another aspect of the present disclosure provides an enzymatic route to heavy isotope-labelled Piz (see e.g., Example 3). Another aspect of the present disclosure provides green biocatalysis of L-Piz in vivo (see e.g., Example 4). Another aspect of the present disclosure provides Directed discovery of drugs and drug-like compounds using heavy isotope L-Piz (see e.g., Example 5). The processes as described herein enable a more efficient and less expensive means to produce L-Piz or isotopically labeled L-Piz. Also provided herein are genes or enzymes encoding Piz production.

Piperazic Acid-Containing Products

As described herein, piperazic acid (Piz)-containing products can be produced using a biochemical or biological approach.

A piperazic acid (Piz)-containing product can be piperazic acid or a derivative thereof (e.g., L-piperazic acid (L-Piz)).

Piperazic acid (Piz) (aka hexahydropyridazine-3-carboxylic acid) is a nonproteinogenic amino acid that contains a characteristic and biochemically unusual N—N bond.

Piz is a proline structural mimic, and Piz-containing compounds are of significant interest for drug discovery. Piz itself is not bioactive, but peptidic compounds incorporating Piz as a building block include antibacterial, antiviral, immunomodulatory, and anticancer drug leads (see e.g., Oelke et al. 2011 Nat. Prod. Rep. (28) 1445-1471. Especially therapeutically interesting are Piz-containing metalloprotease inhibitors for drugging bacterial N-formylpeptidases, validated targets for antibiotic development. Intriguingly, all known naturally-occurring Piz containing compounds discovered thus far are bioactive. Beyond Piz natural products (i.e., naturally occurring compounds produced by live organisms), synthetic chemists are attracted to Piz as a synthetic building block for incorporation into drug-like compounds, molecular probes, and the like. As described herein, there are many bioactive piperazic acid-containing products.

For example, a piperazic acid-containing product can be any product comprising a piperazic acid, piperazic acid moiety, a piperazic add dipeptide fragment, or a derivative thereof.

In some embodiments, a piperazic acid-containing product can be Piz, L-Piz, a Piz derivative, a modified Piz, or a Piz-containing compound. For example, a Piz-containing compound or Piz derivative-containing compound can be:

As another example, a Piz derivative can be a dehydropiperazic acid, a chloropiperazic acid, or a hydroxypiperazic acid. As another example, a Piz derivative can be sanglifehrin or Sch 382583.

As another example, a Piz derivative can be:

A starting material comprising Piz or a Pi-z derivative (e.g., L-Piz) can be a useful reagent for expanding chemical space in small molecule library, molecular analog construction, and molecular probes.

Previous synthetic routes (see e.g., U.S. Pat. No. 6,632,942, incorporated herein by reference) have a lower yield (˜80%) than the processes as described herein (˜100%). Furthermore, the previous methods require multi-step synthetic procedures (6 steps).

As an example, a Piz-containing product can be a monamycin. Exemplary monomycins are shown below.

Compound R¹ R² R³ R⁴ Monamycin A H H Me H Monamycin B₁ H H Me H Monamycin B₂ H Me H H Monemycin B₃ Me H H H Monamycin C Me H Me H Monamycin D₁ Me H Me H Monamycin D₂ H Me Me H Monamycin E Me Me Me H Monamycin F Me Me Me H Monamycin G₁ H H Me Cl Monamycin G₂ H Me H Cl Monamycin G₃ Me H H Cl Monamycin H₁ Me H Me Cl Monamycin H₂ H Me Me Cl Monamycin I Me Me Me Cl

As another example, a Piz-containing product can be an antrimycin. Exemplary antrimycins are shown below.

Compound R¹ R² Antrimycin A Me Et Antrimycin B Et Et Antrimycin C n-Pr Et Antrimycin D i-Bu Et Antrimycin Av Me Me Antrimycin Bv Et Me Antrimycin Cv n-Pr Me Antrimycin Dv i-Bu Me

As another example, a Piz-containing product can be an azinothricin. Exemplary azinothricins are shown below.

Compound R¹ R² R³ R⁴ Azinothricin OMe Me H Me Kettapeptin OMe H H Me A38586C H H H Me GE3 H H i-Pr H

As another example, a Piz-containing product can be chloptosin or himastatin.

As another example, a Piz-containing product can be a luzopeptin or a quinoxapeptin. Exemplary luzopeptins and quinoxapeptins are shown below.

Compound R¹ R² Luzopeptin A Ac Ac Luzopeptin B H Ac Luzopeptin C H H

Compound R¹ R² Quinoxapeptin A

Quinoxapeptin B Ac

Quinoxapeptin C H H

As another example, a Piz-containing product can be a lydiamycin. Exemplary lydiamycins are shown below.

Compound R¹ R² X—Y Lydiamycin A H H CH₂—NH Lydiamycin B OH H CH₂—NH Lydiamycin C H H CH═N Lydiamycin D OH OH CH₂—NH

As another example, a Piz-containing product can be a piperazimycin. Exemplary piperazimycins are shown below.

Compound R¹ R² Piperazimycin A OH Me Piperazimycin B H Me Piperazimycin C OH Et

As another example, a Piz-containing product can be a sanglifehrin. Exemplary sanglifehrins are shown below.

Piperazic acid-containing products can be antibacterial, antiviral, immunomodulatory, or anticancer drug leads. Piperazic acid-containing products can be caspase (apoptosis, cytokine activation) inhibitors, angiotensin converting enzyme (ACE) inhibitors, anti-inflammatory agents (e.g., sanglifehrin), antitumor antibiotics (e.g., azinothricin, verucopeptin, himastatin, luzopeptin A, immunosuppressants (e.g., L-156,602 an inflammatory peptide C5a antagonist), antibiotics (e.g., Aurantimycin A (inhibits Gram-positive bacteria growth), monamycins), oxytocin receptor antagonist (e.g., L-156,373) (modulate behaviors), or Matylastin type-IV collagenase inhibitors. Piperazic acid-containing products can be antivirals (e.g., sangamides NVP018, NVP019 against chronic Hepatitis B).

In some embodiments the Piz-containing product can have the formula:

wherein: R⁵ is a hydrogen, alkyl, a piperazic acid, acetyl, or carboxyl protecting group; and each R¹ and R² are independently selected from hydrogen or an amino protecting group, wherein R¹ and R² may be taken together to form a fused bicyclic or tricyclic amino protecting group; and each R³ and R⁴ are independently selected from hydrogen, halo (e.g., chloro, fluoro, etc.), or hydroxyl.

R groups (e.g., R¹, R², R³, R⁴, R⁵) or formula (I) can be optionally substituted with one or more groups independently selected from the group consisting of hydroxyl; hydroxyl; amine; C₁₋₁₀carboxylic acid; C₁₋₁₀carboxyl, straight chain or branched C₁₋₁₀alkyl, optionally containing unsaturation; a C₂₋₆ cycloalkyl optionally containing unsaturation or one oxygen or nitrogen atom; straight chain or branched C₁₋₁₀alkyl amine; heterocyclyl; heterocyclic amine; and aryl comprising a phenyl; heteroaryl containing from 1 to 4 N, O, or S atoms; unsubstituted phenyl ring; substituted phenyl ring; unsubstituted heterocyclyl; and substituted heterocyclyl, wherein the unsubstituted phenyl ring or substituted phenyl ring can be optionally substituted with one or more groups independently selected from the group consisting of hydroxyl; hydroxyl; amine; C₁₋₁₀carboxylic acid; C₁₋₁₀carboxyl, straight chain or branched C₁₋₁₀alkyl, optionally containing unsaturation; straight chain or branched C₁₋₁₀alkyl amine, optionally containing unsaturation; a C₂₋₆ cycloalkyl optionally containing unsaturation or one oxygen or nitrogen atom; straight chain or branched C₁₋₁₀alkyl amine; heterocyclyl; heterocyclic amine; aryl comprising a phenyl; and heteroaryl containing from 1 to 4 N, O, or S atoms; and the unsubstituted heterocyclyl or substituted heterocyclyl can be optionally substituted with one or more groups independently selected from the group consisting of hydroxyl; hydroxyl; amine; C₁₋₁₀carboxylic acid; C₁₋₁₀carboxyl; straight chain or branched C₁₋₁₀alkyl, optionally containing unsaturation; straight chain or branched C₁₋₁₀alkyl amine, optionally containing unsaturation; a C₂₋₆ cycloalkyl optionally containing unsaturation or one oxygen or nitrogen atom; heterocyclyl; straight chain or branched C₁₋₁₀alkyl amine; heterocyclic amine; and aryl comprising a phenyl; and heteroaryl containing from 1 to 4 N, O, or S atoms.

The term “imine” or “imino”, as used herein, unless otherwise indicated, includes a functional group or chemical compound containing a carbon-nitrogen double bond. The expression “imino compound”, as used herein, unless otherwise indicated, refers to a compound that includes an “imine” or an “imino” group as defined herein.

The term “hydroxyl”, as used herein, unless otherwise indicated, includes —OH.

The terms “halogen” and “halo”, as used herein, unless otherwise indicated, include a chlorine, chloro, Cl; fluorine, fluoro, F; bromine, bromo, Br; or iodine, iodo, or I.

The term “aryl”, as used herein, unless otherwise indicated, include a carbocyclic aromatic group. Examples of aryl groups include, but are not limited to, phenyl, benzyl, naphthyl, or anthracenyl.

The terms “amine” and “amino”, as used herein, unless otherwise indicated, include a functional group that contains a nitrogen atom with a lone pair of electrons and wherein one or more hydrogen atoms have been replaced by a substituent such as, but not limited to, an alkyl group or an aryl group.

The term “alkyl”, as used herein, unless otherwise indicated, includes saturated monovalent hydrocarbon radicals having straight or branched moieties, such as but not limited to, methyl, ethyl, propyl, butyl, pentyl, hexyl, octyl groups, etc. Representative straight-chain lower alkyl groups include, but are not limited to, -methyl, -ethyl, -n-propyl, -n-butyl, -n-pentyl, -n-hexyl, -n-heptyl and -n-octyl; while branched lower alkyl groups include, but are not limited to, -isopropyl, -sec-butyl, -isobutyl, -tert-butyl, -isopentyl, 2-methylbutyl, 2-methylpentyl, 3-methylpentyl, 2,2-dimethylbutyl, 2,3-dimethylbutyl, 2,2-dimethylpentyl, 2,3-dimethylpentyl, 3,3-dimethylpentyl, 2,3,4-trimethylpentyl, 3-methylhexyl, 2,2-dimethylhexyl, 2,4-dimethylhexyl, 2,5-dimethylhexyl, 3,5-dimethylhexyl, 2,4-dimethylpentyl, 2-methylheptyl, 3-methylheptyl, unsaturated C₁-C₈ alkyls include, but are not limited to, -vinyl, -allyl, -1-butenyl, -2-butenyl, -isobutylenyl, -1-pentenyl, -2-pentenyl, -3-methyl-1-butenyl, -2-methyl-2-butenyl, -2,3-dimethyl-2-butenyl, 1-hexyl, 2-hexyl, 3-hexyl, -acetylenyl, -propynyl, -1-butynyl, -2-butynyl, -1-pentynyl, -2-pentynyl, or -3-methyl-1 butynyl. An alkyl can be saturated, partially saturated, or unsaturated.

The term “carboxyl”, as used herein, unless otherwise indicated, includes a functional group consisting of a carbon atom double bonded to an oxygen atom and single bonded to a hydroxyl group (—COOH).

The term “alkenyl”, as used herein, unless otherwise indicated, includes alkyl moieties having at least one carbon-carbon double bond wherein alkyl is as defined above and including E and Z isomers of said alkenyl moiety. An alkenyl can be partially saturated or unsaturated.

The term “alkynyl”, as used herein, unless otherwise indicated, includes alkyl moieties having at least one carbon-carbon triple bond wherein alkyl is as defined above. An alkynyl can be partially saturated or unsaturated.

The term “acyl”, as used herein, unless otherwise indicated, includes a functional group derived from an aliphatic carboxylic acid, by removal of the hydroxyl (—OH) group.

The term “alkoxyl”, as used herein, unless otherwise indicated, includes O-alkyl groups wherein alkyl is as defined above and O represents oxygen. Representative alkoxyl groups include, but are not limited to, —O-methyl, —O-ethyl, —O-n-propyl, —O-n-butyl, —O-n-pentyl, —O-n-hexyl, —O-n-heptyl, —O-n-octyl, —O-isopropyl, —O-sec-butyl, —O-isobutyl, —O-tert-butyl, —O-isopentyl, —O-2-methylbutyl, —O-2-methylpentyl, —O-3-methylpentyl, —O-2,2-dimethylbutyl, —O-2,3-dimethylbutyl, —O-2,2-dimethylpentyl, —O-2,3-dimethylpentyl, —O-3,3-dimethylpentyl, —O-2,3,4-trimethylpentyl, —O-3-methylhexyl, —O-2,2-dimethylhexyl, —O-2,4-dimethylhexyl, —O-2,5-dimethylhexyl, —O-3,5-dimethylhexyl, —O-2,4dimethylpentyl, —O-2-methylheptyl, —O-3-methylheptyl, —O-vinyl, —O-allyl, —O-1-butenyl, —O-2-butenyl, —O-isobutylenyl, —O-1-pentenyl, —O-2-pentenyl, —O-3-methyl-1-butenyl, —O-2-methyl-2-butenyl, —O-2,3-dimethyl-2-butenyl, —O-1-hexyl, —O-2-hexyl, —O-3-hexyl, —O-acetylenyl, —O-propynyl, —O-1-butynyl, —O-2-butynyl, —O-1-pentynyl, —O-2-pentynyl and —O-3-methyl-1-butynyl, —O-cyclopropyl, —O-cyclobutyl, —O-cyclopentyl, —O-cyclohexyl, —O-cycloheptyl, —O-cyclooctyl, —O-cyclononyl and —O-cyclodecyl, —O—CH₂-cyclopropyl, —O—CH₂-cyclobutyl, —O—CH₂-cyclopentyl, —O—CH₂-cyclohexyl, —O—CH₂-cycloheptyl, —O—CH₂-cyclooctyl, —O—CH₂-cyclononyl, —O—CH₂-cyclodecyl, —O—(CH₂)₂-cyclopropyl, —O—(CH₂)₂-cyclobutyl, —O—(CH₂)₂-cyclopentyl, —O—(CH₂)₂-cyclohexyl, —O—(CH₂)₂-cycloheptyl, —O—(CH₂)₂-cyclooctyl, —O—(CH₂)₂-cyclononyl, or —O—(CH₂)₂-cyclodecyl. An alkoxyl can be saturated, partially saturated, or unsaturated.

The term “cycloalkyl”, as used herein, unless otherwise indicated, includes a non-aromatic, saturated, partially saturated, or unsaturated, monocyclic or fused, spiro or unfused bicyclic or tricyclic hydrocarbon referred to herein containing a total of from 3 to 10 carbon atoms, preferably 3 to 8 ring carbon atoms. Examples of cycloalkyls include, but are not limited to, C₃-C₈ cycloalkyl groups include, but are not limited to, -cyclopropyl, -cyclobutyl, -cyclopentyl, -cyclopentadienyl, -cyclohexyl, -cyclohexenyl, -1,3-cyclohexadienyl, -1,4-cyclohexadienyl, -cycloheptyl, -1,3-cycloheptadienyl, -1,3,5-cycloheptatrienyl, -cyclooctyl, and -cyclooctadienyl.

The term “cycloalkyl” also includes -lower alkyl-cycloalkyl, wherein lower alkyl and cycloalkyl are as defined herein. Examples of -lower alkyl-cycloalkyl groups include, but are not limited to, —CH₂-cyclopropyl, —CH₂-cyclobutyl, —CH₂-cyclopentyl, —CH₂-cyclopentadienyl, —CH₂-cyclohexyl, —CH₂-cycloheptyl, or —CH₂-cyclooctyl.

The term “heterocyclic”, as used herein, unless otherwise indicated, includes an aromatic or non-aromatic cycloalkyl in which one to four of the ring carbon atoms are independently replaced with a heteroatom from the group consisting of O, S and N. Representative examples of a heterocycle include, but are not limited to, benzofuranyl, benzothiophene, indolyl, benzopyrazolyl, coumarinyl, isoquinolinyl, pyrrolyl, pyrrolidinyl, thiophenyl, furanyl, thiazolyl, imidazolyl, pyrazolyl, triazolyl, quinolinyl, pyrimidinyl, pyridinyl, pyridonyl, pyrazinyl, pyridazinyl, isothiazolyl, isoxazolyl, (1,4)-dioxane, (1,3)-dioxolane, 4,5-dihydro-1H-imidazolyl, or tetrazolyl. Heterocycles can be substituted or unsubstituted. Heterocycles can also be bonded at any ring atom (i.e., at any carbon atom or heteroatom of the heterocyclic ring). A heterocyclic can be saturated, partially saturated, or unsaturated.

The term “cyano”, as used herein, unless otherwise indicated, includes a —CN group.

The term “alcohol”, as used herein, unless otherwise indicated, includes a compound in which the hydroxyl functional group (—OH) is bound to a carbon atom. In particular, this carbon center should be saturated, having single bonds to three other atoms.

The term “solvate” is intended to mean a solvate form of a specified compound that retains the effectiveness of such compound. Examples of solvates include compounds of the invention in combination with, for example: water, isopropanol, ethanol, methanol, dimethylsulfoxide (DMSO), ethyl acetate, acetic acid, or ethanolamine.

The term “mmol”, as used herein, is intended to mean millimole. The term “equiv”, as used herein, is intended to mean equivalent. The term “mL”, as used herein, is intended to mean milliliter. The term “g”, as used herein, is intended to mean gram. The term “kg”, as used herein, is intended to mean kilogram. The term “μg”, as used herein, is intended to mean micrograms. The term “h”, as used herein, is intended to mean hour. The term “min”, as used herein, is intended to mean minute. The term “M”, as used herein, is intended to mean molar. The term “μL”, as used herein, is intended to mean microliter. The term “μM”, as used herein, is intended to mean micromolar. The term “nM”, as used herein, is intended to mean nanomolar. The term “N”, as used herein, is intended to mean normal. The term “amu”, as used herein, is intended to mean atomic mass unit. The term “° C.”, as used herein, is intended to mean degree Celsius. The term “wt/wt”, as used herein, is intended to mean weight/weight. The term “v/v”, as used herein, is intended to mean volume/volume. The term “MS”, as used herein, is intended to mean mass spectroscopy. The term “HPLC”, as used herein, is intended to mean high performance liquid chromatograph. The term “RT”, as used herein, is intended to mean room temperature. The term “e.g.”, as used herein, is intended to mean example. The term “N/A”, as used herein, is intended to mean not tested.

As used herein, the expression “pharmaceutically acceptable salt” refers to pharmaceutically acceptable organic or inorganic salts of a compound of the invention. Preferred salts include, but are not limited, to sulfate, citrate, acetate, oxalate, chloride, bromide, iodide, nitrate, bisulfate, phosphate, acid phosphate, isonicotinate, lactate, salicylate, acid citrate, tartrate, oleate, tannate, pantothenate, bitartrate, ascorbate, succinate, maleate, gentisinate, fumarate, gluconate, glucaronate, saccharate, formate, benzoate, glutamate, methanesulfonate, ethanesulfonate, benzenesulfonate, p-toluenesulfonate, or pamoate (i.e., 1,1′-methylene-bis-(2-hydroxy-3-naphthoate)) salts. A pharmaceutically acceptable salt may involve the inclusion of another molecule such as an acetate ion, a succinate ion or other counterion. The counterion may be any organic or inorganic moiety that stabilizes the charge on the parent compound. Furthermore, a pharmaceutically acceptable salt may have more than one charged atom in its structure. Instances where multiple charged atoms are part of the pharmaceutically acceptable salt can have multiple counterions. Hence, a pharmaceutically acceptable salt can have one or more charged atoms and/or one or more counterion. As used herein, the expression “pharmaceutically acceptable solvate” refers to an association of one or more solvent molecules and a compound of the invention. Examples of solvents that form pharmaceutically acceptable solvates include, but are not limited to, water, isopropanol, ethanol, methanol, DMSO, ethyl acetate, acetic acid, and ethanolamine. As used herein, the expression “pharmaceutically acceptable hydrate” refers to a compound of the invention, or a salt thereof, that further includes a stoichiometric or non-stoichiometric amount of water bound by non-covalent intermolecular forces.

Host

The host genetically engineered to accumulate a Piz compound can be any microorganism. One aspect of the present disclosure is directed to a transgenic microorganism engineered to accumulate L-piperazic acid (L-Piz). As described herein, a microorganism can be used in the biosynthesis of piperazic acid and piperazic acid derivatives. Exemplary microorganisms that can be engineered to accumulate Piz or Piz containing compounds include, but are not limited to, bacteria (e.g., actinobacteria, proteobacteria) or fungi (e.g., yeast).

As described herein, the microorganism can be a bacterium. In some embodiments, the microorganism can be in the Phylum, Actinobacteria or Proteobacteria. Any actinobacteria or proteiobacteria with native pzBA or pzbB genes can be suitable for use as a heterologous host.

Exemplary Proteobacteria that can be used in the biosynthesis of piperazic acid or piperazic acid derivatives can be Collimonas (a divergent member of the gram negative Burkholderiales). As an example, the Collimonas can be of the species Collimonas arenas; Collimonas fungivorans +; Collimonas pratensis; Collimonas sp. 16.2.3; Collimonas sp. 16.2.7; Collimonas sp. 16.3.1; Collimonas sp. 5.15; Collimonas sp. 8.2.7; Collimonas sp. A6AGF; Collimonas sp. A6ATD5; Collimonas sp. A9 1b-26a; Collimonas sp. AA5ATF; Collimonas sp. AD101; Collimonas sp. AD102; Collimonas sp. AD103; Collimonas sp. AD137; Collimonas sp. AD19; Collimonas sp. AD23; Collimonas sp. AD33; Collimonas sp. AD58; Collimonas sp. AD59; Collimonas sp. AD60; Collimonas sp. AD61; Collimonas sp. AD62; Collimonas sp. AD63; Collimonas sp. AD64; Collimonas sp. AD65; Collimonas sp. AD66; Collimonas sp. AD67; Collimonas sp. AD68; Collimonas sp. AD69; Collimonas sp. AD70; Collimonas sp. AD71; Collimonas sp. AD76; Collimonas sp. AD77; Collimonas sp. AD88; Collimonas sp. AD89; Collimonas sp. AD95; Collimonas sp. AD97; Collimonas sp. AD98; Collimonas sp. AD99; Collimonas sp. AR5(10); Collimonas sp. AR5(11); Collimonas sp. AR5(6); Collimonas sp. AS3(2); Collimonas sp. AS3(5); Collimonas sp. BJC15-A11; Collimonas sp. BJC15-A32; Collimonas sp. BPN72; Collimonas sp. BPN73; Collimonas sp. C2PN21; Collimonas sp. CB13; Collimonas sp. CB20; Collimonas sp. CT; Collimonas sp. CT_MP11E6; Collimonas sp. CT_MP11E8; Collimonas sp. CTO 113 b214; Collimonas sp. DEC-B5; Collimonas sp. ES3-61; Collimonas sp. F11; Collimonas sp. F14; Collimonas sp. GCM11; Collimonas sp. HPML71; Collimonas sp. HPN72; Collimonas sp. HPN73; Collimonas sp. III-15; Collimonas sp. III-27; Collimonas sp. III-32; Collimonas sp. III-35; Collimonas sp. III-47; Collimonas sp. III-48; Collimonas sp. III-5; Collimonas sp. III-9; Collimonas sp. IS343; Collimonas sp. IS0468_OTU1303; Collimonas sp. IS0613_OTU1303; Collimonas sp. ISO615_OTU1303; Collimonas sp. IS0616_OTU1303; Collimonas sp. ISO644_OTU1303; Collimonas sp. ISO648_OTU1303; Collimonas sp. KN-1; Collimonas sp. KW19; Collimonas sp. M1Ju29; Collimonas sp. M1U16; Collimonas sp. M1U8; Collimonas sp. M1U9; Collimonas sp. MF3_1; Collimonas sp. MH6; Collimonas sp. MPS11E8; Collimonas sp. NAR2(8); Collimonas sp. NAR7(1); Collimonas sp. NAR7(12); Collimonas sp. NAR7(15); Collimonas sp. NAS7(14); Collimonas sp. NAS9(14); Collimonas sp. NBRC 3740; Collimonas sp. NCCB 100027; Collimonas sp. RE1; Collimonas sp. RX265; Collimonas sp. S2U21; Collimonas sp. S2U31; Collimonas sp. S3.TSA.015; Collimonas sp. S5.ACT.019; Collimonas sp. S5.CEL.014; Collimonas sp. S5.TSA.011; Collimonas sp. S5.TSA.20; Collimonas sp. UR 9-06; Collimonas sp. wged101; Collimonas sp. wged148; Collimonas sp. wged41; Collimonas sp. wged45; Collimonas sp. wged84; Collimonas sp. wged96; or Collimonas sp. ZL261.

Exemplary Actinomycetes that can be used in the biosynthesis of piperazic acid or piperazic acid derivatives can be Actinoalloteichus, Actinomadura, Actinosynnema, Amycolatopsis, Frankia, Kibdelosporangium, Kutzneria, Lentzea, Mycobacterium, Pseudonocardia, Rhodococcus, Salinispora, Streptacidiphilus, or Streptomyces. These exemplary Actinomycetes are known to have strains with native pzbB, which would indicate that they can be heterologous hosts for Piz or Piz derivative production.

As described herein, an Actinobacteria that can be used in the biosynthesis of piperazic acid or piperazic acid derivatives can be of the genus Actinoalloteichus. As an example, the Actinoalloteichus can be of the species Actinoalloteichus alkalophilus; Actinoalloteichus cyanogriseus +, Actinoalloteichus hymeniacidonis; Actinoalloteichus nanshanensis; Actinoalloteichus sp. 10-82; Actinoalloteichus sp. 2216-6; Actinoalloteichus sp. 3BG8; Actinoalloteichus sp. AH97; Actinoalloteichus sp. CA; Actinoalloteichus sp. CA1, Actinoalloteichus sp. FXJ7.260; Actinoalloteichus sp. JAJ70, Actinoalloteichus sp. JAJ71; Actinoalloteichus sp. L2004; Actinoalloteichus sp. MA-32; Actinoalloteichus sp. MHA15, Actinoalloteichus sp. NPS-702; Actinoalloteichus sp. QAII6; Actinoalloteichus sp. SH18(2011); Actinoalloteichus sp. SHA6; Actinoalloteichus sp. TRM46408; Actinoalloteichus sp. TSI127-17, Actinoalloteichus sp. WH1-2216-6; or Actinoalloteichus spitiensis+.

As described herein, an Actinobacteria that can be used in the biosynthesis of piperazic acid or piperazic acid derivatives can be of the genus Actinomadura. As an example, the Actinomadura can be of the species Actinomadura alba; Actinomadura apis; Actinomadura atramentaria+; Actinomadura bangladeshensis; Actinomadura catellatispora; Actinomadura chibensis+; Actinomadura chokoriensis; Actinomadura citrea; Actinomadura coerulea; Actinomadura cremea+; Actinomadura echinospora; Actinomadura fibrosa; Actinomadura flavalba+; Actinomadura formosensis+; Actinomadura fulvescens; Actinomadura geliboluensis; Actinomadura glauciflava+; Actinomadura hallensis; Actinomadura hibisca+; Actinomadura keratinilytica; Actinomadura kijaniata+; Actinomadura latina+; Actinomadura livida; Actinomadura luteofluorescens; Actinomadura macra+; Actinomadura madurae+; Actinomadura maheshkhaliensis; Actinomadura melliaura; Actinomadura meridiana; Actinomadura mexicana; Actinomadura meyerae; Actinomadura miaoliensis; Actinomadura namibiensis; Actinomadura napierensis; Actinomadura nitritigenes; Actinomadura ochracea; Actinomadura oligospora+; Actinomadura pelletieri+; Actinomadura rifamycini+; Actinomadura rubrobrunea+; Actinomadura rudentiformis; Actinomadura rugatobispora; Actinomadura rupiterrae; Actinomadura scrupuli; Actinomadura sediminis; Actinomadura sp.; Actinomadura sp. 10-124; Actinomadura sp. 10-44; Actinomadura sp. 13670A; Actinomadura sp. 13679C; Actinomadura sp. 171712; Actinomadura sp. 171810; Actinomadura sp. 171812; Actinomadura sp. 171817; Actinomadura sp. 171824; Actinomadura sp. 171828; Actinomadura sp. 171839; Actinomadura sp. 171848; Actinomadura sp. 171849; Actinomadura sp. 172301; Actinomadura sp. 172301y; Actinomadura sp. 172302a; Actinomadura sp. 172315; Actinomadura sp. 172320; Actinomadura sp. 172512; Actinomadura sp. 1A01698; Actinomadura sp. 1g12710; Actinomadura sp. 21G792; Actinomadura sp. 2602GPT1-42; Actinomadura sp. 28a-59-3; Actinomadura sp. 28a-77-2; Actinomadura sp. 2EPS; Actinomadura sp. 3-196; Actinomadura sp. 306D04; Actinomadura sp. 3196; Actinomadura sp. 322C06; Actinomadura sp. 322G01; Actinomadura sp. 334D05; Actinomadura sp. 334E07; Actinomadura sp. 337H02; Actinomadura sp. 387B11; Actinomadura sp. 387H07; Actinomadura sp. 392-1; Actinomadura sp. 40007; Actinomadura sp. 40008; Actinomadura sp. 413D10; Actinomadura sp. 413F04; Actinomadura sp. 413G02; Actinomadura sp. 415A12; Actinomadura sp. 418H03; Actinomadura sp. 419B09; Actinomadura sp. 428G07; Actinomadura sp. 43-45-3; Actinomadura sp. 431D03; Actinomadura sp. 431D09; Actinomadura sp. 6192; Actinomadura sp. 8-104; Actinomadura sp. A16; Actinomadura sp. A17; Actinomadura sp. AC104; Actinomadura sp. AF-555; Actinomadura sp. AML286; Actinomadura sp. AML34; Actinomadura sp. AML691; Actinomadura sp. AMS667; Actinomadura sp. ANSum10; Actinomadura sp. ART34; Actinomadura sp. ART64; Actinomadura sp. AV1; Actinomadura sp. AW310; Actinomadura sp. BK148; Actinomadura sp. CAP 48; Actinomadura sp. CC 0580; Actinomadura sp. CNQ-052_SD01; Actinomadura sp. CNT-075_SF06; Actinomadura sp. CNU-125 PL04; Actinomadura sp. CNU125 PL04; Actinomadura sp. CPCC201357; Actinomadura sp. CPCC202697; Actinomadura sp. DLS-42; Actinomadura sp. DLS-70; Actinomadura sp. DNK540; Actinomadura sp. E6; Actinomadura sp. EGI 80046; Actinomadura sp. EGI 80170; Actinomadura sp. EHA-2; Actinomadura sp. ERI-11; Actinomadura sp. EXM-24-2; Actinomadura sp. EXM-7-1; Actinomadura sp. EYN-10-1; Actinomadura sp. EYN-4-5; Actinomadura sp. FIM95-F26; Actinomadura sp. FXJ1.340; Actinomadura sp. FXJ6.213; Actinomadura sp. FXJ6.337; Actinomadura sp. FXJ7.135; Actinomadura sp. FXJ7.250; Actinomadura sp. FZ04; Actinomadura sp. G08C011; Actinomadura sp. GD15; Actinomadura sp. GKU 128; Actinomadura sp. GKU 147; Actinomadura sp. GKU 154; Actinomadura sp. GKU 157; Actinomadura sp. GKU 505; Actinomadura sp. GKU 822; Actinomadura sp. GMKU359; Actinomadura sp. H590; Actinomadura sp. I43-1; Actinomadura sp. ID05-A0321; Actinomadura sp. IM-1232; Actinomadura sp. IM-1290; Actinomadura sp. IM-2953; Actinomadura sp. IM-3046; Actinomadura sp. IM-3889; Actinomadura sp. IM-5243; Actinomadura sp. IM-5508; Actinomadura sp. IM-5556; Actinomadura sp. IM-5929; Actinomadura sp. IM-6226; Actinomadura sp. IM-6793; Actinomadura sp. IM-6830; Actinomadura sp. IM-6847; Actinomadura sp. IM-6849; Actinomadura sp. IM-6891; Actinomadura sp. IM-6895; Actinomadura sp. IM-6933; Actinomadura sp. IM-6993; Actinomadura sp. IM-7012; Actinomadura sp. IM-7044; Actinomadura sp. IM-7045; Actinomadura sp. IM-7056; Actinomadura sp. IM-7057; Actinomadura sp. IM-7092; Actinomadura sp. IM-7177; Actinomadura sp. IM-7187; Actinomadura sp. IM-7212; Actinomadura sp. IM-7213; Actinomadura sp. IM-7214; Actinomadura sp. IM-7222; Actinomadura sp. IM-7258; Actinomadura sp. IM-7397; Actinomadura sp. IM-7435; Actinomadura sp. IM-8473; Actinomadura sp. J4S16; Actinomadura sp. J4S4; Actinomadura sp. J5S1; Actinomadura sp. J5S10; Actinomadura sp. J5S17; Actinomadura sp. JCM 4674; Actinomadura sp. JSM 082016; Actinomadura sp. K22T; Actinomadura sp. KC-IT-F8; Actinomadura sp. KC-IT-H5; Actinomadura sp. L1958; Actinomadura sp. L2003; Actinomadura sp. L2097; Actinomadura sp. L2187; Actinomadura sp. LZ95; Actinomadura sp. M23; Actinomadura sp. M9; Actinomadura sp. MD49; Actinomadura sp. MNPostmon14; Actinomadura sp. MSSRFDF8; Actinomadura sp. NEAU-Jh1-3; Actinomadura sp. NEAU-Jh2-5; Actinomadura sp. new-30-5s-4-2; Actinomadura sp. new-30-5s-4-5; Actinomadura sp. NN236; Actinomadura sp. NN242; Actinomadura sp. NTRHn4; Actinomadura sp. OS1-43; Actinomadura sp. OS3-82; Actinomadura sp. OS3-83; Actinomadura sp. OS3-87; Actinomadura sp. OS3-89; Actinomadura sp. P3829; Actinomadura sp. P3842; Actinomadura sp. P3874; Actinomadura sp. PM2091; Actinomadura sp. PMPostmon12; Actinomadura sp. PN409; Actinomadura sp. PN414; Actinomadura sp. PN4221; Actinomadura sp. PN4222; Actinomadura sp. PN4223; Actinomadura sp. PN4226; Actinomadura sp. PN425; Actinomadura sp. Postmon13; Actinomadura sp. QAP 98-328-1842; Actinomadura sp. R-Ac152; Actinomadura sp. R10-32; Actinomadura sp. R16-14; Actinomadura sp. R17-27; Actinomadura sp. R39; Actinomadura sp. RD001933; Actinomadura sp. RK2_75; Actinomadura sp. RK59; Actinomadura sp. RK75; Actinomadura sp. RK79; Actinomadura sp. RS-52; Actinomadura sp. RtII23; Actinomadura sp. RtIII29; Actinomadura sp. RtIV13; Actinomadura sp. RtIV2; Actinomadura sp. RY35-68; Actinomadura sp. S14; Actinomadura sp. S19-10; Actinomadura sp. S19-13; Actinomadura sp. S2; Actinomadura sp. S20-30; Actinomadura sp. SBMs009; Actinomadura sp. SBSK-502; Actinomadura sp. Shinshu-MS-02; Actinomadura sp. Shinshu-MS-03; Actinomadura sp. SK74; Actinomadura sp. SpB081030SC-15; Actinomadura sp. SpC090624GE_01; Actinomadura sp. SR-43; Actinomadura sp. T16-1; Actinomadura sp. T3S5; Actinomadura sp. T5S13; Actinomadura sp. T5S5; Actinomadura sp. TCA62003; Actinomadura sp. TF1; Actinomadura sp. TFS 1144; Actinomadura sp. TFS 1200; Actinomadura sp. TFS 455; Actinomadura sp. TP-A0878; Actinomadura sp. UKMCC_L29; Actinomadura sp. VAN305; Actinomadura sp. WMMB 441; Actinomadura sp. WMMB 499; Actinomadura sp. WMMB 616; Actinomadura sp. XM-11-5; Actinomadura sp. XM-17-1; Actinomadura sp. XM-17-10; Actinomadura sp. XM-17-11; Actinomadura sp. XM-17-12; Actinomadura sp. XM-17-13; Actinomadura sp. XM-17-2; Actinomadura sp. XM-17-3; Actinomadura sp. XM-17-4; Actinomadura sp. XM-17-5; Actinomadura sp. XM-17-6; Actinomadura sp. XM-17-7; Actinomadura sp. XM-17-8; Actinomadura sp. XM-18-9; Actinomadura sp. XM-24-1; Actinomadura sp. XM-24-10; Actinomadura sp. XM-24-11; Actinomadura sp. XM-24-12; Actinomadura sp. XM-24-13; Actinomadura sp. XM-24-14; Actinomadura sp. XM-24-15; Actinomadura sp. XM-24-2; Actinomadura sp. XM-24-3; Actinomadura sp. XM-24-4; Actinomadura sp. XM-24-5; Actinomadura sp. XM-24-7; Actinomadura sp. XM-24-8; Actinomadura sp. XM-24-9; Actinomadura sp. XM-4-3; Actinomadura sp. XM-4-4; Actinomadura sp. XM-7-1; Actinomadura sp. XM-7-2; Actinomadura sp. XMU188; Actinomadura sp. Y218; Actinomadura sp. YIM 48842; Actinomadura sp. YIM 61608; Actinomadura sp. YIM 65605; Actinomadura sp. YIM 65650; Actinomadura sp. YIM 65655; Actinomadura sp. YIM 65659; Actinomadura sp. YIM 65663; Actinomadura sp. YIM 65810; Actinomadura sp. YIM 75700; Actinomadura sp. YIM 77502; Actinomadura sp. YIM 77510; Actinomadura sp. YIM M 10855; Actinomadura sp. YIM M 11143; Actinomadura sp. YIM M 11219; Actinomadura sp. YIM M11072; Actinomadura sp. YIM M11327; Actinomadura sp. YN-10-4; Actinomadura sp. YN-5-3; Actinomadura sp. YN-5-4; Actinomadura sp. YN-6-4; Actinomadura sp. YN-7-1; Actinomadura sp. YN-7-10; Actinomadura sp. YN-7-11; Actinomadura sp. YN-7-12; Actinomadura sp. YN-7-13; Actinomadura sp. YN-7-2; Actinomadura sp. YN-7-3; Actinomadura sp. YN-7-6; Actinomadura sp. YN-7-7; Actinomadura sp. YN-7-8; Actinomadura sp. YN-7-9; Actinomadura sp. YN-8-11; Actinomadura sp. ZZY-2013; Actinomadura sputi+; Actinomadura umbrina; Actinomadura verrucosospora; Actinomadura vinacea; Actinomadura viridilutea; Actinomadura viridis; Actinomadura vulgaris+; Actinomadura xylanilytica; Actinomadura yumaensis+; or Excellospora japonica.

As described herein, an Actinobacteria that can be used in the biosynthesis of piperazic acid or piperazic acid derivatives can be of the genus Actinosynnema. As an example, the Actinosynnema can be of the species Actinosynnema mirum or Actinosynnema pretiosum.

As described herein, an Actinobacteria that can be used in the biosynthesis of piperazic acid or piperazic acid derivatives can be of the genus Amycolatopsis. As an example, the Amycolatopsis can be of the species Amycolatopsis alba; Amycolatopsis albidoflavus; Amycolatopsis azurea; Amycolatopsis balhimycina; Amycolatopsis coloradensis; Amycolatopsis decaplanina; Amycolatopsis eurytherma; Amycolatopsis fastidiosa; Amycolatopsis japonica; Amycolatopsis kentuckyensis; Amycolatopsis keratiniphila; Amycolatopsis lexingtonensis; Amycolatopsis lurida; Amycolatopsis mediterranei; Amycolatopsis methanolica; Amycolatopsis orientalis; Amycolatopsis palatopharyngis; Amycolatopsis pretoriensis; Amycolatopsis rubida; Amycolatopsis rugosa; Amycolatopsis sacchari; Amycolatopsis sulphurea; Amycolatopsis thermoflava; Amycolatopsis tolypomycina; or Amycolatopsis vancoresmycina.

As described herein, an Actinobacteria that can be used in the biosynthesis of piperazic acid or piperazic acid derivatives can be of the genus Frankia. As an example, the Frankia can be of the species Frankia brunchorstii or Frankia subtilis.

As described herein, an Actinobacteria that can be used in the biosynthesis of piperazic acid or piperazic acid derivatives can be of the genus Kibdelosporangium. As an example, the Kibdelosporangium can be of the species Kibdelosporangium albatum; Kibdelosporangium aridum; or Kibdelosporangium philippinense.

As described herein, an Actinobacteria that can be used in the biosynthesis of piperazic acid or piperazic acid derivatives can be of the genus Lentzea. As an example, the Lentzea can be of the species Lentzea albida; Lentzea albidocapillata; Lentzea californiensis; Lentzea flaviverrucosa; Lentzea jiangxiensis; Lentzea kentuckyensis; Lentzea sp. 132; Lentzea sp. 173316; Lentzea sp. 173591; Lentzea sp. 173892; Lentzea sp. 18-3; Lentzea sp. 4_C7_44; Lentzea sp. 4_C7_58; Lentzea sp. 7887; Lentzea sp. 84741; Lentzea sp. ACT-0091; Lentzea sp. BJ36; Lentzea sp. DHS C013; Lentzea sp. G-MN-1; Lentzea sp. GP0204; Lentzea sp. 108A-00410; Lentzea sp. IMER-B1-1; Lentzea sp. IR11-RCA120; Lentzea sp. KLBMP 1096; Lentzea sp. LM 058; Lentzea sp. LM 121; Lentzea sp. mCFU23; Lentzea sp. ML457-mF8; Lentzea sp. MS-15; Lentzea sp. MS-20; Lentzea sp. MS-5; Lentzea sp. MS6; Lentzea sp. SAUK6214; Lentzea sp. YIM 48827; Lentzea sp. YIM 48828; Lentzea sp. YIM 65117; Lentzea sp. YIM 75756; Lentzea sp. YIM 75760; Lentzea sp. YIM 75761; Lentzea sp. YIM 75778; Lentzea sp. YIM 75796; Lentzea sp. YM-11; Lentzea sp. YN-8-6; Lentzea violacea; or Lentzea waywayandensis.

As described herein, an Actinobacteria that can be used in the biosynthesis of piperazic acid or piperazic acid derivatives can be of the genus Mycobacterium. As an example, the Mycobacterium can be of the species Mycobacterium abscessus; Mycobacterium africanum; Mycobacterium agri; Mycobacterium aichiense; Mycobacterium alvei; Mycobacterium arupense; Mycobacterium asiaticum; Mycobacterium aubagnense; Mycobacterium aurum; Mycobacterium austroafricanum; Mycobacterium avium+; Mycobacterium boenickei; Mycobacterium bohemicum; Mycobacterium bolletii; Mycobacterium botniense; Mycobacterium bovis +; Mycobacterium branderi; Mycobacterium brisbanense; Mycobacterium brumae; Mycobacterium canariasense; Mycobacterium caprae; Mycobacterium celatum; Mycobacterium chelonae+; Mycobacterium chimaera; Mycobacterium chitae; Mycobacterium chlorophenolicum; Mycobacterium chubuense; Mycobacterium colombiense; Mycobacterium conceptionense; Mycobacterium confluentis; Mycobacterium conspicuum; Mycobacterium cookie; Mycobacterium cosmeticum; Mycobacterium diernhoferi; Mycobacterium doricum; Mycobacterium duvalii; Mycobacterium elephantis; Mycobacterium; Mycobacterium farcinogenes; Mycobacterium flavescens; Mycobacterium florentinum; Mycobacterium fluoranthenivorans; Mycobacterium fortuitum+; Mycobacterium frederiksbergense; Mycobacterium gadium; Mycobacterium gastri; Mycobacterium genavense; Mycobacterium gilvum; Mycobacterium goodie; Mycobacterium gordonae; Mycobacterium haemophilum; Mycobacterium hassiacum; Mycobacterium heckeshornense; Mycobacterium heidelbergense; Mycobacterium hiberniae; Mycobacterium hodleri; Mycobacterium holsaticum; Mycobacterium houstonense; Mycobacterium immunogenum; Mycobacterium interjectum; Mycobacterium intermedium; Mycobacterium intracellulare; Mycobacterium kansasii; Mycobacterium komossense; Mycobacterium kubicae; Mycobacterium lacus; Mycobacterium lentiflavum; Mycobacterium leprae; Mycobacterium lepraemurium; Mycobacterium madagascariense; Mycobacterium mageritense; Mycobacterium malmoense; Mycobacterium marinum; Mycobacterium massiliense; Mycobacterium microti; Mycobacterium montefiorense; Mycobacterium moriokaense; Mycobacterium mucogenicum; Mycobacterium murale; Mycobacterium nebraskense; Mycobacterium neoaurum; Mycobacterium neworleansense; Mycobacterium nonchromogenicum; Mycobacterium novocastrense; Mycobacterium obuense; Mycobacterium palustre; Mycobacterium parafortuitum; Mycobacterium parascrofulaceum; Mycobacterium parmense; Mycobacterium peregrinum; Mycobacterium phlei; Mycobacterium phocaicum; Mycobacterium pinnipedii; Mycobacterium porcinum; Mycobacterium poriferae; Mycobacterium pseudoshottsii; Mycobacterium psychrotolerans; Mycobacterium pulveris; Mycobacterium pyrenivorans; Mycobacterium rhodesiae; Mycobacterium saskatchewanense; Mycobacterium scrofulaceum; Mycobacterium senegalense; Mycobacterium septicum; Mycobacterium shimoidei; Mycobacterium shottsii; Mycobacterium simiae; Mycobacterium smegmatis; Mycobacterium sphagni; Mycobacterium szulgai; Mycobacterium terrae; Mycobacterium thermoresistibile; Mycobacterium tokaiense; Mycobacterium triplex; Mycobacterium triviale; Mycobacterium tuberculosis+; Mycobacterium tusciae; Mycobacterium ulcerans; Mycobacterium vaccae; Mycobacterium vanbaalenii; Mycobacterium wolinskyi; or Mycobacterium xenopi.

As described herein, an Actinobacteria that can be used in the biosynthesis of piperazic acid or piperazic acid derivatives can be of the genus Pseudonocardia. As an example, the Pseudonocardia can be of the species Pseudonocardia alaniniphila; Pseudonocardia alni; Pseudonocardia asaccharolytica; Pseudonocardia aurantiaca; Pseudonocardia autotrophica; Pseudonocardia azurea; Pseudonocardia benzenivorans; Pseudonocardia chloroethenivorans; Pseudonocardia compacta; Pseudonocardia halophobica; Pseudonocardia hydrocarbonoxydans; Pseudonocardia kongjuensis; Pseudonocardia nitrificans; Pseudonocardia petroleophila; Pseudonocardia saturnea; Pseudonocardia spinosa; Pseudonocardia spinosispora; Pseudonocardia sulfidoxydans; Pseudonocardia thermophile; Pseudonocardia xinjiangensis; Pseudonocardia yunnanensis; or Pseudonocardia zijingensis.

As described herein, an Actinobacteria that can be used in the biosynthesis of piperazic acid or piperazic acid derivatives can be of the genus Rhodococcus. As an example, the Rhodococcus can be of the species Rhodococcus luberonensis; Rhodococcus marchali; Rhodococcus perornatus; Rhodococcus rosaeluteae; Rhodococcus sariuoni; Rhodococcus spiraeae; or Rhodococcus turanicus.

As described herein, an Actinobacteria that can be used in the biosynthesis of piperazic acid or piperazic acid derivatives can be of the genus Salinispora. As an example, the Salinispora can be of the species Actinocatenispora; Actinoplanes; Amorphosporangium; Ampullariella; Asanoa; Catellatospora; Catenuloplanes; Couchioplanes; Dactylosporangium; Krasilnikovia; Longispora; Luedemannella; Micromonospora; Myceliochytrium; Pilimelia; Planopolyspora; Planosporangium; Polymorphospora; Salinispora; Spirilliplanes; Verrucosispora; Virgisporangium corrig.

As described herein, an Actinobacteria that can be used in the biosynthesis of piperazic acid or piperazic acid derivatives can be of the genus Streptacidiphilus. As an example, the Streptacidiphilus can be of the species Streptacidiphilus albus, Streptacidiphilus carbonis, Streptacidiphilus neutrinimicus, Streptacidiphilus anmyonensis, Streptacidiphilus durhamensis, Streptacidiphilus hamsterleyensis, Streptacidiphilus jiangxiensis, Streptacidiphilus melanogenes, Streptacidiphilus oryzae, or Streptacidiphilus rugosus.

As described herein, an Actinobacteria that can be used in the biosynthesis of piperazic acid or piperazic acid derivatives can be of the genus Streptomyces. As an example, the Streptomyces can be of the species Streptomyces coelicolor, S. lividans, S. albicans, S. griseus, or S. plicatosporus. As another example, the Streptomyces can be of the species Streptomyces abietis; Streptomyces abikoensis; Streptomyces aburaviensis; Streptomyces achromogenes; Streptomyces acidiscabies; Streptomyces actinomycinicus; Streptomyces acrimycini; Streptomyces actuosus; Streptomyces aculeolatus; Streptomyces abyssalis; Streptomyces afghaniensis; Streptomyces aidingensis; Streptomyces africanus; Streptomyces alanosinicus; Streptomyces albaduncus; Streptomyces albiaxialis; Streptomyces albidochromogenes; Streptomyces albiflavescens; Streptomyces albiflaviniger Streptomyces albidoflavus; Streptomyces albofaciens; Streptomyces alboflavus; Streptomyces albogriseolus; Streptomyces albolongus; Streptomyces alboniger Streptomyces albospinus; Streptomyces albulus; Streptomyces albus; Streptomyces aldersoniae; Streptomyces alfalfae; Streptomyces alkaliphilus; Streptomyces alkalithermotolerans; Streptomyces almquistii; Streptomyces alni; Streptomyces althioticus; Streptomyces amakusaensis; Streptomyces ambofaciens; Streptomyces amritsarensis; Streptomyces anandii; Streptomyces angustmyceticus; Streptomyces anthocyanicus; Streptomyces antibioticus; Streptomyces antimycoticus; Streptomyces anulatus; Streptomyces aomiensis; Streptomyces araujoniae; Streptomyces ardus; Streptomyces arenae; Streptomyces armeniacus; Streptomyces artemisiae; Streptomyces arcticus; Streptomyces ascomycinicus; Streptomyces asiaticus; Streptomyces asterosporus; Streptomyces atacamensis; Streptomyces atratus; Streptomyces atriruber Streptomyces atroolivaceus; Streptomyces atrovirens; Streptomyces aurantiacus; Streptomyces aurantiogriseus; Streptomyces auratus; Streptomyces aureocirculatus; Streptomyces aureofaciens; Streptomyces aureorectus; Streptomyces aureoverticillatus; Streptomyces aureus; Streptomyces avellaneus; Streptomyces avermitilis; Streptomyces avicenniae; Streptomyces avidinii; Streptomyces axinellae; Streptomyces azureus; Streptomyces bacillaris; Streptomyces badius; Streptomyces bambergiensis; Streptomyces bangladeshensis; Streptomyces baliensis; Streptomyces barkulensis; Streptomyces beijiangensis; Streptomyces bellus; Streptomyces bikiniensis; Streptomyces blastmyceticus; Streptomyces bluensis; Streptomyces bobili; Streptomyces bohaiensis; Streptomyces bottropensis; Streptomyces brasiliensis; Streptomyces brevispora; Streptomyces bullii; Streptomyces bungoensis; Streptomyces burgazadensis; Streptomyces cacaoi; Streptomyces caelestis; Streptomyces caeruleatus; Streptomyces calidiresistens; Streptomyces calvus; Streptomyces canarius; Streptomyces canchipurensis; Streptomyces candidus; Streptomyces cangkringensis; Streptomyces caniferus; Streptomyces canus; Streptomyces capillispiralis; Streptomyces capoamus; Streptomyces carpaticus; Streptomyces carpinensis; Streptomyces castelarensis; Streptomyces catbensis; Streptomyces catenulae; Streptomyces cavourensis; Streptomyces cellostaticus; Streptomyces celluloflavus; Streptomyces cellulolyticus; Streptomyces cellulosae; Streptomyces chartreusis; Streptomyces chattanoogensis; Streptomyces cheonanensis; Streptomyces chiangmaiensis; Streptomyces chrestomyceticus; Streptomyces chromofuscus; Streptomyces chryseus; Streptomyces chilikensis; Streptomyces chlorus; Streptomyces chumphonensis; Streptomyces cinereorectus; Streptomyces cinereoruber; Streptomyces cinereospinus; Streptomyces cinereus; Streptomyces cinerochromogenes; Streptomyces cinnabarinus; Streptomyces cinnamonensis; Streptomyces cinnamoneus; Streptomyces cirratus; Streptomyces ciscaucasicus; Streptomyces clavifer Streptomyces clavuligerus; Streptomyces coacervatus; Streptomyces cocklensis; Streptomyces coelescens; Streptomyces coelicoflavus; Streptomyces coelicolor Streptomyces coeruleoflavus; Streptomyces coeruleofuscus; Streptomyces coeruleoprunus; Streptomyces coeruleorubidus; Streptomyces coerulescens; Streptomyces collinus; Streptomyces colombiensis; Streptomyces corchorusii; Streptomyces costaricanus; Streptomyces cremeus; Streptomyces crystallinus; Streptomyces cuspidosporus; Streptomyces cyaneofuscatus; Streptomyces cyaneus; Streptomyces cyanoalbus; Streptomyces cyslabdanicus; Streptomyces daghestanicus; Streptomyces daliensi; Streptomyces deccanensis; Streptomyces decoyicus; Streptomyces demainii; Streptomyces deserti; Streptomyces diastaticus; Streptomyces diastatochromogenes; Streptomyces djakartensis; Streptomyces drozdowiczii; Streptomyces durhamensis; Streptomyces durmitorensis; Streptomyces echinatus; Streptomyces echinoruber Streptomyces ederensis; Streptomyces emeiensis; Streptomyces endophyticus; Streptomyces endus; Streptomyces enissocaesilis; Streptomyces erythrogriseus; Streptomyces erringtonii; Streptomyces eurocidicus; Streptomyces europaeiscabiei; Streptomyces eurythermus; Streptomyces exfoliatus; Streptomyces faba; Streptomyces fenghuangensis; Streptomyces ferralitis; Streptomyces filamentosus; Streptomyces fildesensis; Streptomyces filipinensis; Streptomyces fimbriatus; Streptomyces finlayi; Streptomyces flaveolus; Streptomyces flaveus; Streptomyces flavofungini; Streptomyces flavotricini; Streptomyces flavovariabilis; Streptomyces flavovirens; Streptomyces flavoviridis; Streptomyces fradiae; Streptomyces fragilis; Streptomyces fukangensis; Streptomyces fulvissimus; Streptomyces fulvorobeus; Streptomyces fumanus; Streptomyces fumigatiscleroticus; Streptomyces galbus; Streptomyces galilaeus; Streptomyces gancidicus; Streptomyces gardneri; Streptomyces gelaticus; Streptomyces geldanamycininus; Streptomyces geysiriensis; Streptomyces ghanaensis; Streptomyces gilvifuscus; Streptomyces glaucescens; Streptomyces glauciniger Streptomyces glaucosporus; Streptomyces glaucus; Streptomyces globisporus; Streptomyces globosus; Streptomyces glomeratus; Streptomyces glomeroaurantiacus; Streptomyces glycovorans; Streptomyces gobitricini; Streptomyces goshikiensis; Streptomyces gougerotii; Streptomyces graminearus; Streptomyces gramineus; Streptomyces graminifolii; Streptomyces graminilatus; Streptomyces graminisoli; Streptomyces griseiniger Streptomyces griseoaurantiacus; Streptomyces griseocarneus; Streptomyces griseochromogenes; Streptomyces griseoflavus; Streptomyces griseofuscus; Streptomyces griseoincarnatus; Streptomyces griseoloalbus; Streptomyces griseolus; Streptomyces griseoluteus; Streptomyces griseomycini; Streptomyces griseoplanus; Streptomyces griseorubens; Streptomyces griseoruber Streptomyces griseorubiginosus; Streptomyces griseosporeus; Streptomyces griseostramineus; Streptomyces griseoviridis; Streptomyces griseus; Streptomyces guanduensis; Streptomyces gulbargensis; Streptomyces hainanensis; Streptomyces haliclonae; Streptomyces halophytocola; Streptomyces halstedii; Streptomyces harbinensis; Streptomyces hawaiiensis; Streptomyces hebeiensis; Streptomyces heilongjiangensis; Streptomyces heliomycini; Streptomyces helvaticus; Streptomyces herbaceus; Streptomyces herbaricolor; Streptomyces himastatinicus; Streptomyces hiroshimensis; Streptomyces hirsutus; Streptomyces hokutonensis; Streptomyces hoynatensis; Streptomyces humidus; Streptomyces humiferus; Streptomyces hundungensis; Streptomyces hyderabadensis; Streptomyces hygroscopicus; Streptomyces hypolithicus; Streptomyces iakyrus; Streptomyces iconiensis; Streptomyces incanus; Streptomyces indiaensis; Streptomyces indigoferus; Streptomyces indicus; Streptomyces indonesiensis; Streptomyces intermedius; Streptomyces inusitatus; Streptomyces ipomoeae; Streptomyces iranensis; Streptomyces janthinus; Streptomyces jamaicensis; Streptomyces javensis; Streptomyces jietaisiensis; Streptomyces jiujiangensis; Streptomyces kaempferi; Streptomyces kanamyceticus; Streptomyces karpasiensis; Streptomyces kasugaensis; Streptomyces katrae; Streptomyces kebangsaanensis; Streptomyces klenkii; Streptomyces koyangensis; Streptomyces kunmingensis; Streptomyces kurssanovii; Streptomyces labedae; Streptomyces lacrimifluminis; Streptomyces lacticiproducens; Streptomyces laculatispora; Streptomyces lanatus; Streptomyces lannensis; Streptomyces lateritius; Streptomyces laurentii; Streptomyces lavendofoliae; Streptomyces lavendulae; Streptomyces lavenduligriseus; Streptomyces leeuwenhoekii; Streptomyces lavendulocolor Streptomyces levis; Streptomyces libani; Streptomyces lienomycini; Streptomyces lilacinus; Streptomyces lincolnensis; Streptomyces litmocidini; Streptomyces litoralis; Streptomyces lomondensis; Streptomyces longisporoflavus; Streptomyces longispororuber Streptomyces lopnurensis; Streptomyces longisporus; Streptomyces longwoodensis; Streptomyces lucensis; Streptomyces lunaelactis; Streptomyces lunalinharesii; Streptomyces luridiscabiei; Streptomyces luridus; Streptomyces lusitanus; Streptomyces lushanensis; Streptomyces luteireticuli; Streptomyces luteogriseus; Streptomyces luteosporeus; Streptomyces lydicus; Streptomyces macrosporus; Streptomyces malachitofuscus; Streptomyces malachitospinus; Streptomyces malaysiensis; Streptomyces mangrovi; Streptomyces marinus; Streptomyces marokkonensis; Streptomyces mashuensis; Streptomyces massasporeus; Streptomyces matensis; Streptomyces mayteni; Streptomyces mauvecolor Streptomyces megasporus; Streptomyces melanogenes; Streptomyces melanosporofaciens; Streptomyces mexicanus; Streptomyces michiganensis; Streptomyces microflavus; Streptomyces milbemycinicus; Streptomyces minutiscleroticus; Streptomyces mirabilis; Streptomyces misakiensis; Streptomyces misionensis; Streptomyces mobaraensis; Streptomyces monomycini; Streptomyces mordarskii; Streptomyces morookaense; Streptomyces muensis; Streptomyces murinus; Streptomyces mutabilis; Streptomyces mutomycini; Streptomyces naganishii; Streptomyces nanhaiensis; Streptomyces nanshensis; Streptomyces narbonensis; Streptomyces nashvillensis; Streptomyces netropsis; Streptomyces neyagawaensis; Streptomyces niger Streptomyces nigrescens; Streptomyces nitrosporeus; Streptomyces niveiciscabiei; Streptomyces niveiscabiei; Streptomyces niveoruber Streptomyces niveus; Streptomyces noboritoensis; Streptomyces nodosus; Streptomyces nogalater Streptomyces nojiriensis; Streptomyces noursei; Streptomyces novaecaesareae; Streptomyces ochraceiscleroticus; Streptomyces olivaceiscleroticus; Streptomyces olivaceoviridis; Streptomyces olivaceus; Streptomyces olivicoloratus; Streptomyces olivochromogenes; Streptomyces olivomycini; Streptomyces olivoverticillatus; Streptomyces omiyaensis; Streptomyces osmaniensis; Streptomyces orinoci; Streptomyces pactum; Streptomyces panacagri; Streptomyces panaciradicis; Streptomyces paradoxus; Streptomyces parvulus; Streptomyces parvus; Streptomyces pathocidini; Streptomyces paucisporeus; Streptomyces peucetius; Streptomyces phaeochromogenes; Streptomyces phaeofaciens; Streptomyces phaeogriseichromatogenes; Streptomyces phaeoluteichromatogenes; Streptomyces phaeoluteigriseus; Streptomyces phaeopurpureus; Streptomyces pharetrae; Streptomyces pharmamarensis; Streptomyces phytohabitans; Streptomyces pilosus; Streptomyces platensis; Streptomyces plicatus; Streptomyces plumbiresistens; Streptomyces pluricolorescens; Streptomyces pluripotens; Streptomyces polyantibioticus; Streptomyces polychromogenes; Streptomyces polygonati; Streptomyces polymachus; Streptomyces poonensis; Streptomyces prasinopilosus; Streptomyces prasinosporus; Streptomyces prasinus; Streptomyces pratens; Streptomyces pratensis; Streptomyces prunicolor Streptomyces psammoticus; Streptomyces pseudoechinosporeus; Streptomyces pseudogriseolus; Streptomyces pseudovenezuelae; Streptomyces pulveraceus; Streptomyces puniceus; Streptomyces puniciscabiei; Streptomyces purpeofuscus; Streptomyces purpurascens; Streptomyces purpureus; Streptomyces purpurogeneiscleroticus; Streptomyces qinglanensis; Streptomyces racemochromogenes; Streptomyces radiopugnans; Streptomyces rameus; Streptomyces ramulosus; Streptomyces rapamycinicus; Streptomyces recifensis; Streptomyces rectiviolaceus; Streptomyces regensis; Streptomyces resistomycificus; Streptomyces reticuliscabiei; Streptomyces rhizophilus; Streptomyces rhizosphaericus; Streptomyces rimosus; Streptomyces rishiriensis; Streptomyces rochei; Streptomyces rosealbus; Streptomyces roseiscleroticus; Streptomyces roseofulvus; Streptomyces roseolilacinus; Streptomyces roseolus; Streptomyces roseosporus; Streptomyces roseoviolaceus; Streptomyces roseoviridis; Streptomyces ruber Streptomyces rubidus; Streptomyces rubiginosohelvolus; Streptomyces rubiginosus; Streptomyces rubrisoli; Streptomyces rubrogriseus; Streptomyces rubrus; Streptomyces rutgersensis; Streptomyces samsunensis; Streptomyces sanglieri; Streptomyces sannanensis; Streptomyces sanyensis; Streptomyces sasae; Streptomyces scabiei; Streptomyces scabrisporus; Streptomyces sclerotialus; Streptomyces scopiformis; Streptomyces scopuliridis; Streptomyces sedi; Streptomyces seoulensis; Streptomyces seranimatus; Streptomyces seymenliensis; Streptomyces shaanxiensis; Streptomyces shenzhenensis; Streptomyces showdoensis; Streptomyces silaceus; Streptomyces sindenensis; Streptomyces sioyaensis; Streptomyces smyrnaeus; Streptomyces sodiiphilus; Streptomyces somaliensis; Streptomyces sudanensis; Streptomyces sparsogenes; Streptomyces sparsus; Streptomyces specialis; Streptomyces spectabilis; Streptomyces speibonae; Streptomyces speleomycini; Streptomyces spinoverrucosus; Streptomyces spiralis; Streptomyces spiroverticillatus; Streptomyces spongiae; Streptomyces spongiicola; Streptomyces sporocinereus; Streptomyces sporoclivatus; Streptomyces spororaveus; Streptomyces sporoverrucosus; Streptomyces staurosporininus; Streptomyces stelliscabiei; Streptomyces stramineus; Streptomyces subrutilus; Streptomyces sulfonofaciens; Streptomyces sulphureus; Streptomyces sundarbansensis; Streptomyces synnematoformans; Streptomyces tacrolimicus; Streptomyces tanashiensis; Streptomyces tateyamensis; Streptomyces tauricus; Streptomyces tendae; Streptomyces termitum; Streptomyces thermoalcalitolerans; Streptomyces thermoautotrophicus; Streptomyces thermocarboxydovorans; Streptomyces thermocarboxydus; Streptomyces thermocoprophilus; Streptomyces thermodiastaticus; Streptomyces thermogriseus; Streptomyces thermolineatus; Streptomyces thermospinosisporus; Streptomyces thermoviolaceus; Streptomyces thermovulgaris; Streptomyces thinghirensis; Streptomyces thioluteus; Streptomyces torulosus; Streptomyces toxytricini; Streptomyces tremellae; Streptomyces tritolerans; Streptomyces tricolor, Streptomyces tsukubensis; Streptomyces tubercidicus; Streptomyces tuirus; Streptomyces tunisiensis; Streptomyces turgidiscabies; Streptomyces tyrosinilyticus; Streptomyces umbrinus; Streptomyces variabilis; Streptomyces variegatus; Streptomyces varsoviensis; Streptomyces verticillus; Streptomyces vastus; Streptomyces venezuelae; Streptomyces vietnamensis; Streptomyces vinaceus; Streptomyces vinaceusdrappus; Streptomyces violaceochromogenes; Streptomyces violaceolatus; Streptomyces violaceorectus; Streptomyces violaceoruber Streptomyces violaceorubidus; Streptomyces violaceus; Streptomyces violaceusniger Streptomyces violarus; Streptomyces violascens; Streptomyces violens; Streptomyces virens; Streptomyces virginiae; Streptomyces viridis; Streptomyces viridiviolaceus; Streptomyces viridobrunneus; Streptomyces viridochromogenes; Streptomyces viridodiastaticus; Streptomyces viridosporus; Streptomyces vitaminophilus; Streptomyces wedmorensis; Streptomyces wellingtoniae; Streptomyces werraensis; Streptomyces wuyuanensis; Streptomyces xanthochromogenes; Streptomyces xanthocidicus; Streptomyces xantholiticus; Streptomyces xanthophaeus; Streptomyces xiamenensis; Streptomyces xinghaiensis; Streptomyces xishensis; Streptomyces yaanensis; Streptomyces yanglinensis; Streptomyces yangpuensis; Streptomyces yanii; Streptomyces yatensis; Streptomyces yeochonensis; Streptomyces yerevanensis; Streptomyces yogyakartensis; Streptomyces yokosukanensis; Streptomyces youssoufiensis; Streptomyces yunnanensis; Streptomyces zagrosensis; Streptomyces zaomyceticus; Streptomyces zhaozhouensis; Streptomyces zinciresistens; or Streptomyces ziwulingensis. As another example, the microorganism can be a streptomyces species with azinothricin as the founding member, Steptomyces flaveolus DSM 9954, Streptomyces MK498-98F14 strain, Steptomyces sp. RJA2928, Streptomyces hygroscopicus strain ATCC 53653, Streptomyces lycidus (strain HKI0343), Streptomyces strain CNQ-593, Streptomyces sp. (A92-308110), or Streptomyces himastatinicus ATCC 53653. As another example, the microorganism can be a Streptomyces strain BB10EC, ES09EC, LM04EC, CS08EC, CM04EC, PF8EC, MRY08EC, LM08EC, JMO5EC, BB04EC, PF1EC, PF5EC, JV594, or JV596.

As another example, an Actinobacteria that can be used in the biosynthesis of piperazic acid or piperazic acid derivatives can be of the genus, Corynebacterium. As another example, the Corynebacterium can be of the species Corynebacterium glutamicum. As another example, the Corynebacterium can be of the species Corynebacterium efficiens, Corynebacterium diphtheriae group, Corynebacterium xerosis, Corynebacterium striatum, Corynebacterium minutissimum, Corynebacterium amycolatum, Corynebacterium glucuronolyticum, Corynebacterium argentoratense, Corynebacterium matruchotii, Corynebacterium glutamicum, Corynebacterium sp., Nonfermentative corynebacteria, Corynebacterium afermentans subsp. Afermentans, Corynebacterium auris, Corynebacterium pseudodiphtheriticum, Corynebacterium propinquum, Corynebacterium uropygiale, Corynebacterium jeikeium, Corynebacterium urealyticum, Corynebacterium afermentans subsp. lipophilum, Corynebacterium accolens, Corynebacterium macginleyi, CDC coryneform groups F-1 and G, Corynebacterium bovis, or Corynebacterium kroppenstedtii.

As another example, an Actinobacteria that can be used in the biosynthesis of piperazic acid or piperazic acid derivatives can be of the genus, Kutzneria. As another example, the Kutzneria can be of the species Kutzneria spp. 744, Kutzneria albida, Kutzneria kofuensis, Kutzneria viridogrisea), (see e.g., Neuman et al. 2012 13(7) 972-976). Kutzneria were previously known to be in the family of Streptosporangiaceae (suborder Streptosporangineae) and were known as Streptosporangium albidum, Streptosporangium viridogriseum (subspecies kofuense), or Streptosporangium viridogriseum.

As described herein, an Actinobacteria that can be used in the biosynthesis of piperazic acid or piperazic acid derivatives can be of the genus Actinomadura. As an example, the Actinomadura can be of the species Actinomadura luzonensis, Actinomadura dassonvillei, Actinomadura madurae, Actinomadura pelletieri, Actinomadura sputi, Actinomadura meyerae, Actinomadura hibisca, Actinomadura pusilla, A. fastidiosa, A. ferruoinea, A. helvata, A. kijaniata, A. libanotica, A. roseola, A. roseoviolacea, A. rubra., A. salmonea, or A. spiralis.

As described herein, the microorganism can be a fungi. For example, the gene can be refactored and insterted into eukaryal vectors for yeast or fungal expression. In fact, some fungi also encode functionally orthologous PzbA enzymes (SidA). In some embodiments, the microorganism can be in the Phylum, Ascomycota or the genus, Aspergillus. As an example, the species can be Aspergillus caesiellus, Aspergillus candidus, Aspergillus carneus, Aspergillus clavatus, Aspergillus deflectus, Aspergillus flavus, Aspergillus fumigatus, Aspergillus glaucus, Aspergillus israelii, Aspergillus nidulans, Aspergillus niger, Aspergillus ochraceus, Aspergillus oryzae, Aspergillus parasiticus, Aspergillus penicilloides, Aspergillus restrictus, Aspergillus sojae, Aspergillus sydowii, Aspergillus tamari, Aspergillus terreus, Aspergillus ustus, or Aspergillus versicolor.

In some embodiments, transformed microorganisms, as described herein, can accumulate at least about 1 μM to at least about 1 M L-Piz. For example, in some embodiments, transformed microorganisms can accumulate about 1 μM; about 10 μM; about 20 μM; about 30 μM; about 40 μM; about 50 μM; about 60 μM; about 70 μM; about 80 μM; about 90 μM; about 100 μM; about 110 μM; about 120 μM; about 130 μM; about 140 μM; about 150 μM; about 160 μM; about 170 μM; about 180 μM; about 190 μM; about 200 μM; about 210 μM; about 220 μM; about 230 μM; about 240 μM; about 250 μM; about 260 μM; about 270 μM; about 280 μM; about 290 μM; about 300 μM; about 310 μM; about 320 μM; about 330 μM; about 340 μM; about 350 μM; about 360 μM; about 370 μM; about 380 μM; about 390 μM; about 400 μM; about 410 μM; about 420 μM; about 430 μM; about 440 μM; about 450 μM; about 460 μM; about 470 μM; about 480 μM; about 490 μM; about 500 μM; about 510 μM; about 520 μM; about 530 μM; about 540 μM; about 550 μM; about 560 μM; about 570 μM; about 580 μM; about 590 μM; about 600 μM; about 610 μM; about 620 μM; about 630 μM; about 640 μM; about 650 μM; about 660 μM; about 670 μM; about 680 μM; about 690 μM; about 700 μM; about 710 μM; about 720 μM; about 730 μM; about 740 μM; about 750 μM; about 760 μM; about 770 μM; about 780 μM; about 790 μM; about 800 μM; about 810 μM; about 820 μM; about 830 μM; about 840 μM; about 850 μM; about 860 μM; about 870 μM; about 880 μM; about 890 μM; about 900 μM; about 910 μM; about 920 μM; about 930 μM; about 940 μM; about 950 μM; about 960 μM; about 970 μM; about 980 μM; about 990 μM; or about 1000 μM. Recitation of each of these discrete values is understood to include ranges between each value. Recitation of each of a range is understood to include discrete values within the range.

In some embodiments, transformed microorganisms, as described herein, can accumulate between at least about 1 mg and at least about 3 mg of Piz or Piz derivatives (e.g., L-Piz, see e.g., Examples 4 or 14) per liter in about 3 days (or at least about 14 μg/L per hour or at least about 0.2 μg/L per minute). In some embodiments, transformed microorganisms can accumulate at least about 0.1 μg up to about 10 μg of a Piz or Piz derivatives (e.g., L-Piz) per minute per L. For example, transformed microorganisms can accumulate at least about 0.1 μg, at least about 0.2 μg, at least about 0.3 μg, at least about 0.4 μg, at least about 0.5 μg, at least about 0.6 μg, at least about 0.7 μg, at least about 0.8 μg, at least about 0.9 μg, or at least about 1 μg of Piz or Piz derivatives (e.g., L-Piz) per minute per L. In other embodiments, various transformed microorganisms accumulate similar amounts of Piz or Piz derivatives (e.g., L-Piz). Recitation of each of these discrete values is understood to include ranges between each value. Recitation of each of a range is understood to include discrete values within the range.

Hydroxylase, Cyclase, and Dehydratase

A microorganism (e.g., the bacteria, Streptomyces lividans) can be transformed so as to have hydroxylase, cyclase, or dehydratase activity (e.g., L-Ornithine N⁵-hydroxylase, L-Ornithine cyclase, L-Ornithine dehydratase activity).

Hydroxylase (e.g., L-Ornithine N⁵-hydroxylase) activity can be engineered into a microorganism by way of one or more individual genes encoding a polypeptide having hydroxylase (e.g., L-Ornithine N⁵-hydroxylase) activity. It is contemplated these activities can likewise be engineered in other microorganisms.

Cyclase (e.g., L-Ornithine N⁵-cyclase) activity or dehydratase (e.g., L-Ornithine N⁵-dehydratase) activity can be engineered into a microorganism by way of one or more of the individual genes. For example, cyclase (e.g., L-Ornithine N⁵-cyclase) activity or dehydratase (e.g., L-Ornithine N⁵-dehydratase) activity can be engineered into a microorganism by way of one or more genes encoding a polypeptide having cyclase (e.g., L-Ornithine N⁵-cyclase) activity or encoding a polypeptide having dehydratase (e.g., L-Ornithine N⁵-dehydratase) activity; or by one gene encoding both cyclase (e.g., L-Ornithine N⁵-cyclase) and dehydratase (e.g., L-Ornithine N⁵-dehydratase). For example, L-Ornithine N⁵-cyclase activity and L-Ornithine N⁵-dehydratase activity can be present in a polypeptide or a fusion polypeptide. It is contemplated these activities can likewise be engineered in other microorganisms.

The Piz (e.g., L-Piz) can be endogenous or exogenous to the microorganism. Where the Piz is endogenous, the microorganism can be engineered to produce increased levels of Piz. Where Piz is exogenous, the microorganism can be engineered to produce such exogenous Piz.

The microorganism can be engineered to synthesize and accumulate the desired Piz continuously, after some developmental state, or upon being induced to do so. Induction of Piz synthesis can be according to the actions of an inducible promoter associated with the encoded hydroxylase, cyclase, or dehydratase and an inducing agent, as discussed in further detail herein. Also, the promoters as recited herein are only as examples of useful promoters. It is contemplated to adjust copy number (e.g., plasmid as self replicating high copy, low copy, or chromosomally insertional), in conjunction with promoters driving high, medium, or low expression of pzbA and pzbB combinations.

Radiolabeled

One embodiment of the present disclosure provides for a radiolabeled compound. The composition can be Piz, a Piz derivative, or a Piz-containing compound. According to another embodiment, the radiolabeled compound can be for use as a drug discovery agent or an imaging agent.

References herein to “radiolabeled” include a compound where one or more atoms are replaced or substituted by an atom having an atomic mass or mass number different from the atomic mass or mass number typically found in nature (i.e., naturally occurring). One non-limiting exception is ¹⁹F, which allows detection of a molecule which contains this element without enrichment to a higher degree than what is naturally occurring. Compounds carrying the substituent ¹⁹F may thus also be referred to as “labelled” or the like. The term radiolabeled may be interchangeably used with “isotopically-labelled”, “labelled”, “isotopic tracer group”, “isotopic marker”, “isotopic label”, “detectable isotope”, or “radioligand”.

In one embodiment, the compound comprises a single radiolabeled group.

Examples of suitable, non-limiting radiolabel groups can include: ²H (D or deuterium), ³H (T or tritium), ¹¹C, ¹³C, ¹⁴C ¹³N, ¹⁵N, ¹⁵O, ¹⁷O, ¹⁸O, ¹⁸F, ³⁵S, ³⁶Cl, ⁸²Br, ⁷⁵Br, ⁷⁶Br, ⁷⁷Br, ¹²³I, ¹²⁴I, ¹²⁵I, or ¹³¹I. It is to be understood that an isotopically labeled compound needs only to be enriched with a detectable isotope to, or above, the degree which allows detection with a technique suitable for the particular application, e.g., in a detectable compound labeled with ¹¹C, the carbon-atom of the labeled group of the labeled compound may be constituted by ¹²C or other carbon-isotopes in a fraction of the molecules. The radionuclide that is incorporated in the radiolabeled compounds will depend on the specific application of that radiolabeled compound. For example, “heavy” isotope-labeled compounds (e.g., compounds containing deuterons/heavy hydrogen, heavy nitrogen, heavy oxygen, heavy carbon) can be useful for mass spectrometric and NMR based studies. As another example, for in vitro labelling or in competition assays, compounds that incorporate ³H, ¹⁴C, or ¹²⁵I can be useful. For in vivo imaging applications ¹¹C, ¹³C, ¹⁸F, ¹⁹F, ¹²⁰I, ¹²³I, ¹³¹I, ⁷⁵Br, or ⁷⁶Br can generally be useful. In one embodiment, the radiolabel is ¹¹C. In an alternative embodiment, the radiolabel is ¹⁴C. In a yet further alternative embodiment, the radiolabel is ¹³C.

Molecular Engineering

A gene of particular interest for engineering a microorganism to accumulate Piz or Piz derivative is the active pzbB gene from Streptomyces flaveolus (see e.g., Example 3). Another gene of interest for engineering a microorganism to accumulate Piz is the active pzbA gene. As shown herein, pzbA is natively encoded on the S. lividans chromosome. But pzbA or pzbB can be expressed in another host that does not natively express the pzbA or pzbB gene or the host can be engineered to carry more than one copy of the a non-natively expressed pzbA or pzbB gene.

In some embodiments, an pzbA- or pzbB-encoding nucleotide sequence is cloned from its native source (e.g., Streptomyces flaveolus, S. lividans) and inserted into a host microorganism (see e.g., Example 3). In some embodiments, a transformed host microorganism comprises a pzbA or pzbB polynucleotide of SEQ ID NO: 177-SEQ ID NO: 178 (pzbA) or SEQ ID NO: 179-SEQ ID NO: 181 (pzbB). In some embodiments, a microorganism is transformed with a nucleotide sequence encoding pzbA or pzbB polypeptide of SEQ ID NO: 1-SEQ ID NO: 81 or SEQ ID NO: 82-SEQ ID NO: 166. In some embodiments, a transformed host microorganism comprises a pzbA and pzbB polynucleotides of SEQ ID NO: 167-SEQ ID NO: 176.

In some embodiments, a transformed host microorganism comprises a nucleotide sequence having at least about 25% sequence identity to SEQ ID NO: 177-SEQ ID NO: 178 or a nucleotide sequence encoding a polypeptide having L-Ornithine N⁵ hydroxylase activity and at least about 80% sequence identity to SEQ ID NO: 1-SEQ ID NO: 81. As an example, a transformed host microorganism, such as a bacterium, can comprise a nucleotide sequence having at least about 85%, at least about 90%, at least about 95%, or at least about 99% sequence identity to SEQ ID NO: 177-SEQ ID NO: 178, wherein the transformed host exhibits L-Ornithine N⁵ hydroxylase activity, pzbA activity, and/or accumulation of Piz. As an example, a transformed host microorganism can comprise a nucleotide sequence encoding a polypeptide having at least about 85%, at least about 90%, at least about 95%, or at least about 99% sequence identity to SEQ ID NO: 1-SEQ ID NO: 81, wherein the transformed host exhibits L-Ornithine N⁵ hydroxylase activity, pzbA activity and/or accumulation of Piz. As another example, a transformed host microorganism can comprise a nucleotide sequence that hybridizes under stringent conditions to SEQ ID NO: 177-SEQ ID NO: 178 over the entire length of SEQ ID NO: 177-SEQ ID NO: 178, and which encodes an active pzbA polypeptide. As a further example, a transformed host microorganism can comprise the complement to any of the above sequences.

In some embodiments, a transformed host microorganism comprises a nucleotide sequence having at least about 80% sequence identity to SEQ ID NO: 179-SEQ ID NO: 181 or a nucleotide sequence encoding a polypeptide having L-Ornithine N⁵ cyclase activity or L-Ornithine N⁵ dehydratase activity and at least about 80% sequence identity to SEQ ID NO: 82-SEQ ID NO: 166. As an example, a transformed host microorganism, such as a bacterium, can comprise a nucleotide sequence having at least about 85%, at least about 90%, at least about 95%, or at least about 99% sequence identity to SEQ ID NO: 179-SEQ ID NO: 181, wherein the transformed host exhibits L-Ornithine N⁵ cyclase activity or L-Ornithine N⁵ dehydratase activity, or pzbB activity and/or accumulation of Piz. As an example, a transformed host microorganism can comprise a nucleotide sequence encoding a polypeptide having at least about 85%, at least about 90%, at least about 95%, or at least about 99% sequence identity to SEQ ID NO: 82-SEQ ID NO: 166, wherein the transformed host exhibits L-Ornithine N⁵ cyclase activity or L-Ornithine N⁵ dehydratase activity, or pzbB activity and/or accumulation of Piz. As another example, a transformed host microorganism can comprise a nucleotide sequence that hybridizes under stringent conditions to SEQ ID NO: 179-SEQ ID NO: 181 over the entire length of SEQ ID NO: 179-SEQ ID NO: 181, and which encodes an active pzbB polypeptide. As a further example, a transformed host microorganism can comprise the complement to any of the above sequences.

In some embodiments, L-Ornithine N⁵ hydroxylase (see e.g., SEQ ID NO: 177-SEQ ID NO: 178 encoding pzbA gene and SEQ ID NO: 1-SEQ ID NO: 81 encoding pzbA polypeptide), or homologue thereof, is engineered to be expressed or overexpressed in a transformed microorganism. For example, a microorganism can be transformed with a nucleotide having a sequence of 1SEQ ID NO: 177-SEQ ID NO: 178 so as to express L-Ornithine N⁵ hydroxylase. As another example, a microorganism can be transformed with a nucleotide having at least about 80%, at least about 85%, at least about 90%, at least about 95%, or at least about 99% percent identity to SEQ ID NO: 177-SEQ ID NO: 178 encoding a polypeptide having L-Ornithine N⁵ hydroxylase activity. As another example, a transformed host microorganism can comprise a nucleotide sequence encoding a polypeptide having at least about 85%, at least about 90%, at least about 95%, or at least about 99% sequence identity to SEQ ID NO: 1-SEQ ID NO: 81, wherein the transformed host exhibits L-Ornithine N⁵ hydroxylase activity, pzbA activity, and/or accumulation of Piz.

In some embodiments, L-Ornithine N⁵ cyclase or L-Ornithine N⁵ dehydratase (see e.g., SEQ ID NO: 179-SEQ ID NO: 181 encoding pzbB gene and SEQ ID NO: 82-SEQ ID NO: 166 encoding pzbB polypeptide), or homologue thereof, is engineered to be expressed or overexpressed in a transformed microorganism. For example, a microorganism can be transformed with a nucleotide having a sequence of SEQ ID NO: 179-SEQ ID NO: 181 so as to express L-Ornithine N⁵ cyclase or L-Ornithine N⁵ dehydratase. As another example, a microorganism can be transformed with a nucleotide having at least about 80%, at least about 85%, at least about 90%, at least about 95%, or at least about 99% percent identity to SEQ ID NO: 179-SEQ ID NO: 181 encoding a polypeptide having L-Ornithine N⁵ hydroxylase activity. As another example, a transformed host microorganism can comprise a nucleotide sequence encoding a polypeptide having at least about 85%, at least about 90%, at least about 95%, or at least about 99% sequence identity to SEQ ID NO: 82-SEQ ID NO: 166, wherein the transformed host exhibits L-Ornithine N⁵ cyclase activity, L-Ornithine N⁵ dehydratase activity, pzbB activity, and/or accumulation of Piz.

In some embodiments, a microorganism (e.g., a bacterium) is engineered to express one or more of pzbA, pzbB, L-Ornithine N⁵ hydroxylase, L-Ornithine N⁵ cyclase, or L-Ornithine N⁵ dehydratase.

Design, generation, and testing of the variant nucleotides, and their encoded polypeptides, having the above required percent identities to an pzbA or pzbB sequence and retaining a required activity of the expressed protein and/or Piz accumulation phenotype is within the skill of the art.

The following definitions and methods are provided to better define the present invention and to guide those of ordinary skill in the art in the practice of the present invention. Unless otherwise noted, terms are to be understood according to conventional usage by those of ordinary skill in the relevant art.

The terms “heterologous DNA sequence”, “exogenous DNA segment” or “heterologous nucleic acid,” as used herein, each refer to a sequence that originates from a source foreign to the particular host cell or, if from the same source, is modified from its original form. Thus, a heterologous gene in a host cell includes a gene that is endogenous to the particular host cell but has been modified through, for example, the use of DNA shuffling. The terms also include non-naturally occurring multiple copies of a naturally occurring DNA sequence. Thus, the terms refer to a DNA segment that is foreign or heterologous to the cell, or homologous to the cell but in a position within the host cell nucleic acid in which the element is not ordinarily found. Exogenous DNA segments are expressed to yield exogenous polypeptides. A “homologous” DNA sequence is a DNA sequence that is naturally associated with a host cell into which it is introduced.

Expression vector, expression construct, plasmid, or recombinant DNA construct is generally understood to refer to a nucleic acid that has been generated via human intervention, including by recombinant means or direct chemical synthesis, with a series of specified nucleic acid elements that permit transcription or translation of a particular nucleic acid in, for example, a host cell. The expression vector can be part of a plasmid, virus, or nucleic acid fragment. Typically, the expression vector can include a nucleic acid to be transcribed operably linked to a promoter.

A “promoter” is generally understood as a nucleic acid control sequence that directs transcription of a nucleic acid. An inducible promoter is generally understood as a promoter that mediates transcription of an operably linked gene in response to a particular stimulus. In some embodiments, the promoter is iducible by an agent selected from the group consisting of temperature, pH, a metabolite, light, an osmotic agent, a heavy metal, and an antibiotic. In some embodiments, the promoter is selected from the group consisting of a constitutive promoter to produce L-Piz.

A promoter can include necessary nucleic acid sequences near the start site of transcription, such as, in the case of a polymerase II type promoter, a TATA element. A promoter can optionally include distal enhancer or repressor elements, which can be located as much as several thousand base pairs from the start site of transcription.

A “transcribable nucleic acid molecule” as used herein refers to any nucleic acid molecule capable of being transcribed into a RNA molecule. Methods are known for introducing constructs into a cell in such a manner that the transcribable nucleic acid molecule is transcribed into a functional mRNA molecule that is translated and therefore expressed as a protein product. Constructs may also be constructed to be capable of expressing antisense RNA molecules, in order to inhibit translation of a specific RNA molecule of interest. For the practice of the present disclosure, conventional compositions and methods for preparing and using constructs and host cells are well known to one skilled in the art (see e.g., Sambrook and Russel (2006) Condensed Protocols from Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory Press, ISBN-10: 0879697717; Ausubel et al. (2002) Short Protocols in Molecular Biology, 5th ed., Current Protocols, ISBN-10: 0471250929; Sambrook and Russel (2001) Molecular Cloning: A Laboratory Manual, 3d ed., Cold Spring Harbor Laboratory Press, ISBN-10: 0879695773; Elhai, J. and Wolk, C. P. 1988. Methods in Enzymology 167, 747-754).

The “transcription start site” or “initiation site” is the position surrounding the first nucleotide that is part of the transcribed sequence, which is also defined as position +1. With respect to this site all other sequences of the gene and its controlling regions can be numbered. Downstream sequences (i.e., further protein encoding sequences in the 3′ direction) can be denominated positive, while upstream sequences (mostly of the controlling regions in the 5′ direction) are denominated negative.

“Operably-linked” or “functionally linked” refers preferably to the association of nucleic acid sequences on a single nucleic acid fragment so that the function of one is affected by the other. For example, a regulatory DNA sequence is said to be “operably linked to” or “associated with” a DNA sequence that codes for an RNA or a polypeptide if the two sequences are situated such that the regulatory DNA sequence affects expression of the coding DNA sequence (i.e., that the coding sequence or functional RNA is under the transcriptional control of the promoter). Coding sequences can be operably-linked to regulatory sequences in sense or antisense orientation. The two nucleic acid molecules may be part of a single contiguous nucleic acid molecule and may be adjacent. For example, a promoter is operably linked to a gene of interest if the promoter regulates or mediates transcription of the gene of interest in a cell.

A “construct” is generally understood as any recombinant nucleic acid molecule such as a plasmid, cosmid, virus, autonomously replicating nucleic acid molecule, phage, or linear or circular single-stranded or double-stranded DNA or RNA nucleic acid molecule, derived from any source, capable of genomic integration or autonomous replication, comprising a nucleic acid molecule where one or more nucleic acid molecule has been operably linked.

A constructs of the present disclosure can contain a promoter operably linked to a transcribable nucleic acid molecule operably linked to a 3′ transcription termination nucleic acid molecule. In addition, constructs can include but are not limited to additional regulatory nucleic acid molecules from, e.g., the 3′-untranslated region (3′ UTR). Constructs can include but are not limited to the 5′ untranslated regions (5′ UTR) of an mRNA nucleic acid molecule which can play an important role in translation initiation and can also be a genetic component in an expression construct. These additional upstream and downstream regulatory nucleic acid molecules may be derived from a source that is native or heterologous with respect to the other elements present on the promoter construct.

The term “transformation” refers to the transfer of a nucleic acid fragment into the genome of a host cell, resulting in genetically stable inheritance. Host cells containing the transformed nucleic acid fragments are referred to as “transgenic” cells, and organisms comprising transgenic cells are referred to as “transgenic organisms”.

“Transformed,” “transgenic,” and “recombinant” refer to a host cell or organism such as a bacterium, cyanobacterium, animal or a plant into which a heterologous nucleic acid molecule has been introduced. The nucleic acid molecule can be stably integrated into the genome as generally known in the art and disclosed (Sambrook 1989; Innis 1995; Gelfand 1995; Innis & Gelfand 1999). Known methods of PCR include, but are not limited to, methods using paired primers, nested primers, single specific primers, degenerate primers, gene-specific primers, vector-specific primers, partially mismatched primers, and the like. The term “untransformed” refers to normal cells that have not been through the transformation process.

“Wild-type” refers to a virus or organism found in nature without any known mutation.

Design, generation, and testing of the variant nucleotides, and their encoded polypeptides, having the above required percent identities and retaining a required activity of the expressed protein is within the skill of the art. For example, directed evolution and rapid isolation of mutants can be according to methods described in references including, but not limited to, Link et al. (2007) Nature Reviews 5(9), 680-688; Sanger et al. (1991) Gene 97(1), 119-123; Ghadessy et al. (2001) Proc Natl Acad Sci USA 98(8) 4552-4557. Thus, one skilled in the art could generate a large number of nucleotide (e.g. pzbA, pzbB) and/or polypeptide (e.g., pzbA, pzbB) variants having, for example, at least 95%-99% identity to the reference sequence described herein and screen such for desired phenotypes according to methods routine in the art.

Nucleotide and/or amino acid sequence identity percent (%) is understood as the percentage of nucleotide or amino acid residues that are identical with nucleotide or amino acid residues in a candidate sequence in comparison to a reference sequence when the two sequences are aligned. To determine percent identity, sequences are aligned and if necessary, gaps are introduced to achieve the maximum percent sequence identity. Sequence alignment procedures to determine percent identity are well known to those of skill in the art. Often publicly available computer software such as BLAST, BLAST2, ALIGN2 or Megalign (DNASTAR) software is used to align sequences. Those skilled in the art can determine appropriate parameters for measuring alignment, including any algorithms needed to achieve maximal alignment over the full-length of the sequences being compared. When sequences are aligned, the percent sequence identity of a given sequence A to, with, or against a given sequence B (which can alternatively be phrased as a given sequence A that has or comprises a certain percent sequence identity to, with, or against a given sequence B) can be calculated as: percent sequence identity=X/Y100, where X is the number of residues scored as identical matches by the sequence alignment program's or algorithm's alignment of A and B and Y is the total number of residues in B. If the length of sequence A is not equal to the length of sequence B, the percent sequence identity of A to B will not equal the percent sequence identity of B to A.

Generally, conservative substitutions can be made at any position so long as the required activity is retained. So-called conservative exchanges can be carried out in which the amino acid which is replaced has a similar property as the original amino acid, for example the exchange of Glu by Asp, Gin by Asn, Val by lie, Leu by lie, and Ser by Thr. For example, amino acids with similar properties can be Aliphatic amino acids (e.g., Glycine, Alanine, Valine, Leucine, Isoleucine); Hydroxyl or sulfur/selenium-containing amino acids (e.g., Serine, Cysteine, Selenocysteine, Threonine, Methionine); Cyclic amino acids (e.g., Proline); Aromatic amino acids (e.g., Phenylalanine, Tyrosine, Tryptophan); Basic amino acids (e.g., Histidine, Lysine, Arginine); or Acidic and their Amide (e.g., Aspartate, Glutamate, Asparagine, Glutamine). Deletion is the replacement of an amino acid by a direct bond. Positions for deletions include the termini of a polypeptide and linkages between individual protein domains. Insertions are introductions of amino acids into the polypeptide chain, a direct bond formally being replaced by one or more amino acids. Amino acid sequence can be modulated with the help of art-known computer simulation programs that can produce a polypeptide with, for example, improved activity or altered regulation. On the basis of this artificially generated polypeptide sequences, a corresponding nucleic acid molecule coding for such a modulated polypeptide can be synthesized in-vitro using the specific codon-usage of the desired host cell.

“Highly stringent hybridization conditions” are defined as hybridization at 65° C. in a 6×SSC buffer (i.e., 0.9 M sodium chloride and 0.09 M sodium citrate). Given these conditions, a determination can be made as to whether a given set of sequences will hybridize by calculating the melting temperature (T_(m)) of a DNA duplex between the two sequences. If a particular duplex has a melting temperature lower than 65° C. in the salt conditions of a 6×SSC, then the two sequences will not hybridize. On the other hand, if the melting temperature is above 65° C. in the same salt conditions, then the sequences will hybridize. In general, the melting temperature for any hybridized DNA:DNA sequence can be determined using the following formula: T_(m)=81.5° C.+16.6(log₁₀[Na⁺])+0.41 (fraction G/C content)−0.63(% formamide)−(600/l). Furthermore, the T_(m) of a DNA:DNA hybrid is decreased by 1-1.5° C. for every 1% decrease in nucleotide identity (see e.g., Sambrook and Russel, 2006).

Host cells can be transformed using a variety of standard techniques known to the art (see, e.g., Sambrook and Russel (2006) Condensed Protocols from Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory Press, ISBN-10: 0879697717; Ausubel et al. (2002) Short Protocols in Molecular Biology, 5th ed., Current Protocols, ISBN-10: 0471250929; Sambrook and Russel (2001) Molecular Cloning: A Laboratory Manual, 3d ed., Cold Spring Harbor Laboratory Press, ISBN-10: 0879695773; Elhai, J. and Wolk, C. P. 1988. Methods in Enzymology 167, 747-754). Such techniques include, but are not limited to, viral infection, calcium phosphate transfection, liposome-mediated transfection, microprojectile-mediated delivery, receptor-mediated uptake, cell fusion, electroporation, and the like. The transfected cells can be selected and propagated to provide recombinant host cells that comprise the expression vector stably integrated in the host cell genome.

Exemplary nucleic acids which may be introduced to a host cell include, for example, DNA sequences or genes from another species, or even genes or sequences which originate with or are present in the same species, but are incorporated into recipient cells by genetic engineering methods. The term “exogenous” is also intended to refer to genes that are not normally present in the cell being transformed, or perhaps simply not present in the form, structure, etc., as found in the transforming DNA segment or gene, or genes which are normally present and that one desires to express in a manner that differs from the natural expression pattern, e.g., to over-express. Thus, the term “exogenous” gene or DNA is intended to refer to any gene or DNA segment that is introduced into a recipient cell, regardless of whether a similar gene may already be present in such a cell. The type of DNA included in the exogenous DNA can include DNA which is already present in the cell, DNA from another individual of the same type of organism, DNA from a different organism, or a DNA generated externally, such as a DNA sequence containing an antisense message of a gene, or a DNA sequence encoding a synthetic or modified version of a gene.

Host strains developed according to the approaches described herein can be evaluated by a number of means known in the art (see e.g., Studier (2005) Protein Expr Purif. 41(1), 207-234; Gellissen, ed. (2005) Production of Recombinant Proteins: Novel Microbial and Eukaryotic Expression Systems, Wiley-VCH, ISBN-10: 3527310363; Baneyx (2004) Protein Expression Technologies, Taylor & Francis, ISBN-10: 0954523253).

Methods of down-regulation or silencing genes are known in the art. For example, expressed protein activity can be down-regulated or eliminated using antisense oligonucleotides, protein aptamers, nucleotide aptamers, and RNA interference (RNAi) (e.g., small interfering RNAs (siRNA), short hairpin RNA (shRNA), and micro RNAs (miRNA) (see e.g., Fanning and Symonds (2006) Handb Exp Pharmacol. 173, 289-303G, describing hammerhead ribozymes and small hairpin RNA; Helene, C., et al. (1992) Ann. N.Y. Acad. Sci. 660, 27-36; Maher (1992) Bioassays 14(12): 807-15, describing targeting deoxyribonucleotide sequences; Lee et al. (2006) Curr Opin Chem Biol. 10, 1-8, describing aptamers; Reynolds et al. (2004) Nature Biotechnology 22(3), 326-330, describing RNAi; Pushparaj and Melendez (2006) Clinical and Experimental Pharmacology and Physiology 33(5-6), 504-510, describing RNAi; Dillon et al. (2005) Annual Review of Physiology 67, 147-173, describing RNAi; Dykxhoorn and Lieberman (2005) Annual Review of Medicine 56, 401-423, describing RNAi). RNAi molecules are commercially available from a variety of sources (e.g., Ambion, Tex.; Sigma Aldrich, Mo.; Invitrogen). Several siRNA molecule design programs using a variety of algorithms are known to the art (see e.g., Cenix algorithm, Ambion; BLOCK-iT™ RNAi Designer, Invitrogen; siRNA Whitehead Institute Design Tools, Bioinofrmatics & Research Computing). Traits influential in defining optimal siRNA sequences include G/C content at the termini of the siRNAs, Tm of specific internal domains of the siRNA, siRNA length, position of the target sequence within the CDS (coding region), and nucleotide content of the 3′ overhangs.

Definitions and methods described herein are provided to better define the present disclosure and to guide those of ordinary skill in the art in the practice of the present disclosure. Unless otherwise noted, terms are to be understood according to conventional usage by those of ordinary skill in the relevant art.

In some embodiments, numbers expressing quantities of ingredients, properties such as molecular weight, reaction conditions, and so forth, used to describe and claim certain embodiments of the present disclosure are to be understood as being modified in some instances by the term “about.” In some embodiments, the term “about” is used to indicate that a value includes the standard deviation of the mean for the device or method being employed to determine the value. In some embodiments, the numerical parameters set forth in the written description and attached claims are approximations that can vary depending upon the desired properties sought to be obtained by a particular embodiment. In some embodiments, the numerical parameters should be construed in light of the number of reported significant digits and by applying ordinary rounding techniques. Notwithstanding that the numerical ranges and parameters setting forth the broad scope of some embodiments of the present disclosure are approximations, the numerical values set forth in the specific examples are reported as precisely as practicable. The numerical values presented in some embodiments of the present disclosure may contain certain errors necessarily resulting from the standard deviation found in their respective testing measurements. The recitation of ranges of values herein is merely intended to serve as a shorthand method of referring individually to each separate value falling within the range. Unless otherwise indicated herein, each individual value is incorporated into the specification as if it were individually recited herein.

In some embodiments, the terms “a” and “an” and “the” and similar references used in the context of describing a particular embodiment (especially in the context of certain of the following claims) can be construed to cover both the singular and the plural, unless specifically noted otherwise. In some embodiments, the term “or” as used herein, including the claims, is used to mean “and/or” unless explicitly indicated to refer to alternatives only or the alternatives are mutually exclusive.

The terms “comprise,” “have” and “include” are open-ended linking verbs. Any forms or tenses of one or more of these verbs, such as “comprises,” “comprising,” “has,” “having,” “includes” and “including,” are also open-ended. For example, any method that “comprises,” “has” or “includes” one or more steps is not limited to possessing only those one or more steps and can also cover other unlisted steps. Similarly, any composition or device that “comprises,” “has” or “includes” one or more features is not limited to possessing only those one or more features and can cover other unlisted features.

All methods described herein can be performed in any suitable order unless otherwise indicated herein or otherwise clearly contradicted by context. The use of any and all examples, or exemplary language (e.g. “such as”) provided with respect to certain embodiments herein is intended merely to better illuminate the present disclosure and does not pose a limitation on the scope of the present disclosure otherwise claimed. No language in the specification should be construed as indicating any non-claimed element essential to the practice of the present disclosure.

Groupings of alternative elements or embodiments of the present disclosure disclosed herein are not to be construed as limitations. Each group member can be referred to and claimed individually or in any combination with other members of the group or other elements found herein. One or more members of a group can be included in, or deleted from, a group for reasons of convenience or patentability. When any such inclusion or deletion occurs, the specification is herein deemed to contain the group as modified thus fulfilling the written description of all Markush groups used in the appended claims.

Citation of a reference herein shall not be construed as an admission that such is prior art to the present disclosure.

Having described the present disclosure in detail, it will be apparent that modifications, variations, and equivalent embodiments are possible without departing the scope of the present disclosure defined in the appended claims. Furthermore, it should be appreciated that all examples in the present disclosure are provided as non-limiting examples.

EXAMPLES

The following non-limiting examples are provided to further illustrate the present disclosure. It should be appreciated by those of skill in the art that the techniques disclosed in the examples that follow represent approaches the inventors have found function well in the practice of the present disclosure, and thus can be considered to constitute examples of modes for its practice. However, those of skill in the art should, in light of the present disclosure, appreciate that many changes can be made in the specific embodiments that are disclosed and still obtain a like or similar result without departing from the spirit and scope of the present disclosure.

Example 1: Discovery of the Complete Biosynthetic Pathway to L-Piz from the Central Metabolite L-Orn

The following example describes the discovery of the complete biosynthetic pathway to L-Piz from the central metabolite, L-Orn.

Select examples of piperazic acid (Piz) family of natural products are shown in FIG. 2. Piz and modified Piz (e.g., dehydropiperazic, chloropiperazic, hydroxypiperazic acid) molecular components are shown in red in FIG. 2. All of these molecules are bioactive, with sanglifehrin (top left of FIG. 2) under consideration as an immunosuppressant and Hepatitis-C antiviral. The small molecule in the center of FIG. 2 (Sch 382583) is a member of an emerging group of Piz containing metalloprotease inhibitors with clinical relevance as metastatic cancer and antibacterial antibiotic leads. All of these molecules are exclusively produced by actinobacteria.

Orthologs of both PzbA (yellow) and PzbB (red) were found within biosynthetic gene clusters for known Piz-containing antibiotics (see e.g., FIG. 2). As these clusters encode molecules that are structurally dissimilar except for the incorporation of Piz, parsimony suggests both pzbA (previously known) and pzbB (previously unrecognized) are involved in Piz biosynthesis.

In vitro reconstitution of L-Piz production from L-Orn in a coupled enzymatic reaction containing purified PzbA, PzbB, buffer salts, NADPH cofactor, Fe⁺² salts, and catalytic FAD (Flavin Adenine Dinucleotide) cofactor according to Scheme 2.

FIG. 2 shows the HPLC-ESI-MS detection of products and substrates with assay time points at time 0 min, 15 min, and 30 min showing the consumption of L-Orn, accumulation of the known intermediate N⁵—OH-Orn, and the concomitant formation of Piz. Data (not shown) in the same assay lacking PzbB, the enzyme product is N⁵—OH-Orn and no Piz is formed.

Example 2: Green Biocatalysis of L-Piz In Vitro

L-Piz can be synthesized chemically, but to date a fermentative pathway to the amino acid has eluded researchers. Enantiopure synthetic L-Piz is expensive: ($2800/gram, 95% pure). DL-Piz synthesized as a mix of isomers, which is significantly less chemically desirable, is less expensive ($800/gram, 95% pure), but still of significant cost. Using a coupled enzyme assay containing a suitable L-Ornithine N⁵—OHase (PzbA), and a suitable PzbB (L-N⁵—OH Orn cyclase/dehydratase), enantiopure (as currently understood) L-Piz can be made from the inexpensive feedstock enantiopure L-Ornithine ($1.40/gram, >99% pure, Sigma-Aldrich), buffer salts, NADPH cofactor, Fe⁺² salts, and catalytic FAD (Flavin Adenine Dinucleotide) cofactor (see e.g., FIG. 3).

Example 3: An Enzymatic Route to Heavy Isotope-Labelled Piz

Heavy isotope-labeled compounds (e.g., compounds containing deuterons/heavy hydrogen, heavy nitrogen, heavy oxygen, heavy carbon) are valuable tools for mass spectrometric and NMR based studies. Currently, no vendors, custom or otherwise, that offer L-Piz having any combination of these isotopes. Using d₇-L-Orn, the feasible production of d₇ L-Piz using the reaction described in Example 2 above has been demonstrated. In principle, any heavy isotope labeled L-Orn could yield similarly labeled L-Piz. Coupled PzbA/PzbB enzymatic reactions could be scaled to produce and market variously heavy isotopically labeled or radioisotopically labeled versions of L-Piz, for which there are current no known synthetic paths.

Example 4: Green Biocatalysis of L-Piz In Vivo

This example shows a greener production of L-Piz (no organic solvents and fewer reagents than conventional methods).

Micro-organisms such as bacteria and fungi are preferred producers of amino acids in the biotechnology industry. This is because the cellular enzyme catalysts of life are typically stereospecific, giving enantiopure products. Enantiopurity can be more difficult to achieve in synthetic chemistry. Also, inexpensive feedstocks are provided for growth, significantly reducing the cost of amino acid production in contrast to fine chemical starting points often required for synthetic chemistry. Here, L-Piz fermentation in a heterologous, genetically engineered host (Streptomyces lividans) grown on standard lab media, and with no investment in yield optimization (see e.g., FIG. 4) has been demonstrated.

S. lividans (WT parent, no Piz production) is compared against S. lividans harboring a single copy of pzbA (sfaB) alone, pzbB (sfaC) alone, or co-expressing pzbA and pzbB (sfaBC) cloned from the sanglifehrin biosynthetic locus of Streptomyces flaveolus in FIG. 4. LC/MS detection of biosynthetic Piz was compared against an authentic L-Piz standard (top row, FIG. 4). In contrast with the in vitro data in FIG. 4, pzbA is dispensable in the heterologous system because S. lividans encodes a native copy of the gene as part of a siderophore biosynthetic pathway unrelated to Piz production. Thus, pzbA remains required for Piz production, but its role in bacteria is not limited to Piz anabolism. In contrast, to our knowledge, pzbB is only found associated with Piz production.

Using a mass-spectrometric (MS/MS) method for sensitive quantification, it was estimated that S. lividans is carrying at minimum a single copy of a suitable pzbB gene (one or more native pzbA's are natively encoded on the S. lividans chromosome, and therefore is not absolutely required for heterologous expression) under a constitutive promoter to produce micromolar L-Piz. Measurably higher (˜1 mM) L-Piz titers can be achieved using a heterologous S. lividans producer carrying one or more copies of a non-native pzbA in conjunction with heterologous pzbB. S. lividans serves as a proof of concept host, not necessarily an industrial endpoint. Much higher L-Piz production can likely be achieved by expressing suitable pzbA and pzbB genes in a heterologous host that overproduces the critical feedstock L-Ornithine. One such candidate host is the actinobacterial industrial producer of L-Orn, Corynebacterium glutamicum (20.8-51.5 grams/liter). Importantly, at least one such industrial L-Orn producing strain is publicly available through the American Type Culture Collection (ATCC), making strain engineering from a high producer feasible.

L-Piz Fermentation Production Rate.

The following describes the rate of fermented L-Piz in heterologous hosts (Streptomyces lividans), plated in 1 L. S. lividans makes at least 1 mg/L plates in 3 days. This translates to ˜14 μg/L per hour or 0.2 μg/L per minute.

Example 5: Directed Discovery of Drugs and Drug-Like Compounds Using Heavy Isotope L-Piz

This example shows how newfound ability to recognize biosynthetic genes encoding Piz-derived small molecules (e.g., isotopically labeled Piz compound) can facilitate genomic discovery of new natural products that can be used as drug leads.

Current technologies can only enable a rough estimate what the final chemical structures encoded by these biosynthetic genes are. To link biosynthetic genes to the compounds they produce, especially in the case of L-Piz containing compounds, supplying d₇-L-Orn to microorganisms of interest can link the biosynthetic compounds to the produced compounds. Some percentage of this labeled compound is expected to become d₇ L-Piz in cellulo, and consequently become incorporated into the natural products that will be discovered.

Differential mass spectrometry allows for the detection of the labeled compounds in a much more specific way than absence of such a technology. However, L-Orn can be incorporated into many natural compounds, confusing the analyses. Isotopically labeled L-Piz would be a much more useful molecular probe for the specific and directed discovery of L-Piz-containing drug leads compared to labeled L-Orn for the reasons above.

Data indicating L-Piz successfully penetrates at least one Piz-compound producing actinomycete was obtained, followed by subsequent incorporation into a Piz drug-like compound sanglifehrin (see e.g., FIG. 5). FIG. 5 shows LC/MS detection of sanglifehrin, a Piz-containing compound produced by Streptomyces flaveolus. Four major isobaric isomers of sanglifehrin A detected in WT S. flaveolus fermentation extracts. As expected from the results in FIG. 5, an unmarked gene deletion of pzbB (sfaC) from S. flaveolus abrogates sanglifehrin production. Genetic complementation of this mutant with an additional copy of pzbB, or exogenously supplied 50 μM authentic L-Piz (top, FIG. 5), restore the production of the four sanglifehrin A isobars. L-Piz is therefore cell penetrant and qualitatively nontoxic. These data (see e.g., FIG. 5) additionally link pzbB function with Piz production in vivo, which agrees with the in vitro assay data.

Thus, it is expected that isotopically labeled L-Piz will penetrate cells and label Piz compounds without significant complications from poor cell penetrance, transport, or toxicity.

Example 6: Characterization of L-Piperazic Acid Sterochemistry

The following example describes the characterization of the synthesized piperazic acid compound. It was shown that the product is an L-Piz and is enantiomerically pure.

FIG. 6 shows the Marfey's derivatization analysis of the product of PzbB in an assay with L-N5 hydroxy Ornithine substrate (the product of PzbA). This conclusively shows the product of PzbB has the same stereochemistry (L) and mass as the same derivative produced using L-Piz authentic standard (see e.g., FIG. 6).

Example 7: PzbB Ortholog Identity with PzbB Activity

The following example shows that a PzbB ortholog can have as little as around 25% sequence identity to another PzbB ortholog and still produce L-Piz or retain PzbB activity.

Bioinformatic data showed PzbB orthologs that can be used to produce L-Piz have an estimated protein identity (functional cutoff) to be around 25% (some predicted PzbB orthologs have identity scores in the 30% range and most have 45% or above.

Example 8: SfaBC (Co-Expressing pzbA and pzbB) Combined Ornithine In Vitro Assay Method

100 μL of reaction in 50 mM Tris.HCl at pH 8.0 was set up with L-orn (500 μM), FAD (50 μM), His₆-SfaB (10 μM), SfaC-His₆ (135 μM), NADPH (2 mM), and FeSO₄ (10 mM). 30 μL aliquots were removed at 0 min, 15 min, and 30 min, and combined with 30 μL acetonitrile. The cloudy mixture was centrifuged, and 30 μL of the supernatant was acidified with 3 μL 2 M HCl. Sample was analyzed for piperazic acid by HPLC/MS. Analysis was performed using an Imtakt Intrada Amino Acid column (50×3 mm, 3 μm pore size) installed on an Agilent 1260 Infinity HPLC connected to an Agilent 6420 Triple-Quad mass spectrometer using the following method: T=0, 0% B; T=2, 0% B; T=8, 100% B; T=14, 100% B; A: water (30%)/methanol (70%)+0.3% formic acid, B: water+100 mM ammonium formate; 0.4 mL/min. A novel peak at T=5.4 min eluted with a [M+H]⁺ of 131, corresponding to piperazic acid.

Example 9: SfaBC (Co-Expressing pzbA and pzbB) Combined D⁷-Ornithine In Vitro Assay Method

100 μL of reaction in 50 mM Tris.HCl at pH 8.0 was set up with d⁷-L-orn (500 μM), FAD (50 μM), His₆-SfaB (10 μM), SfaC-His₆ (135 μM), NADPH (2 mM), and FeSO₄ (10 mM). 30 μL aliquots were removed at 0 min, 15 min, and 30 min, and combined with 30 μL acetonitrile. The cloudy mixture was centrifuged, and 30 μL of the supernatant was acidified with 3 μL 2 M HCl. Sample was analyzed for piperazic acid by HPLC/MS. Analysis was performed using an Imtakt Intrada Amino Acid column (50×3 mm, 3 μm pore size) installed on an Agilent 1260 Infinity HPLC connected to an Agilent 6420 Triple-Quad mass spectrometer using the following method: T=0, 0% B; T=2, 0% B; T=8, 100% B; T=14, 100% B; A: water (30%)/methanol (70%)+0.3% formic acid, B: water+100 mM ammonium formate; 0.4 mL/min. A novel peak at T=5.4 min eluted with a [M+H]⁺ of 138, corresponding to piperazic acid.

Example 10: PzbAB (Amycolatopsis alba) Ornithine In Vitro Assay

100 μL of reaction in 50 mM Tris.HCl at pH 7.0 was set up with L-orn (500 μM), FAD (50 μM), PzbAB (Amycolatopsis alba) (14 μM), NADPH (2 mM), and FeSO₄ (10 mM). 30 μL aliquots were removed at 0 min, 15 min, and 30 min, and combined with 30 μL acetonitrile. The cloudy mixture was centrifuged, and 30 μL of the supernatant was acidified with 3 μL 2 M HCl. Sample was analyzed for piperazic acid by HPLC/MS. Analysis was performed using an Imtakt Intrada Amino Acid column (50×3 mm, 3 μm pore size) installed on an Agilent 1260 Infinity HPLC connected to an Agilent 6420 Triple-Quad mass spectrometer using the following method: T=0, 0% B; T=2, 0% B; T=8, 100% B; T=14, 100% B; A: water (30%)/methanol (70%)+0.3% formic acid, B: water+100 mM ammonium formate; 0.4 mL/min. A novel peak at T=5.4 min eluted with a [M+H]⁺ of 131, corresponding to piperazic acid.

Example 11: SfaC (Expressing pzbB) N⁵—OH-L-Ornithine In Vitro Assay

100 μL of reaction in 50 mM Tris.HCl at pH 8.0 was set up with N⁵—OH-L-orn (1 mM), His₆-SfaC (18 μM). 30 μL aliquots were removed at 0 min, 10 min, and 20 min, and combined with 30 μL 6% 5-sulfosalicylic acid. The cloudy mixture was centrifuged, and the supernatant was used for analysis. Sample was analyzed for piperazic acid by HPLC/MS. Analysis was performed using an Imtakt Intrada Amino Acid column (50×3 mm, 3 μm pore size) installed on an Agilent 1260 Infinity HPLC connected to an Agilent 6420 Triple-Quad mass spectrometer using the following method: T=0, 86% B; T=3, 86% B; T=10, 0% B; T=11, 0% B; T=12, 86% B; T=14, 86% B; A: water+100 mM ammonium formate, B: acetonitrile+0.1% formic acid; 0.6 mL/min. A peak at 5.6 min with a [M+H]⁺ of 131, corresponded to piperazic acid.

Example 12: Marfey's Analysis of SfaC (Expressing pzbB) Product

The following example confirms that the product of PzbAB from L-Orn is actually L-Piz. Marfey's analysis was performed on the PzbAB reaction product and compared the results with synthetic L-Piz standard. The data so far are consistent with the PzbAB reaction yielding an enantiopure L-Piz.

100 μL of reaction in 50 mM Tris.HCl at pH 8.0 was set up with N⁵—OH-L-orn (1 mM), His₆-SfaC (20 μM), hemin (20 μM). Reaction was allowed to proceed for a few minutes. A control was also set up in 50 mM Tris.HCl at pH 8.0 with L-Piz (0.25 mg/mL) and hemin (20 μM). To 100 μL of aqueous reaction or control was added 50 μL of 1% FDAA in acetone. The reaction was incubated at 50° C. for 1 hour. 100 μL of 1 M HCl was then added. Finally, 300 μL of water/MeCN (50:50) was added to dissolve the precipitate. The supernatant was filtered (Agilent Captiva Econo Filter, 0.2 μL) into HPLC vials for HPLC/MS analysis.

Analysis was performed using a Phenomenex Luna C18 column (75×3 mm, 3 μm pore size) installed on an Agilent 1260 Infinity HPLC connected to an Agilent 6420 Triple-Quad mass spectrometer using the following method: T=0, 10% B; T=5, 10% B; T=25, 100% B; T=27, 100% B, T=29, 10% B, T=30, 10% B; A: water+0.1% formic acid, B: acetonitrile+0.1% formic acid; 0.6 mL/min. 10 μL of the sample was injected per run, and a total ion count chromatogram was obtained for each sample. An extracted ion count chromatogram at m/z 383.1 (monoisotopic mass of protonated FDAA-derivatized piz) was used to detect derivatization. The UV response at 340 nm was also monitored.

Example 13: Hemin Influence on SfaC (Expressing pzbB)

This example shows that the PzbB's cofactor is now confirmed to be Fe⁺³-protoporphryin IX (aka hemin). As expected for a bona fide cofactor, adding hemin increases the rate of turnover.

100 μL of reaction in 50 mM Tris.HCl at pH 8.0 was set up with N⁵—OH-L-orn (1 mM), SfaC-His₆ (2 μM), and either hemin in DMSO (10 μM) or just DMSO. The two reactions were incubated at 4° C. for 7 hours. Then, 30 μL aliquots were removed at 30, 60, and 90 sec, and combined with 30 μL 6% 5-sulfosalicylic acid. The cloudy mixture was centrifuged, and the supernatant was used for analysis. Sample was analyzed for piperazic acid by HPLC/MS. Analysis was performed using an Imtakt Intrada Amino Acid column (50×3 mm, 3 μm pore size) installed on an Agilent 1260 Infinity HPLC connected to an Agilent 6420 Triple-Quad mass spectrometer using the following method: T=0, 86% B; T=3, 86% B; T=10, 0% B; T=11, 0% B; T=12, 86% B; T=14, 86% B; A: water+100 mM ammonium formate, B: acetonitrile+0.1% formic acid; 0.6 mL/min. An extracted ion count chromatogram at m/z 131.1 (monoisotopic mass of protonated piperazic acid) was used to detect piperazic acid. For quantification, an SRM transition (m/z 131.1=>56.3; source voltage, 86 V; collision energy, 37 V) was monitored, and a standard curve (second order polynomial, R2=0.9996) was generated between 0.1 μM and 100 μM using a chemically synthesized L-piperazic acid dihydrochloride standard. The concentrations in time were plotted, and fitted to a line. The slope of the line was used as the rate of the reaction. Hemin increased the slope by 14.4 times.

Example 14: Fermentative L-Piz Production from Various Streptomyces Strains

This example describes L-Piz production from various Streptomyces strains (see e.g., FIG. 7) (methods are as described above unless stated otherwise). Randomly selected environmental Streptomyces isolates were transformed with pYH015 via intergeneric conjugation as described for S. lividans. L-Piz production was quantified via SRM LC/MS from triplicate growths essentially as noted for the S. lividans transformants. Resulting strain to strain Piz production is variable, ranging from very low to nearly the same as S. lividans carrying pYH015 (JV594). Note S. lividans JV 596 expressing both sfaB and sfaC produces more L-Piz, with less titer variability, than all sfaC-alone strains in the panel. L-Piz was not detected in any non-transformed parent strains (not shown).

It is noted that the value reported here for for JV596 (˜2.5 mg/L) is higher that what we previously reported (˜1 mg/L).

SEQUENCE LISTING PzbA 1. >Mycobacterium_marinum_M MQQRLTMWSATGLIFGHALCMNTCRTMVVPRGKPLCIERVPPLPCQPKMGESTMPSGGIA DPELALVDRTLSVVGVGFGVTGLALAAALHEAEMTEDALFLESRPKFGWHDDMLIEGSSM QVSFLKDIVTMRNPTSRFSFISYLHAMGRLTNFINHGVLTPSRREFADYLRWVARQLDHL VRYDVHVTDVRPVYEGATVSALDIVAGENAVVRTRNLVLGTGLRPRMPQGVIPNRRVWHS SELLSRLAECGDYLARQIVVVGAGQSAAEIALYLLDRYPDSQVCPVFARYGYSAVDASPF ANRIFDPSGVDDFYAASPSVKASLLRYHGNTNYSVVSSDVLGALYRRQYEQSVIGDPRLR IFHASRLHLVSFNDDSVVADIEFLPTGEVTRLDTDLVVIYATGYESRDPKHLLTSLAGYL RTDELGALRLDRRYRVKTVEGFRCGIFVQGATESTHGIASTLLSVAAVRAGEISQSLMET SQARPPAGSVTHRH 2. >Lentzea_flaviverrucosa_DSM_44664 VTSEPYDVVGIGFGPSNLSLAIALEETGGLSAAFFEKQDSLRWHSGMLVPGAKMQVSFLK DLATPRNPVSSYSFVSYLHDRGRFARFVNNSDFFPTRREFQDYLRWAEARLSPPVHYRAE VVSVRRAEGVLRVHVRDTESGATRTVDTRNIVISTGLVPRMPVGLEAGESVWHSSQFLHR FHALGDRDVRRVAVVGAGQSAAELVRYLHENLPSAQVFAVLPSYGYAIADSTPFANEVFD ADAVDVFYDASDKAKAAIWRYHRNTNYSVVDDEVIRDLYQRAYDDEVRGEPRLRFLPLTR VVGAKQDRDGITLLTHSTVDDQARDLPLDLVVCATGYDPMDPGELLAGLGCSVAYDELGR HLVGRDHRLVTEPDQDCGIYLQGGTEHTHGLTSSLLSNIAVRGGEITQSILRRRAEQRNG APA 3. >Streptomyces_aureofaciens_ATCC_10762 VGERQRSGVVAGTGIVDVAGIGFGPSNLALAAAIAEIAGEAPVSARFFEA QPRFGWHRGMLIEGATMQVSYLKDLVTMRNPTSPYSFLCYLQARGRLADF INTKSPYPLRVEFHDYLEWVAESFADLVSYGARVVSVEPVSAEQGVEFLD VHFVAPDGTRQVQRARNLVIAAGIEPRLPAGLPASPRIWHTAKFLPEVDR IARQDPRSFVVLGSGQSAAEAIEHLHARFPRAQVHSVHARYGFSVADDSP FANQVFNPEAVDRFHTAPDDVRQRLIDYHASTNYSVVDADLLHSLFQQAY LEKVAGNPRLNFHNVSRVSEVTETPDGLRIDVESLSSGTSTVIEAQALVC ATGYTRTDPAVFLDGLLPHCPLDDQGRLRLDREHRVVTDESVRCGIYVQG FGEHSHGLSETLLSLSAVRAGEIGDMLVKALSG 4. >Streptomyces_diastatochromogenes_NRRL_B-1698 VNVSEPGSDQVVDVVGIGFGPSNLALAVALGEGGRKASEKPVTSVFFERK ERFTWHGGMLIDGATMQISFLKDLVTLRDPRSPYTFLHYLHQVGRLPDFI NHKLLFPSRIEFHDYLCWVAESFDHQVRYGADVVDVRPVHSDGAVNHLDV VVRHEGPEGERISVQRTRNVVVGTGLEAHMPAGAAPGDRVWHTSELLHKV AALKEEPRRIVVVGAGQSAAEATEYLHRRFEAAEICPVFTRYGYSPADDS PFANRIFDPLAVDDYYAATPEVKRMLLGYHRNTNYSVVDAELIDELYRRV YQEKVQGRHRLKVFNASRLAEVKAGAEGVQVTVESVISRCRTVLDADCVV YATGYRPTDVRRLIGGMAGLCKADEMGRLHADRDYRVVTEGDVHCGIYLQ GATEHSHGISSSLLSNTAVRAGEIADSIVAGVVGATASE 5. >Streptomyces_sp._DvalAA-43 MDASARETYDVVGIGFGPSNLSLAIALEEHEANVPARPISAAFFERQPSF GWHRNMLLPAATMQISFLKDLATFRNPVSRYSFIAYLHAADRLVQFVNNQ TFFPTRQEFHQYLEWAESSFSDRVSYNSEVTAIRRATGTGPGEPDCLQIE VRDGIGGGCRLVHARNVAISTGLVPRMPAGVERDDRVWHSSEFLEKYGQV DPNALKSVAVVGAGQSAAEITRFLHDALPHARVFAVVPSYGYSVADDTPF ANRVFDPSAVDDYYFGTEQTREAFWRYHRNTNYSVVDDEIIRDLHQRSYD EDVRNDRRLHFLNLTRVDDVQRIGTEIRVGLRSLIDVEAQTLDVDALVFA TGYGAMQPTGLLGDLDRHCLRDAAGRHRAERDYRLVTTPELSCGIYLQGG TEHTHGLTSSLLSNVAVRSGEIADSIVRRRAEEHEPVASLGTSGRTS 6. >Collimonas_fungivorans_Ter6 MQVCFLKDLAMLRNPTSPFTFLSYLHDKNRLVDFVNHKILFSSRVEFHDY LEWAAAKLKRLVQYDAEVVEVSPVICDGVVKWLDVVVQRDGNPSHHEIYR THNLVIAPGLEPTMPPGISRSERVWHSSEVLDRIAHLTEEPQQFTVVGAG QSAAEITAYLHDHFKYAKVRSIFSRYGYSAADDSPFTNRIFDPLAVDEYY QARDDVKKMLLNFHRNTNYSVVDADLLEDLYRRHYQEMVRGESRLEFMNV SKVFGAVADRDSVDLSVEFLPTGDMRKLRSDIVVFGSGYKIADPIRYFSD FAGKCIRDSFGQLRVARNYRICTSEDVECGIYLQGTTEHTHGLSSTLLSN TAVRAGEILEAMTWERDNKKISSHA 7. >Streptomyces_reticuli_TUE45 MTRLAGQAPTAQHSPESEVRDVTGIGFGAANLALAVALHESGAGDRALFL EKQKEFGWHRGMLIEGSSLQVSFLKDIATMRNPTSDFGFLSYLQEKGRLV DFINQHTLLPSRIEYHDYLQWAADRLGHMVEYGVEATGVRPVTDAGEVVA LDVLAGDRVVTRTRNLVIASGLRPRLPEGAETGERVWHSSQLLHRLPAFD ERPPRRAVVVGAGQSAAEVAAHLMERYPQAEVCAVFSRYGYSVADSSPFA NRVFDPAAVDDFYFAPPEVKQAIMRYHGGTNYAVVDEDVLQGLYRRQYEQ KVTGTPRLRVMNASRLVSVEPRGETAAVRVEFLPTGEHADLDADLVVYAT GYRSADPAELLGGVAGSLRRDAAGQVLIGRDYRLSTTGDFRCGIYVQGAT EATHGIASTLLSMVAVRAGEIAQSIIGGRRDPDRTAGTKAVAGNRG 8. >Streptomyces_scabiei_NCPPB_4086 MEAHTDAYEVVGIGFGPSNLSLAIALEEQRGKDEKPLTAAFFEKQASLGW HRNMLLPDTKMQISFLKDLATFRNPASQWSFIAYLHAAGRLAQFVNNQNF FPTRNEFHDYLDWAESSFSDRVTYNCEVNAVHLPDGYTGGPVDTVRVEVK DNTPRGGTRLVEARNLVISTGLVPTMPTGIERGERVWHSSEFLGRFGTLD RDRVRRFAVVGAGQSAAEITRYVYDIVPNAEVYAIMPSYGYSIADDTPYA NRIFDADAVDDYYGGTDHTRESFWRYHRNTNYGVADDEVIRDLYQRAYDD EVARIKRLHLLNLSRVRTVEQTVDGARLTMHSVRDDSTYGLDVDAIVFAT GYDSMDPTALLGDLAPHCLRDEEGRLRVERDYRLVTSPDLNVGIYLQGGT EHTHGLASALLSNIAIRSGEIADAIAIDLAARQHTTARSTIG 9. >Kutzneria_albida_DSM_43870 MQRDYRVVTVPEMRCGIYLQGGTEHTHGLTSSLLSNIVIRTGEITDSIIT RRAELNVGERRTVNG 10. >Streptomyces_albus_ZpM MTGPEVYDIVGVGFGPANLALAVALTERGSSTPLRALFLDRNESFSWHPG MLIHDATMQVNFLKDLITLRNPASDFSFLSYLKARGRLVDFINHKTFFPT RVEFHDYLEWAAGRVGDVVEYGTEVVDVRPVERDGEVVYFDVVGHQQVGG VSQAVVCRARNVVVAPGLVPRLPGEASQSERVWHSSELLHRVGDLPTDKR MQFVVVGAGQSAAEVVGYLHARYECADVHAVHSRYGYSPADDTPFANRVF DPAAVEHFFHAPPSVKDKFFEYHANTNYSVVDVELIEDLYARVYRESVTE RRRLHIHGMSELTEVADGPEGLRVSVRFLPDGTTTVLEPDHVVYATGYKP ADVNRVIGVVAELCKRDSSGNLRLLHDYRVDMASHVRCGIYLQGGTEHSH GITSSLLSNLADRAAEILDSVLAHGGQLSADAAAWEVAS 11. >Rhodococcus_fascians_02-815 MGAQSGSSVADVVGVGFGPSNLALAIALQESIQPGPVPAKFSMKFYELQP RFGWHRGMLMEDATMQVSFLKDLATMRNPMSRYTFVSYLREKERIAEFIN SKTLYPLRVEFHDYLEWAASQFQSNVSYGSEIKDIRPVVENGVVEYVDVV GPDDVVQRARNIVIGMGLTPRLPDGVNRSERIWHSSQLLGRAAAVTYVPQ NFVVVGSGQSAAEVADYLHRTFPRANVHTVLSRYGYSVADDSPYANGIFD PEGVDRFFSAPTDEKQRLLEYHANTNYSVVDLDISQSLYLKSYQEKVLGK QRLRMINTSRVTSVDEDTDGVRVEVTSSATGLTHTIEADVIVYATGYRPS DPAPLLQGLMRECKHDEQGRLSVGRDYRVTTSDAVRAGIYVHGASTEHSH GLSAGLLSNTAVRSGEIAQSILRR 12. >Streptomyces_neyagawaensis_NRRL_B-3092 MEANTEAYEVVGIGFGPANLSLAIALEEQRGKDEKQLTAAFFEKQPSLGW HRNMLLPDTKMQISFLKDLATFRNPASQWSFIAYLHAAGRLAQFVNNQNF FPTRNEFHDYLEWAESSFSDRVTYNSEVNAVHLPDGHDGGPVDTVRVEVK DNGPRGGTRLVEARNLVISTGLVPKMPDGVDRGERVWHSSEFLGRFHTLD PSRVRRFAVVGAGQSAAEITRYVYDTIPDAEVYAIMPSYGYSIADDTPYA NRIFDADAVDDYYGGTDRTRESFWRYHRNTNYGVADDEVIRDLYQRAYDD EVARIKRLHLLNLSRVQRVDQRADGARLTMHSVRDDSVYDLDVDAIVFAT GYDSMDPTALLGDLAPYCLRDDEGRLRVERDYRLVTKPELNVGIYLQGGT EHTHGLASSLLSNIAIRSGEIADAIAIAIDLASRRHTTV 13. >Kutzneria_buriramensis_DSM_45791 MDTRGSETYDVVGIGFGPANLSLAIALEESPQRLTSAFFERQPSLGWHRG MLVPAAKMQVAFLKDLVTFRNPTSTFSFVSYLHDRGRLARFVNNQDFFPT RREFHDYLEWAESRVSHRVSYQSEVTAMRLPCAQRPGEDDHVEVEVRDRT APSGSRTVAARNVVISTGLVPRMPAGLQTDEFVWHSSEFLHKFSRADHSG LKRVAVVGAGQSAAEIVRFLYDMLPDANVFAIIPSYGYSIADNTPFANQI FDPAAVDDFYAGSDQAKDAIWRYHRNTNYSVVDDEVIKDLYRRQYDDDLG RPGRLAFLNLSRVLDVKRVGEDTRVTVHSTATEQAADLDVDVLVCATGYS PMEPADLLGDLARYCVYDGDGRYQVDRDYRLVTPDLDCGIYLQGGTEHTH GLSSSLLSNIAVRSGEIAASIARRRLSTNGNGVHA 14. >Streptomyces_yanglinensis_CGMCC_4.2023 MSNREQTYDVVGIGFGPSNLSLAIALEEFGAHGMENEISSLFLERQPSFG WHRNMLLPSATMQISFLKDLVTFRNPTSGFSFIAYLHASGRLPQFVNNQD FFPTRQEFHQYLEWAQAQVAGRIEYGAEVTSIRLPSGTAPQEGADRLVLE VAEGAGRTGRAVEARNVVISTGLVPSMPAGAERDERVWHSSEFLDKYRRT DHRELRRVAVVGAGQSAAEIARFLYDELPHAQVSAIIPSYGYAVADDTPF ANRIFDPSAVDDYYFGTEQTRESFWRYHRNTNYSVVDDEVIRDLYRRSYD DEVRGVTRLQLLNLTRVTGVKRAGAETRVSLQVGPDAELRELDFDLLVCA TGYDGMEPTGLLGELDRYCLRDEAGRYRVERDYRIVTTPELRCGIYLQGG TEHTHGLTSSLLSNLAVRSGEIADSIIARRAGYGAEREVLAKIGGDIA 15. >Streptomyces_griseochromogenes_ATCC_14511 MSDREHETYDVVGIGFGPSNLSLAIALEEYRANGPENEISALFLERQSAF GWHRNMLLPSTTMQISFLKDLVTFRNPTSSFSFIAYLHASGRLPQFVNNQ DFFPTRQEFHQYLEWAQARVADRVAYGSEVTSIRLPPGADPERSDRLRLE VADATGRNGRVVEARNVVISTGLVPSMPVGTERDERVWHSSEFLEKYRRM NPAELRRVAVVGAGQSAAEITRFLYDELPHAEVCAVIPSYGYSVADDTPF ANQIFDPGAVDDYYFGTEQTREAFWRYHRNTNYSVVDDEVIRDLYRRSYD DEVRGVRRLQFLNLTRVTSVKRVGAETRVSLQVGPDDEVRELDFDALVCA TGYSTMEPTDLLGDLDRHCLRDEAGRYRVERDYRIVTAPEMRCGIYLQGG TEHTHGLTSSLLSNIAVRSGEIADSIVAGRAGRNAERALLAEVGGDTR 16. >Streptomyces_incarnatus_NRRL_8089 MDIAGRPSQEIYDVVGIGFGPSNMSLAIALEEHEASSPQHPLKCHFFERQ PTFGWHRNMLLPSTTMQISFLKDLATFRNPTSRFSFISYLHAADRLVQFV NNQDFFPTRQEFHQYLEWAAAGLRDRVTYGAEVTSIRPAGEAGSGTSDIL EIEVRGGDGTTSVVSARNVVISTGLVPRLPEGVTSDERVWHSSEFLSRFH AQAPGDLKSVAVVGAGQSAAEITRFLYDSLPHAQVTAVIPSYGYSVADDT PFANQVFDPSAVDEYYFGTERARDSFWRYHRNTNYSVVDADVIRALYQRS YDEQVRGSQRLHFRNLTRVDEVERVGSGARVVVRSVLDDRTEELALDALV FATGYDGLDPARLLGDFDRHFLRDAAGRHRVERDYRLVPASGLTAGVYLQ GGTEHTHGLSSALLSNIAVRSGEIADSIVLRRTERELGSGRPVQAARSAA 17. >Streptomyces_albulus_PD-1 MESHRMTGPEVYDIVGVGFGPANLALAVALTERGSSTPLRALFLDRNESFSWHPGMLIHD ATMQVNFLKDLITLRNPASDFSFLSYLKARGRLVDFINHKTFFPTRVEFHDYLEWAAGRV GDVVEYGTEVVDVRPVERDGEVVYFDVVGHQQVGGVSQAVVCRARNVVVAPGLVPRLPGE ASQSERVWHSSELLHRVGDLPTDKRMQFVVVGAGQSAAEVVGYLHARYECADVHAVHSRY GYSPADDTPFANRVFDPAAVEHFFHAPPSVKDKFFEYHANTNYSVVDVELIEDLYARVYR ESVTERRRLHIHGMSELTEVADGPEGLRVSVRFLPDGTTTVLEPDHVVYATGYKPADVNR VIGVVAELCKRDSSGNLRLLHDYRVDMASHVRCGIYLQGGTEHSHGITSSLLSNLADRAA EILDSVLAHGGQLSADAAAWEVAS 18. >Streptomyces_tsukubaensis_NRRL_18488 MGITGRGKHEVLDLVGIGFGPSNLALAIALDEHGASAPQHPVTSHFFERQPAFGWHRNML LPSTTMQISFLKDLATFRNPMSRFSFVSYLHASNRLVQFVNNQDFYPTRQEFHQYLEWAA AALGDRVTYGAEVASIRPRTGPGSRTADLLEIEVRRGDGTTGTVTARNVAISTGLVPRLP KGVTSGPRVWHSSEFLGRFGAQTPADLRHVAVVGAGQSAAEITRFLHDSLPHAQVSAVIP SYGYSIADDTPFANQVFDPGAVDEYYYGTQRARDAFWRYHGNTNYSVVDADVIRDLYRRS YDEEVRGGRRLHFRNLTRVVEVEGSASGAWVMLRSLLDDRREELAVDALVFATGYDGMDP ARLLGDFDRHFQRDAAGRHRLERDYRLVSASGLTCGVYLQGGTEHSHGLSSSLLSNTAVR SGEIADSIVMRRTRQELGRSRSVAESPSAA 19. >Streptomyces_himastatinicus_ATCC_53653_hmtM MAHETEIYDVVGIGFGPSNLSLAIALEESPDPVTSLFFERQPTLGWHRGMLLPSAKMQVS FLKDLATFRNPASGFGFISYLHDMGRLTRFVNNQDFFPTRREFHDYLEWAASKLTGRVSY DSEVTAVSAVAAAGEGPADRVRVTVRGADGAPRQVEARNVVISTGLVPRMPVNLEAGERV WHSSEFLHRFRQREGELTRVAVVGAGQSAAEIVRFLYDTLPEVRVSAVIPSFGYAIADDT PFANQVFDPDAVDSYYHGTQASKDAVWQYHKNTNYSVVDDEVIRGLYERAYEDELSGHGR LDFRNLARVLDAEPTGDGTRITVYSLVDDASYDLDVDVLICATGYDPMNPARVLGELDKY CVHDTEGRHRVDRDYRLVTTSDLTCGIYLQGGTEHTHGLGSSLLSNIAVRSGDIAQSITA RCAGAPKKGLTA 20. >Streptomyces_flaveolus_DSM_9954_sfaB MTRLAEQSSTAQQSPESEVLDVTGIGFGAANLALAVALHESEAAGKALFLEKQKEFGWHR GMLLGGSSLQVSFLKDIATMRNPTSDFGFLSYLQEKDRLVDFINQHTLLPSRIEYHDYLQ WAADRLNHLVEYGVEATGVRPVTEAGEVVALDVLAGDRVVARTRNLVLASGLRPRLPEGA ETGERVWHSSQLLHRLPAFDERPPRRAVVVGAGQSAAEVAAHLMDRYPQAEVCAVFARYG YSVADSSPFANRVFDPAAVDDFYFAPPEVKQAIMRYHGGTNYAVVDEDVLQGLYRRQYEQ KVSGAPRLRVMNASRLVSVEPRQESAAVRVEFLPTGEHTDLDADLVVYATGYDSTDPAEL LGGVSGALRRDEAGELLIGRDYRLGTTGDFRCGIYVQGATEATHGIASTLLSMVAVRAGE IARSITGGRCDPDRSTGSKAAAGNRG 21. >Streptomyces_aurantiacus_JA_4570 MGTREHEIYDIVGIGFGPSNLSLAIALEEHQANSSQQPVRAAFFERQPSFGWHRNMLLPQ ATMQISFLKDLATFRNPLSRYSFVSYLHASDRLVQFVNNQDFFPTRQEFHQYLEWAESGF RDRVTYNSEVTEIRVSDEGSGGEQLLEIVVRDTVGGGTRVVQARNVTVSTGLVPRMPDGM LRDERVWHSSEFLAKYGRMRPEDLKNVAVVGAGQSAAEITKYLHDKLPHAQVSAILPSYG YSVADDTPFANQVFDPTAVDHYYFGTENTRDAFWRYHKNTNYSVVDDDVIRELFRRSYEE EVAGEKRLHFLNLTRVKEVKRSGNDTRVVLHSLLDGESEQEMDVDALVFATGYSTMDATR LLGDLDRFCERDEEGRHRVERDYRVVTSGELSCGIYLQGGTEHTHGLTSSLLSNIAVRSG EIADSIVERRGAGQRV 22. >Streptomyces_sp._RJA2928_padN MTDSAPEDRTVDVTGIGFGPSNLALATALAEPSATGPGRPLEAVYFERKNRFSWHGGMLL DGATMQISFLKDLVTLRDPRSPYSFLSYLHHAGRLSDFINHKLLFPSRIEFHDYLEWVAG FFEEQVVYGSEVVDVRPVAREDAVEHMDVVVRQRTAAGERTVVQRTRDLVVATGLEPSLP PGTVCSDRVWHSSELLYRVERLPPTPRRIVVVGAGQSAAEAAEFLHSRFPSTDICAVFSR YGYSPSDDSPFANRIFDPAAVDDYCAAAPETRRMLLDYHRNTNYSVVDPELIDELYRRVY QEKVRGRPRLNILGASRLMAAEPAGDGVDVVVESLVTGERTPMRADCVVYATGYRPTDAR GLLGSMAGLCKADELGRLEADRRYRVITEGDVRCAIYLQGATEHSHGISSSLLSNTAVRA GEIADAIRADAVRAGARATTRSQPQPQT 23. >Frankia_alni_str._ACN14A MSAREFDIYDVVGIGFGPSNLSLAVALDEFRVNGMGNVFSNIFFERRSSFAWHPSMLLPS ATMQISFLKDLVTFRNPTSSFSFVAYLHESGRLPRFVNNQDFFPTREEFHQYLEWAQARV AHRVAYGSEARSLRLPAGVGPERADRLCLQVADAASGTSRMVEARNVVISTGLVPTMPTG VERGERVWHSSEFLERFRRTSPARIRRVAVVGAGQSAAEITRFLYDELPHAEVSAIIPSY GYCVADDTPFANEVFDPEAIDDYYYATERTREALWRYHSNTNYSVVDDSVIRDLYRRSYE DDLRDVGRLRFLRLTRVAGVRSVGAQTRVSLRAGIDGDLRDLDVDVLVCATGYAAMEPTG LLGDLDQYCLRDEAGRYRIERDYRIVTAPEMQCGIYLQGGTEHTHGLSSSLLSNIAVRSG EIIDSIVARSAERTAPCAVLAEA 24. >Actinosynnema_mirum_DSM_43827 MTAVVQGADAPRDVVGVGFGPSNLALAVALAERDGPSSAFFERQPRFGWH RGMLLDGATMQVSFLKDLVSMRNPTSPYSFVSYLHARGRMPEFVNAKTLY PLRVEFHDYLEWVAGHFAGSVSYGSEITALEPVAEDGVVGHLDVVARRDG RTTTTRARNVVVATGLEPRLPDGVTGGERVWHSGELLHRVPWLRERRVRK VAVVGAGQSAAEVTEYLHRTLPGAEVIAVFSRFGYSVADDTPFVNEVFDP DSVDLFYGSPPSVRQALLAHHGNTNYSVVDADLSLELYRRRYQERVTGSS RLRVVNVSRVRSVRERPDGVALQVEYLPTGVVGTLAADAVVCATGYRPAD PTPLLRGLAKLDGAGRPVLDRDHRVVTSGSVRAGIYLQGAVTEPTHGLSA GLLSTTAVRAGEIVRAILDEGR 25. >Kutzneria_sp._744_ktzl MTVAHAGESPTHDVVGVGFGPANLSLAVALEESPAALTSAFFERRASISWHQGMLLPAAK MQVSFLKDLATFRNPASRFSFVSFLHERGRLVRFANNHDFFPTRREFHDYLEWAESKLAH EVSYDSEVTAIRPGPGRPVDSVLVDVSTPEATRTVEARNIVISTGLVPRMPAGVQSDEFV WHSSRFLDHFRDRDPRSLRRVAVAGGGQSAAEIVRFLHDNRPDTVVHAIMPSYGYVVADN TPFANQIFDPAAVDDYFDGSKQAKDAFWRYHRNTNYSVVDDEVIRDLYRRGYDDEVAGAP RLNFVNLAHVVGAKRIADDTRVTVYSMAREESYDLDVDVLVCATGYDPMDPGDLLGELAE HCVQDAEGRWQVDRDYRMVTTPDLRCGIYLQGGTEHTHGLSSSLLSNLATRSGEIVSSIE RRKS 26. >Kibdelosporangium_sp._MJ126-NF4 VTDIHDLVGVGFGPSNLALSIAAAEADVPLRAVFLERSERFGWHRDMLIDDATMQVAFLK DLATPRNPVSRFGFVPYLWARDRLSAFINQKTLFPTRVEFHDYLEWAAAQVDDVVEYAAE VVDIRPVHDNGEVAFLDVVSVRPDGQARVRRTRNVVLALGLQPVVPPGVHPSPRVWHSAD LLGRAATLDRAKPLRFAVVGAGQSAAECVSYLHRAFEQAEVHAVFGRYGYSPADDSPFAN RIFDPAAVDDYFVSPDQVKQRFFDYHANTNYSAVDTELLEELSHRVYRESLSGRQRLFTH HLSAITDLADTDDGVSVSVEFLPTGERTMLRVDHVIHATGYRPTDPIPLLGTTAELCHKD TLGRLRVERDYRVVTKPDVRTGIYLQGGTEHSHGISSSLLSNVAVRAGEILASIQERPQR RDGDQDERTARAGDDPARRAAALPRR 27. >Mycobacterium_xenopi_RIVM700367 MLPGEDDSDLDFIGIGFGPSNLALAVAAEELIPNWRGLFLERSQSFQWHPGMMLEGARMQ ISFLKDLATLRNPASRYTFLQYAKARGRLEQFVNINEFRPTRLEYNDYLKWVAESFADRV RYGAVVTAVVPLRDSPSPAGRFGRLRVYVRDESTGVETCFSSPNVVYGGGGVPRLLGARN TSAVVHSSAFLPNFPNRFNEPDKAYRFAVVGNGQSAAEIAEYLLSHYRRATTHLFISDHT LRATDHSPFINEHFFSVNAAEFYDYPPAKRAALRNELRLTNYGVVDADVLQKLYQIAYLD EVRGCRRLFLHGESRLSRVEEIDGRVVARFEDRFSGESHEFDFDGAVLATGYDRVLDAEI FREVLPHVLRDESGEISLSRSCRVNTGPALTAGLFLQG 28. >Streptomyces_mirabilis_YR139 MGITGRRSQEIYDVVGIGFGPSNLSLAIALEEHGASAPQHPVKSLFFERQSRFGWHRNML LPSTTMQISFLKDLATYRNPTSRFSFISYLHASNRLVQFVNNQDFYPTRQEFHQYLEWAA AGLRDRVTYGAEVTSIRPGTEAGSRTPDLLEVEVRTGDGTTSVVTARNVVISTGLVPRLP QGVTSDERVWHSSEFLSRFNAQAPGDLKSVAVVGAGQSAAEITRFLHDSLPHAQVCAVIP SYGYSVADDTPFANQVFDPGAVDEYYFGTEQAQDAFWRYHRNTNYAVVDADVIRALYQRS YDEQVHGSRRLHFRNLTRVAEVKRTGSGTRVVLRSLLEDRTEELAVDALVFATGYDGLDP AHLLGDFDQHFLRDAAGRHRVERDYSLVTASGLTCGVYLQGGTEHSHGLSSSLLSNIAVR SGEIADSIVLRRTERELGSTCPVKVASSAA 29. >Streptomyces_scabrisporus_DSM_41855 MGMFGHEIHDVVGIGFGPSNLSLAIALEEHQANESARPVTAAFFERQPAFGWHRNMLLPS TTMQISFLKDLATFRNPVSRFGFISYLHASGRLPQFVNAQDFFPTRQEFHQYLEWAESSV TDRVSYGSDVTSIRPPQGIAARDAKHLEIEVEDLVSGATRLVKARNVIVSTGLVPRLPQG IERDERVWHSSEFLEKFGRMDAAGLGSVAVVGAGQSAAEITRFLYDTLPHARVSAILPAY GYSVADDTPFANQVFDPGAVDEYYFGSDRTREAFWRYHKNTNYSVVDDEVIRDLYRRSYE EEVRGVRRLNFLNLTRVDQVKRSGDETRVSLRSLLDDRVRELDVDALVFATGYDSPEPSG LLGDLDRYCLRDEAGRHRVGRDYRLVTSPELSCGIYLQGGTEHTHGLTSSLLSNIAIRSG EIADSVIRRRVEHELELERNAALEVARETR 30. >Streptomyces_sp._TAA040 MHDLVVVGAGPYGLSIAAHAAAAGLQPRVLGTPMASWRDHMPQGMYLKSEPWSSDLSDPA GAHTLAAYCATRGLVAEHGNPLPIEVFTDYGCWFAGRAAPPVEERIVVAVRPHGDGYRVE TAEGERITTRTVALAVGVMPFVHHPSALAALPAELATHSSDHRDLARFRGRDVTVVGAGQ AALETATLLTEHGARARVLARADRINWNTPPQPLERGLWKSLRDPHCGLGTGWSSWLWSE RPSAVRRLPAGLRAAIAGSALGPAGAWWLRERFEQAVPVLLGHRLLAAEQVGGRVRLDVR LADGTARNLHTDHVVAATGFTPELDRLGLLALSLTGTLRRVPGTGAPELGRCFESSRPGL FFGGLLTAPSFGPAMRFVHGAGFTAGRLVEGVRRRLGSGAASRTRAVPQAAGSVGRAAAE RPPG 31. >Actinoalloteichus_cyanogriseus_DSM_43889 MYGSVPVDGNQVSDVVGVGFGPSNLALAVAIAEHNETAPPKTRLRAQFLERQPVFGWHRG MLLPDTTLQVSFLKDLVTLRNPRSSFGFVSYLHDRNRLVDFVNHQSFFPSRREYHDYLEW VAGRFTGSVHYGHEVVDVLPVNEGPDVVAFDVVAAHGGVGATRRVRTRNVVLAPGLEPVL PQGITPSDRVWHSSELLHRLDGVRELLPSRPRFVVVGAGQSAAEVMAHLHDAFPTATVRS VCSRYGFAPADDSPFVNQLFDPAGVDEFFEAALPARENLLRTHAGTNYSAVDGGLINELY RRSYQERVAGEPRLLFERLSRVVATEEGDDEVSVAVRSLADGRVTNRRCDVVVLATGYRP RDALRPLGELAALCKLDANGWPRVERDYRITTTETVRAGIYLQGGTEHSHGLSSTLLSNL AVRSGEITRALVSR 32. >Streptomyces_sp._HNS054 MGITGRRHQEIYDVIGIGFGPSNMSLAIALEEHEASAPQQPLRYHFFERQPTFGWHRNML LPSTTMQISFLKDLATFRNPLSRFSFISFLHSSNRLVQFVNNQDFFPTRQEFHQYLEWAA AGLSDRVTYGTEVVSIRPGTEGGTLTPDLLEIEVRDGDGTTSVVVTRNVVISTGLVPRLP EGVTADERVWHSSQFLSKFHARDPRELKRVAVVGAGQSAAEITRFFYDSLPHAEVLAVIP SYGYSVADDTPFANQVFDPGAVDEYYYGTDRARDAFWRYHRNTNYSVVDTDVIRALYQRS YDEQVRGTQRLHFRNLTRVVEVGSTGEGTRVVLRSLLDDRREDLAVDALVFATGYDGVDP ARLLGDGFDAHFERDAAGRHRVERDYRLVSSSGLTCGVYLQGGTEHSHGLTSSLLSNMAV RSGEIADSIVLGRTGRELDRTHSVEEASSAA 33. >Streptomyces_sp._AW19M42 VCRGAATFLETTLTTPLETARSAAPHDPADGAPLDVLGVGFGPSNLALAIALSEVERPRP RVHFYDRSSRFSWHGGMLLKGATMQVHFLKDLVTLRNPGSPYSFLSYLHDRERLVDFINH KALFPSRVEFHDYLEWAAQACSDRVTYGSEVSRIEPEWVDGEVHRFRVHLTHSEPGERGV RHEVRSARNVVLAPGLRPHLPEGTAESEHVWHSSRLLSRLEDIPKDAPVRFTVVGAGQSG AEVTAYLHGRFPQAQVRAVFSPYGYNPADDSPFANRIFDPAAVDEFFGAPQAVREMLVDR HGNTNYSVVDQDLIAELYRIWYQEKVTDERRLIIDNVSRLVGVREASGLRLTIESLATRE RHEVDSDYLVYATGYRPVAPDDLVDPEIMKLCRRDAAGGLRVNRDYRVQTEDMVRCGLYV QGATEHTHGLSSTLLSNTAVRAGEIASSLLGRM 34. >Salinispora_pacifica_DSM_45549 VFDEPSVYDVLGIGFGPSNLSLAIALHEMGDVEGRPLAARFFEQQPSFGWHRNMLLPSAK MQVSFLKDLVTFRNPHSRFTFVSYLHEMNRLARFINNCDFFPTREEFHGYLEWAAANFAD QVTYGATITSISVPPDSGPGDPIDRVRVNLASGPTGAESSSVEARNVVLGTGLVPRFPAG LTSDDRVWHSSEFLGKFQRCDTTKLKRVLVVGGGQSAAEIAHFVYDNVPGVTVTAVIPSY GYSIADATPFANRVFDPSAIDDYYYGDENSKDAFWRYHRNTNYAVVDSNLISDLNRKAYD EAVTGETRLRFAELSRLSGVRRRDDGVVVSIHSMLSNRTSEVDADIVICATGYEPMEIGD MLGPLDRFCIRDEQGRYRVERDYRLATTEHLRCGIYLQGGMEHTHGLSSSLLSNLAVRNG DISTSVARRAQSQSHDDGRVLQGLVPTGS 35. >Salinispora_pacifica_CNT150 VFDEPSVYDVLGIGFGPSNLSLAIALHEMGDVEGRPLAARFFEQQPSFGW HRNMLLPSAKMQVSFLKDLVTFRNPHSRFTFVSYLHEMNRLARFINNCDF FPTREEFHGYLEWAAANFADQVTYGATITSISVPPDSGPGDPIDRVRVNL ASGPTGAESSSVEARNVVLGTGLVPRFPAGLTSDDRVWHSSEFLGKFQRC DTTKLKRVLVVGGGQSAAEIAHFVYDNVPGVTVTAVIPSYGYSIADATPF ANRVFDPSAIDDYYYGDENSKDAFWRYHRNTNYAVVDSNLISDLNRKAYD EAVTGETRLRFAELSRLSGVRRRDDGVVVSIHSMLSNRTSEVDADIVICA TGYEPMEIGDMLGPLDRFCIRDEQGRYRVERDYRLATTEHLRCGIYLQGG MEHTHGLSSSLLSNLAVRNGDISTSVARRAQSQSHDDGRVLQGLVPTGS 36. >Salinispora_tropica_CNB536 VTGKVHIVFDEPSVYDVLGIGFGPSNLSLAIALHEMGDVEGRPLAARFFEQQPSFGWHRN MLLPSAKMQVSFLKDLVTFRNPHSRFTFVSYLHEMNRLARFVNNCDFFPTREEFHGYLEW AATNFADQVTYGATITSISVPPDSGPGDPIDRVRVHLASGPTGTESSSVEARNVVLGTGL VPRFPAGLTSDDRVWHSSEFLGKFQRCDTTKLKRVLVVGGGQSAAEIAHFVYENVPGATV TAVIPSYGYSIADATPFANRVFDPSAIDDYYYGDENSRDAFWRYHRNTNYAVVDSDLISD LNRKAYDEAVTGEIRLRFAELSRLSGVRRRDDGVVVSIHSMLSNRTSEVDADIVICATGY EPMEIGDMLGPLDRFCIRDEHGRYRVERDYRLATTEHLRCGIYLQGGMEHTHGLSSSLLS NLAVRNGDISTSVARRAQSQPHGDGRVLQGLVPTGS 37. >Salinispora_arenicola_CNH996 VFDEPSVYDVLGIGFGPSNLSLAIALHEMGDVEGRPLAARFFEQQPSFGWHRNMLLPSAK MQVSFLKDLVTFRNPHSRFTFVSYLHEMNRLARFINNCDFFPTREEFHGYLEWAAATFAD QVTYGATITSISVPPDSGPGDPIDRVRVHLASGPTGTESSSVEARNVVLGTGLVPRFPAG LTSDDRVWHSSEFLGKFQRCDTTKLKRVLVVGGGQSAAEIAHFVYENVPGATVTAVIPSY GYSIADATPFANRVFDPSAIDDYYYGDENSKDAFWRYHRNTNYAVVDSDLISDLNRKAYD EAVTGETRLRFAELSRLSGVRRRDDGVVVSIHSMLSNRTSEVDADIVICATGYEPMEIGD MLGPLDRFCIRDEQGRYRVERDYRLATTEHLRCGIYLQGGMEHTHGLSSSLLSNLAVRNG DISTSVARRAQSQPHDDGRVLQGLVPTGS 38. >Salinispora_arenicola_CNH996B VFDEPSVYDVLGIGFGPSNLSLAIALHEMGDVEGRPLAARFFEQQPSFGW HRNMLLPSAKMQVSFLKDLVTFRNPHSRFTFVSYLHEMNRLARFINNCDF FPTREEFHGYLEWAAATFADQVTYGATITSISVPPDSGPGDPIDRVRVHL ASGPTGTESSSVEARNVVLGTGLVPRFPAGLTSDDRVWHSSEFLGKFQRC DTTKLKRVLVVGGGQSAAEIAHFVYENVPGATVTAVIPSYGYSIADATPF ANRVFDPSAIDDYYYGDENSKDAFWRYHRNTNYAVVDSDLISDLNRKAYD EAVTGETRLRFAELSRLSGVRRRDDGVVVSIHSMLSNRTSEVDADIVICA TGYEPMEIGDMLGPLDRFCIRDEQGRYRVERDYRLATTEHLRCGIYLQGG MEHTHGLSSSLLSNLAVRNGDISTSVARRAQSQPHDDGRVLQGLVPTGS 39. >Salinispora_tropica_CNY012 VTGKVHIVFDEPSVYDVLGIGFGPSNLSLAIALHEMGDVEGRPLAARFFEQQPSFGWHRN MLLPSAKMQVSFLKDLVTFRNPHSRFTFVSYLHEMNRLARFVNNCDFFPTREEFHGYLEW AATNFADQVTYGATITSISVPPDSGPGDPIDRVRVHLASGPTGTESSSVEARNVVLGTGL VPRFPAGLTSDDRVWHSSEFLGKFQRCDTTKLKRVLVVGGGQSAAEIAHFVYENVPGATV TAVIPSYGYSIADATPFANRVFDPSAIDDYYYGDENSRDAFWRYHRNTNYAVVDSDLISD LNRKAYDEAVTGEIRLRFAELSRLSGVRRRDDGVVVSIHSMLSNRTSEVDADIVICATGY EPMEIGDMLGPLDRFCIRDEHGRYRVERDYRLATTEHLRCGIYLQGGMEHTHGLSSSLLS NLAVRNGDISTSVARRAQSQPHGDGRVLQGLVPTGS 40. >Salinispora_tropica_CNT261 VTGKVHIVFDEPSVYDVLGIGFGPSNLSLAIALHEMGDVEGRPLAARFFEQQPSFGWHRN MLLPSAKMQVSFLKDLVTFRNPHSRFTFVSYLHEMNRLARFVNNCDFFPTREEFHGYLEW AATNFADQVTYGATITSISVPPDSGPGDPIDRVRVHLASGPTGTESSSVEARNVVLGTGL VPRFPAGLTSDDRVWHSSEFLGKFQRCDTTKLKRVLVVGGGQSAAEIAHFVYENVPGATV TAVIPSYGYSIADATPFANRVFDPSAIDDYYYGDENSRDAFWRYHRNTNYAVVDSDLISD LNRKAYDEAVTGEIRLRFAELSRLSGVRRRDDGVVVSIHSMLSNRTSEVDADIVICATGY EPMEIGDMLGPLDRFCIRDEHGRYRVERDYRLATTEHLRCGIYLQGGMEHTHGLSSSLLS NLAVRNGDISTSVARRAQSQPHGDGRVLQGLVPTGS 41. >Salinispora_tropica_CNH898 VTGKVHIVFDEPSVYDVLGIGFGPSNLSLAIALHEMGDVEGRPLAARFFEQQPSFGWHRN MLLPSAKMQVSFLKDLVTFRNPHSRFTFVSYLHEMNRLARFVNNCDFFPTREEFHGYLEW AATNFADQVTYGATITSISVPPDSGPGDPIDRVRVHLASGPTGTESSSVEARNVVLGTGL VPRFPAGLTSDDRVWHSSEFLGKFQRCDTTKLKRVLVVGGGQSAAEIAHFVYENVPGATV TAVIPSYGYSIADATPFANRVFDPSAIDDYYYGDENSRDAFWRYHRNTNYAVVDSDLISD LNRKAYDEAVTGETRLRFAELSRLSGVRRRDDGVVVSIHSMLSNRTSEVDADIVICATGY EPMEIGDMLGPLDRFCIRDEHGRYRVERDYRLATTEHLRCGIYLQGGMEHTHGLSSSLLS NLAVRNGDISTSVARRAQSQPHGDGRVLQGLVPTGS 42. >Streptomyces_sp._PsTaAH-137 MDTPGSLSQEIYDVVGIGFGPSNLSLAVALEEQGASSAQHPV 43. >Salinispora_arenicola_CNS296 MSNQHETYDLVGIGFGPSNLSLAIALKEYEANGQENGISTLFFERQSSFGWHRNMLLPST TMQISFLKDLVTFRNPTSGFSFISYLHASGRLPQFVNNQDFFPTRQEFHQYLEWAEERMA GRVAYGSEVTSIRLPSGTVPELSDRLRLEVTDAAGRVGRVVEARNVVISTGLVPRMPEGI ERDERVWHSSEFLQKYRRMNPGDLRRVAVVGAGQSAAEITRFLHDELPHAEVWVVIPSYG YSVADDTPFANQIFDPEAVDDYYFGTEQTRDAFWRYHRNTNYSVVDDEVIRDLYRRVYDA EVRGIKRLQILNLTRITGVKRAAAETRVELQVGPDSEVRELDVDALVCATGYDGMEPTHL LGDLDRLCLRDKAGRHQIERDYRIATAPEMRCGIYLQGGTEHTHGLSSSLLSNIAVRSGE IADSIVSRRARHNSEYALAAGAEGDTC 44. >Salinispora_arenicola_CNS299 MSNQHETYDLVGIGFGPSNLSLAIALKEYEANGQENGISTLFFERQSSFGWHRNMLLPST TMQISFLKDLVTFRNPTSGFSFISYLHASGRLPQFVNNQDFFPTRQEFHQYLEWAEERMA GRVAYGSEVTSIRLPSGTVPELSDRLRLEVTDAAGRVGRVVEARNVVISTGLVPRMPEGI ERDERVWHSSEFLQKYRRMNPGDLRRVAVVGAGQSAAEITRFLHDELPHAEVWVVIPSYG YSVADDTPFANQIFDPEAVDDYYFGTEQTRDAFWRYHRNTNYSVVDDEVIRDLYRRVYDA EVRGIKRLQILNLTRITGVKRAAAETRVELQVGPDSEVRELDVDALVCATGYDGMEPTHL LGDLDRLCLRDKAGRHQIERDYRIATAPEMRCGIYLQGGTEHTHGLSSSLLSNIAVRSGE IADSIVSRRARHNSEYALAAGAEGDTC 45. >Salinispora_pacifica_CNY363 MSNQHETYDLVGIGFGPSNLSLAIALKEYEANGQENGISTLFFERQSSFGWHRNMLLPST TMQISFLKDLVTFRNPTSGFSFISYLHASGRLPQFVNNQDFFPTRQEFHQYLEWAEERMA GRVAYCSEVTSIRLPSGIVPELSDRLRLEVTDAAGRVGRVVEARNVVISTGLVPRMPEGI ERDERVWHSSEFLQKYRRMNPGDLRRVAVVGAGQSAAEITRFLHDELPHAEVWVVIPSYG YSVADDTPFANQIFDPEAVDDYYFGTEQTRDAFWRYHRNTNYSVVDDEVIRDLYRRVYDA EVRGIKRLQILNLTRITGVKRAAAETRVELQVGPDSEVRELDVDALVCATGYDGMEPTHL LGDLDRLCLRDKAGRHQIERDYRIATAPEMRCGIYLQGGTEHTHGLSSSLLSNIAVRSGE IADSIVSRRARHNSEYALAAGAEGDTC 46. >Actinomadura_atramentaria_DSM_43919 VTGPATDADDILDIVGVGFGPSNLALAVAVREHNADRPAAEHLTQVYFEKQPAFGWHRGM LIDGATMQVSFIKDLVTMRNPASEYGFLSYLHDNDRLADFINHKSLFPSRVEFHDYLEWV ARRFQDVARYGSEVVAMRPGPGGDHIEVIVRRGGEHRVQRARNVVVAVGQEPALPDDIEL GDRIWHCAQLLERVERLTEEPRRAVVVGAGQSAAETTEFLHRRFENAEVSAIFLRYGYSV ADDTPFANRIFDPESVDVFYGAPENVKRMLFDYHRNTNYSVVDQELADELYRRVYQERVR GVERLRILNASRLHAVRRDVTGDGLRVDVEHLPTGEKRSFGVDLVVYATGYRPIDPANVL GEVAEYCRRDAGKRPAITRDYRLETDDRLRAGIYLQGGTEQTHGISAQLLSNTAVRAGEI VRSIAGARVGAV 47. >Streptomyces_drozdowiczii_SCSI0_10141 MTVNLGSTSVLEVAGIGFGPSNMALAIALEEMHGARANSPGPAMEFFEKQPAFGWHRGML MEDATMQVSFLKDLATMRDPQSRYTFMAYLKAKGRIARFINSKTLFPLRVEFHDYLEWVA DLLAPVVSYGSDVLAIRPVVEDGVMECLDVVVRTSAGDGEPIVRRARNVVIGTGLTPRLP DGTEESARVWHSSRLMDRAASIAAAPRGFVVVGAGQSAAEATEYLHRSFPGTPVSAVFAR YGYSVADDSPFTNGIFDPEAVDEFYAASRDVKQDLLDYHGNTNYAVVDLSLTEELYRRAY QEEVLGRERLRFHNASRVLKVEEHPDRVRVIVEHLPDRTVETLDADAVVYATGYRPSDPT PLLQNLLPECKLDDAGRITLDRDYRIVTSGDVRCGIYLHGASAECTHGLSAGLLSNTAVR SGEIADSIIKR 48. >Streptomyces_sp._RSD-27 MGITGRRDEEIYDVIGIGFGPSNMSLAIALQEHGAGVPLHPVRSHFFERQ PTFGWHRNMLLPSTTMQISFLKDLATFRNPMSRFSFVSYLHASNRLVQFV NNQSFIPTRQEFHQYLEWAAAGLRDQVTYGAEVTSVRPVTAAGSRTPDLL EVEVRTGDEVSVVTARNVVVSTGLVPRMPEGVPAGERVWHSSEFLARFNA QDPAELKSVAVVGAGQSAAEVTRFLYDSLPHAEVSAVIPSYGYSVADDTP FANQVFDPDTVDEYYFGTEGARDAFWRYHRNTNYSVVDADVIRSLYQRWY DEQVRGVQRLRFRNLTRVDGVEGSGSGARMVLRSLLDDSREELAVDAVVF ASGYDGLDPARLLGEDFDRHFQRDAAGRHRVERDYRLVSTSGLTCGVYLQ GGTEHSHGLTSALLSNIAIRSGEIADSIVLRRTERELGRHAEEAPSAA 49. >Actinoalloteichus_spitiensis_RMV-1378 MDGSFPVDGNQVSDVVGVGFGPSNLALAVAVAEHNEAVGPEERLRARFLERQPDFGWHRG MLLPDTTLQVSFLKDLVSLRNPRSSFSFISYLHDRNRLVDFVNHQCFFPSRREYHDYLEW VAGRFVDSVHYDHDVVDVLPVHEGPDVVAFDVVAVQGGAGATRRLRTRNVVLAPGLEPVL PQGITPSDRVWHSSELLHRLDGFRDRLPDRPRFVVVGAGQSAAEVMAHLHGVFPKATVRS VCSRYGFAPADDSPFVNQLFDPAAVDEFFEAALPARENILRVHAGTNYSAVDGDLISELY RRSYQERVSGEPRLHFERLARVVATEERDEEVSVSVLSLTDGRVTDRGCDVVVLATGYRP RDALRPLGQLAALCKLDANGWPRVERNYRITTTETVRAGIYLQGGTEHSHGLSSTLLSNL AVRSGEITRALAAP 50. >Streptomyces_sp._PBH53 MTRLAGQAPTAQHSPESEVRDVTGIGFGAANLALAVALHESGAGGRALFLEKQKEFGWHR GMLIEGSSLQVSFLKDIATMRNPTSDFGFLSYLQEKGRLVDFINQHTLLPSRIEYHDYLQ WAADRLGHMVEYGVEATGVRPVTDAGEVVALDVLAGDRVVTRTRNLVIASGLRPRLPEGA ETGERVWHSSQLLHRLPAFDERPPRRAVVVGAGQSAAEVAAHLMERYPQAEVCAVFSRYG YSVADSSPFANRVFDPAAVDDFYFAPPEVKQAIMRYHGGTNYAVVDEDVLQGLYRRQYEQ KVTGTPRLRVMNASRLVSVEPRGETAAVRVEFLPTGEHADLDADLVVYATGYRSADPAEL LGGVAGSLRRDAAGQVLIGRDYRLSTTGDFRCGIYVQGATEATHGIASTLLSMVAVRAGE IAQSIIGGRRDPDRTAGTKAVAGNRG 51. >Salinispora_arenicola_CNS-991_DSM_45545 MSNQHETYDLVGIGFGPSNLSLAIALKEYEANGQENGISTLFFERQSSFGWHRNMLLPST TMQISFLKDLVTFRNPTSGFSFISYLHASGRLPQFVNNQDFFPTRQEFHQYLEWAEERMA GRVAYGSEVTSIRLPSGTVPELSDRLRLEVTDAAGRVGRVVEARNVVISTGLVPRMPEGI ERDERVWHSSEFLQKYRRMNPGDLRRVAVVGAGQSAAEITRFLHDELPHAEVWVVIPSYG YSVADDTPFANQIFDPEAVDDYYFGTEQTRDAFWRYHRNTNYSVVDDEVIRDLYRRVYDA EVRGIKRLQILNLTRITGVKRAAAETRVELQVGPDSEVRELDVDALVCATGYDGMEPTHL LGDLDRLCLRDKAGRHQIERDYRIATAPEMRCGIYLQGGTEHTHGLSSSLLSNIAVRSGE IADSIVSRRARHNSEYALAAGAEGDTC 52. >Streptomyces_sp._MNU77 VEASASVTDVVGVGFGPANLALAIALRELGAGPPGGDGLTAAFLEAQPQFGWHSGMLIED STMQVSFLKDLVTPRNPVSPFSFVAYLHAVGRLGRFMDSKMMYPLRIEFHNYLEWVAGHF ANQVAYSRRVTALRPVHGQDGVEALDVVARDADGTERVLRARSVVLACGLRPRLPEGLTG SDRVWHTADLLPRARRLLESGAAPTSFVVLGAGQSSAEAAHYLHRTFTRSSVSVVHSRYG FSVSDDSPFANAVFGAKAVDEFYGAPDEVKRMVLDYHANTNYAVVDEDLIHRLYGDVYRE SLTGDDRLRFHHLSRLSTVTPGEDAVRVEVEALHDGRRTVIDADALVCATGYRPSDPADL MGDLLPLCARDEQDRLVLDRDRRLVTREPLAGGVYVTGYGEHTHGIAESLLSLTAQRAGE LTEALAKTFVT 53. >Micromonospora_pattaloongensis_DSM_45245 MSETDSATVRQVVGVGFGPANLALAIAAGEVAGPDGRTLLDECVFLERQP SFGWHRGMLLDGATMQVSFLKDLATLRSPSSRYTFTSYLHDVGRLTDFIN SKTLYPYRTDFHTYLEWAADRLPADVRYGTEVVSVTPERTDDVVRELLVR TGDGRTFRTRNLVIGTGMTPCFPDGVQRGPRVWHSAELLTRLAAPAPTRP RTFAVVGAGQSAAEVVEHLHATHPEADVHAIFGRFGYSMSDDSPFANQIF DPDSVDEFYHAPGEVRDALMGYHANTNYSVVDLDLIRSLHGTAYREHIAG RRRLHFHHASRITRQTVTGEGVHLDVEFLPTGTIRQIDADAIVYATGYRP SDPRQLLGDLADECKTDDRGRLALARDYRVITSDGVRCGIYVHGAAAERT HGLSAGLLSNVAVRAGEILAAIRSL 54. >Streptacidiphilus_carbonis_NBRC_100919 MGARENATYDVVGIGFGPSNLSLAIALEERCANVLTNSITSAFFERQSSF GWHRNMLLPSATMQISFLKDLVTFRNPVSRFSFVAFLHAKGRLGQFVNRK DFFPTRQEFHQYLEWAAAKMADAVTYDSTVTSVQLPPDHGSGGDGYVQLE VRDTAAGSTRRVNTRNVVVSTGLVPRMPDGIARDDRVWHSSEFLTRYGRT DPEVLRSVAVVGAGQSAAEITQFFHGRLPHAQVHAIMPSYGYSVADDTPF ANQVFDADAVEDYYDGDEPARDAFWRYHRNTNYGVVDSADIQALYQTQYD EGVAGAKRLHFHNLTKVRAVERNGSARRVTLQSLRHHEVRQLDVDAIVFA TGYASMDPTQLLGDLDRYCLRDESGHHRVTRDYRLVTTPELSCGIYLQGG TEHTHGLTSSLLSNIAVRSGEIADSIICRRAESELATIAAEVREAVAERL 55. >Streptomyces_sp._MnatMP-M27 MTDSAPGDRTVDVTGIGFGPSNLALATALAEPSATGPGRPLEAVYFERKN RFSWHGGMLLDGATMQISFLKDLVTLRDPRSPYSFLSYLHHAGRLSDFIN HKLLFPSRIEFHDYLEWVAGFFEEQVVYGSEVVDVRPVAREDAVEHMDVV VRQRTAAGERTVVQRTRDLVVATGLEPSLPPGTVCSDRVWHSSELLYRVE RLPPTPRRIVVVGAGQSAAEAAEFLHSRFPSTDICAVFSRYGYSPSDDSP FANRIFDPAAVDDYCAAAPETRRMLLDYHRNTNYSVVDPELIDELYRRVY QEKVRGRPRLNILGASRLTAAEPAGDGVDVVVESLVTGERTPMRADCVVY ATGYRPTDARGLLGSMAGLCKADELGRLEADRRYRVITEGDVRCAIYLQG ATEHSHGISSSLLSNTAVRAGEIADAIRADAVRAGARATTRSQPQPQT 56. >Pseudonocardia_sp._EC080625-04 MCTCKSDVYDVVGIGFGPSNLSLAIALGEHQGNRAGHPVKAAFFERQQSF GWHRNMLLPETTMQISFMKDLVTFRNPRSRFSFVNYLHESGRLTQFCNNQ DFFPTRQEFHRYLEWVGSSFDDQVSYDSEVLGVTLAPEPCECAQRYLKLE ISNGAIGATEIVNARNISISTGLVPKVPDNVATGDRIWHSSQFLEKLRDV DPADLRNVAVVGGGQSAAEIARYLHATLPEAQIYAIVPSYGYSVADDTPF ANQVFDPEAVDDYYFGSDETRDAFWRYHRNTNYSVVDDDIIRDLHRASYA EQVTGERRLHFLNLTRVRAVTRNGATNRVSLHSLIDRETRELDIDALVLA TGYTEMTPTGLIGDVDHFCHRDPEGRYRIERDYRLMTDPEFPCGIYLQGG TEHTHGLTSSLLSNVAVRGGEIADSVITRTRADAPTMQRSTRRIEQAWER AG 57. >Pseudonocardia_sp._HH130629-09 MCTCKSDVYDVVGIGFGPSNLSLAIALGEHQGNRAGHPVKAAFFERQQSF GWHRNMLLPETTMQISFMKDLVTFRNPRSRFSFVNYLHESGRLTQFCNNQ DFFPTRQEFHRYLEWVGSSFDDQVSYDSEVLGVTLAPEPCECAQLYLKLE ISNGAIGATEIVNARNISISTGLVPKVPDNVPTGDRIWHSSQFLEKLRDV DPADLRNVAVVGGGQSAAEIARYLHATLPEAQIYAIVPSYGYSVADDTPF ANQVFDPEAVDDYYFGSDETRDAFWRYHRNTNYSVVDDDIIRDLHRASYA EQVTGERRLHFLNLTRVRAVTRNGATNRVSLHSLIDRETRELDIDALVLA TGYTEMTPTGLIGDVDHFCHRDPEGRYRIERDYRLMTDPEFPCGIYLQGG TEHTHGLTSSLLSNVAVRGGEIADSVITRTRADAPTMQRSTRRIEQAWER AG 58. >Streptomyces_parvulus_2297 MGITGRRNEEILDVVGIGFGPSNLSLAIALEEHGASAPRHPVTSHFFERQ PTFGWHRNMLLPSTTMQISFLKDLATFRNPMSRFSFISYLHASDRLVQFV NNQDFFPTRQEFHQYLEWAASGLSDRVTYGAEVTAIRPGSDGNGLSPDLL EVEARTADGTTRVVTARNVAISTGLVPRLPEGVTADERVWHSSQFLSRFN AQSPDDLKSVAVVGAGQSAAEITRFLHDALPHAQVCAVVPSYGYSVADDT PFANQVFDPAAVDDYYFGTDRGRDAFWRYHRNTNYSVVDADVIRDLHQRT YDEEVRGTRRLHFRNLTRVAEVERSGSTTRVVLRSLLDDRTEDLSVDALV FATGYDGLDPVRLLGDFDRHFRRDAAGRHRLERDYRLVPATDLTCGVYLQ GGTEHSHGLSSSLLSNIAVRSGEIADSIVLRRTERELERDRPVEVAPPVA 59. >Streptomyces_sp._CFMR_7 MAIRAGSHILDVVGIGFGPSNLALAIALQEMIKADTGRTEYAMAFHERQP RFGWHRGMLMEDATMQVSFLKDLATMRNATSRYTFVAYLQEQGRVAEFIN SKTLYPLRVEFHDYLEWAAQQFDASVSYGSEIVAVRPVIESGSVEYVDVV ARSASGGSSTVVQRARNVVIGMGLTPRLPDGIEESERIWHSSQLLHRADS LPYRPRNFVVVGSGQSAAEVADYLHRTFSDANVHTVLSRYGYSVADDSPF ANGVFDPEAVDRFYTSSADAKQRLLDYHGNTNYSVVDLEVSQDLYRRSYQ EKVLGKQRLRMLNSSRVTSAEEHADGVRVIVEAMDSGSVRTMDADVIVYA TGYRPSDAAPLLSELAGECKRDEEGRLAVERDYRVITSEAVRCGIYVHGA VTEHSHGLSAGLLSNTAVRSGEIARSILRR 60. >Streptomyces_sp._DvalAA-19 MAIRAGSHISDVVGIGFGPSNLALAIALQEMIKADTGRTEYAMAFHERQP RFGWHRGMLMEDATMQVSFLKDLATMRNATSRYTFVAYLQEKGRVAEFIN SKTLYPLRVEFHDYLEWAAQQFDASVSYGSEIVAVRPVIESGSVEYVDVV ARSASGGSSTVVQRARNVVIGMGLTPRLPDGIEESERIWHSSQLLHRADS LPYRPRNFVVVGSGQSAAEVADYLHRTFSDANVHTVLSRYGYSVADDSPF ANGVFDPEAVDRFYTSSADAKQRLLDYHGNTNYSVVDLEVSQDLYRRSYQ EKVLGKQRLRMLNSSRVTSAEEHADGVRVIVEAMDSGSVRTMDADVIVYA TGYRPSDAAPLLSELAGECKRDEEGRLAVERDYRVITSEAVRCGIYVHGA VTEHSHGLSAGLLSNTAVRSGEIARSILRR 61. >Rhodococcus_fascians_A3b MGAQSGSSVADVVGVGFGPSNLALAIALQESIQPGPVPAKFSMKFYELQP RFGWHRGMLMEDATMQVSFLKDLATMRNPMSRYTFVSYLREKERIAEFIN SKTLYPLRVEFHDYLEWAASQFQSNVSYGSEIKDIRPVVENGVVEYVDVV GPDDVVQRARNIVIGMGLTPRLPDGVNRSERIWHSSQLLGRAAAVTYVPQ NFVVVGSGQSAAEVADYLHRTFPRANVHTVLSRYGYSVADDSPYANGIFD PEGVDRFFSAPTDEKQRLLEYHANTNYSVVDLDISQSLYLKSYQEKVLGK QRLRMINTSRVTSVDEDTDGVRVEVTSSATGLTHTIEADVIVYATGYRPS DPAPLLQGLMRECKHDEQGRLSVGRDYRVTTSDAVRAGIYVHGASTEHSH GLSAGLLSNTAVRSGEIAQSILRR 62. >Rhodococcus_fascians_A73a MGAQSGSSVADVVGVGFGPSNLALAIALQESIQPGPVPAKFSMKFYELQP RFGWHRGMLMEDATMQVSFLKDLATMRNPMSRYTFVSYLREKERIAEFIN SKTLYPLRVEFHDYLEWAASQFQSNVSYGSEIKDIRPVVENGVVEYVDVV GPDDVVQRARNIVIGMGLTPRLPDGVNRSERIWHSSQLLGRAAAVTYVPQ NFVVVGSGQSAAEVADYLHRTFPRANVHTVLSRYGYSVADDSPYANGIFD PEGVDRFFSAPTDEKQRLLEYHANTNYSVVDLDISQSLYLKSYQEKVLGK QRLRMINTSRVTSVDEDTDGVRVEVTSSATGLTHTIEADVIVYATGYRPS DPAPLLQGLMRECKHDEQGRLSVGRDYRVTTSDAVRAGIYVHGASTEHSH GLSAGLLSNTAVRSGEIAQSILRR 63. >Rhodococcus_fascians_A76 MGAQSGSSVADVVGVGFGPSNLALAIALQESIQPGPVPAKFSMKFYELQP RFGWHRGMLMEDATMQVSFLKDLATMRNPMSRYTFVSYLREKERIAEFIN SKTLYPLRVEFHDYLEWAASQFQSNVSYGSEIKDIRPVVENGVVEYVDVV GPDDVVQRARNIVIGMGLTPRLPDGVNRSERIWHSSQLLGRAAAVTYVPQ NFVVVGSGQSAAEVADYLHRTFPRANVHTVLSRYGYSVADDSPYANGIFD PEGVDRFFSAPTDEKQRLLEYHANTNYSVVDLDISQSLYLKSYQEKVLGK QRLRMINTSRVTSVDEDTDGVRVEVTSSATGLTHTIEADVIVYATGYRPS DPAPLLQGLMRECKHDEQGRLSVGRDYRVTTSDAVRAGIYVHGASTEHSH GLSAGLLSNTAVRSGEIAQSILRR 64. >Rhodococcus_fascians_A78 MGAQSGSSVADVVGVGFGPSNLALAIALQESIQPGPVPAKFSMKFYELQP RFGWHRGMLMEDATMQVSFLKDLATMRNPMSRYTFVSYLREKERIAEFIN SKTLYPLRVEFHDYLEWAASQFQSNVSYGSEIKDIRPVVENGVVEYVDVV GPDDVVQRARNIVIGMGLTPRLPDGVNRSERIWHSSQLLGRAAAVTYVPQ NFVVVGSGQSAAEVADYLHRTFPRANVHTVLSRYGYSVADDSPYANGIFD PEGVDRFFSAPTDEKQRLLEYHANTNYSVVDLDISQSLYLKSYQEKVLGK QRLRMINTSRVTSVDEDTDGVRVEVTSSATGLTHTIEADVIVYATGYRPS DPAPLLQGLMRECKHDEQGRLSVGRDYRVTTSDAVRAGIYVHGASTEHSH GLSAGLLSNTAVRSGEIAQSILRR 65. >Rhodococcus_fascians_D188 MGAQSGSSVADVVGVGFGPSNLALAIALQESIQPGPVPAKFSMKFYELQP RFGWHRGMLMEDATMQVSFLKDLATMRNPMSRYTFVSYLREKERIAEFIN SKTLYPLRVEFHDYLEWAASQFQSNVSYGSEIKDIRPVVENGVVEYVDVV GPDDVVQRARNIVIGMGLTPRLPDGVNRSERIWHSSQLLGRAAAVTYVPQ NFVVVGSGQSAAEVADYLHRTFPRANVHTVLSRYGYSVADDSPYANGIFD PEGVDRFFSAPTDEKQRLLEYHANTNYSVVDLDISQSLYLKSYQEKVLGK QRLRMINTSRVTSVDEDTDGVRVEVTSSATGLTHTIEADVIVYATGYRPS DPAPLLQGLMRECKHDEQGRLSVGRDYRVTTSDAVRAGIYVHGASTEHSH GLSAGLLSNTAVRSGEIAQSILRR 66. >Rhodococcus_fascians_02-816c MGAQSGSSVADVVGVGFGPSNLALAIALQESIQPGPVPAKFSMKFYELQP RFGWHRGMLMEDATMQVSFLKDLATMRNPMSRYTFVSYLREKERIAEFIN SKTLYPLRVEFHDYLEWAASQFQSNVSYGSEIKDIRPVVENGVVEYVDVV GPDDVVQRARNIVIGMGLTPRLPDGVNRSERIWHSSQLLGRAAAVTYVPQ NFVVVGSGQSAAEVADYLHRTFPRANVHTVLSRYGYSVADDSPYANGIFD PEGVDRFFSAPTDEKQRLLEYHANTNYSVVDLDISQSLYLKSYQEKVLGK QRLRMINTSRVTSVDEDTDGVRVEVTSSATGLTHTIEADVIVYATGYRPS DPAPLLQGLMRECKHDEQGRLSVGRDYRVTTSDAVRAGIYVHGASTEHSH GLSAGLLSNTAVRSGEIAQSILRR 67. >Rhodococcus_fascians_05-339-1 MGAQSGSSVADVVGVGFGPSNLALAIALQESIQPGPVPAKFSMKFYELQP RFGWHRGMLMEDATMQVSFLKDLATMRNPMSRYTFVSYLREKERIAEFIN SKTLYPLRVEFHDYLEWAASQFQSNVSYGSEIKDIRPVVENGVVEYVDVV GPDDVVQRARNIVIGMGLTPRLPDGVNRSERIWHSSQLLGRAAAVTYVPQ NFVVVGSGQSAAEVADYLHRTFPRANVHTVLSRYGYSVADDSPYANGIFD PEGVDRFFSAPTDEKQRLLEYHANTNYSVVDLDISQSLYLKSYQEKVLGK QRLRMINTSRVTSVDEDTDGVRVEVTSSATGLTHTIEADVIVYATGYRPS DPAPLLQGLMRECKHDEQGRLSVGRDYRVTTSDAVRAGIYVHGASTEHSH GLSAGLLSNTAVRSGEIAQSILRR 68. >Rhodococcus_fascians_LMG_3605 MGAQSGSSVADVVGVGFGPSNLALAIALQESIQPGPVPAKFSMKFYELQP RFGWHRGMLMEDATMQVSFLKDLATMRNPMSRYTFVSYLREKERIAEFIN SKTLYPLRVEFHDYLEWAASQFQSNVSYGSEIKDIRPVVENGVVEYVDVV GPDDVVQRARNIVIGMGLTPRLPDGVNRSERIWHSSQLLGRAAAVTYVPQ NFVVVGSGQSAAEVADYLHRTFPRANVHTVLSRYGYSVADDSPYANGIFD PEGVDRFFSAPTDEKQRLLEYHANTNYSVVDLDISQSLYLKSYQEKVLGK QRLRMINTSRVTSVDEDTDGVRVEVTSSATGLTHTIEADVIVYATGYRPS DPAPLLQGLMRECKHDEQGRLSVGRDYRVTTSDAVRAGIYVHGASTEHSH GLSAGLLSNTAVRSGEIAQSILRR 69. >Rhodococcus_fascians_LMG_3616 MGAQSGSSVADVVGVGFGPSNLALAIALQESIQPGPVPAKFSMKFYELQP RFGWHRGMLMEDATMQVSFLKDLATMRNPMSRYTFVSYLREKERIAEFIN SKTLYPLRVEFHDYLEWAASQFQSNVSYGSEIKDIRPVVENGVVEYVDVV GPDDVVQRARNIVIGMGLTPRLPDGVNRSERIWHSSQLLGRAAAVTYVPQ NFVVVGSGQSAAEVADYLHRTFPRANVHTVLSRYGYSVADDSPYANGIFD PEGVDRFFSAPTDEKQRLLEYHANTNYSVVDLDISQSLYLKSYQEKVLGK QRLRMINTSRVTSVDEDTDGVRVEVTSSATGLTHTIEADVIVYATGYRPS DPAPLLQGLMRECKHDEQGRLSVGRDYRVTTSDAVRAGIYVHGASTEHSH GLSAGLLSNTAVRSGEIAQSILRR 70. >Rhodococcus_fascians_LMG_3623 MGAQSGSSVADVVGVGFGPSNLALAIALQESIQPGPVPAKFSMKFYELQP RFGWHRGMLMEDATMQVSFLKDLATMRNPMSRYTFVSYLREKERIAEFIN SKTLYPLRVEFHDYLEWAASQFQSNVSYGSEIKDIRPVVENGVVEYVDVV GPDDVVQRARNIVIGMGLTPRLPDGVNRSERIWHSSQLLGRAAAVTYVPQ NFVVVGSGQSAAEVADYLHRTFPRANVHTVLSRYGYSVADDSPYANGIFD PEGVDRFFSAPTDEKQRLLEYHANTNYSVVDLDISQSLYLKSYQEKVLGK QRLRMINTSRVTSVDEDTDGVRVEVTSSATGLTHTIEADVIVYATGYRPS DPAPLLQGLMRECKHDEQGRLSVGRDYRVTTSDAVRAGIYVHGASTEHSH GLSAGLLSNTAVRSGEIAQSILRR 71. >Rhodococcus_fascians_A22b MGAQSGSSVADVVGVGFGPSNLALAIALQESIQPGPVPAKFSMKFYELQP RFGWHRGMLMEDATMQVSFLKDLATMRNPMSRYTFVSYLREKERIAEFIN SKTLYPLRVEFHDYLEWAASQFQSNVSYGSEIKDIRPVVENGVVEYVDVV GPDDVVQRARNIVIGMGLTPRLPDGVNRSERIWHSSQLLGRAAAVTYVPQ NFVVVGSGQSAAEVADYLHRTFPRANVHTVLSRYGYSVADDSPYANGIFD PEGVDRFFSAPTDEKQRLLEYHANTNYSVVDLDISQSLYLKSYQEKVLGK QRLRMINTSRVTSVDEDTDGVRVEVTSSATGLTHTIEADVIVYATGYRPS DPAPLLQGLMRECKHDEQGRLSVGRDYRVTTSDAVRAGIYVHGASTEHSH GLSAGLLSNTAVRSGEIAQSILRR 72. >Salinispora_arenicola_CNS848 MSNQHETYDLVGIGFGPSNLSLAIALKEYEANGQENGISTLFFERQSSFG WHRNMLLPSTTMQISFLKDLVTFRNPTSGFSFISYLHASGRLPQFVNNQD FFPTRQEFHQYLEWAEERMAGRVAYGSEVTSIRLPSGTVPELSDRLRLEV TDAAGRVGRVVEARNVVISTGLVPRMPEGIERDERVWHSSEFLQKYRRMN PGDLRRVAVVGAGQSAAEITRFLHDELPHAEVWVVIPSYGYSVADDTPFA NQIFDPEAVDDYYFGTEQTRDAFWRYHRNTNYSVVDDEVIRDLYRRVYDA EVRGIKRLQILNLTRITGVKRAAAETRVELQVGPDSEVRELDVDALVCAT GYDGMEPTHLLGDLDRLCLRDKAGRHQIERDYRIATAPEMRCGIYLQGGT EHTHGLSSSLLSNIAVRSGEIADSIVSRRARHNSEYALAAGAEGDTC 73. >Salinispora_arenicola_CNY231 MSNQHETYDLVGIGFGPSNLSLAIALKEYEANGQENGISTLFFERQSSFG WHRNMLLPSTTMQISFLKDLVTFRNPTSGFSFISYLHASGRLPQFVNNQD FFPTRQEFHQYLEWAEERMAGRVAYGSEVTSIRLPSGTVPELSDRLRLEV TDAAGRVGRVVEARNVVISTGLVPRMPEGIERDERVWHSSEFLQKYRRMN PGDLRRVAVVGAGQSAAEITRFLHDELPHAEVWVVIPSYGYSVADDTPFA NQIFDPEAVDDYYFGTEQTRDAFWRYHRNTNYSVVDDEVIRDLYRRVYDA EVRGIKRLQILNLTRITGVKRAAAETRVELQVGPDSEVRELDVDALVCAT GYDGMEPTHLLGDLDRLCLRDKAGRHQIERDYRIATAPEMRCGIYLQGGT EHTHGLSSSLLSNIAVRSGEIADSIVSRRARHNSEYALAAGAEGDTC 74. >Salinispora_arenicola_CNY280 MSNQHETYDLVGIGFGPSNLSLAIALKEYEANGQENGISTLFFERQSSFG WHRNMLLPSTTMQISFLKDLVTFRNPTSGFSFISYLHASGRLPQFVNNQD FFPTRQEFHQYLEWAEERMAGRVAYGSEVTSIRLPSGTVPELSDRLRLEV TDAAGRVGRVVEARNVVISTGLVPRMPEGIERDERVWHSSEFLQKYRRMN PGDLRRVAVVGAGQSAAEITRFLHDELPHAEVWVVIPSYGYSVADDTPFA NQIFDPEAVDDYYFGTEQTRDAFWRYHRNTNYSVVDDEVIRDLYRRVYDA EVRGIKRLQILNLTRITGVKRAAAETRVELQVGPDSEVRELDVDALVCAT GYDGMEPTHLLGDLDRLCLRDKAGRHQIERDYRIATAPEMRCGIYLQGGT EHTHGLSSSLLSNIAVRSGEIADSIVSRRARHNSEYALAAGAEGDTC 75. >Salinispora_arenicola_CNT005 MSNQHETYDLVGIGFGPSNLSLAIALKEYEANGQENGISTLFFERQSSFG WHRNMLLPSTTMQISFLKDLVTFRNPTSGFSFISYLHASGRLPQFVNNQD FFPTRQEFHQYLEWAEERMAGRVAYGSEVTSIRLPSGTVPELSDRLRLEV TDAAGRVGRVVEARNVVISTGLVPRMPEGIERDERVWHSSEFLQKYRRMN PGDLRRVAVVGAGQSAAEITRFLHDELPHAEVWVVIPSYGYSVADDTPFA NQIFDPEAVDDYYFGTEQTRDAFWRYHRNTNYSVVDDEVIRDLYRRVYDA EVRGIKRLQILNLTRITGVKRAAAETRVELQVGPDSEVRELDVDALVCAT GYDGMEPTHLLGDLDRLCLRDKAGRHQIERDYRIATAPEMRCGIYLQGGT EHTHGLSSSLLSNIAVRSGEIADSIVSRRARHNSEYALAAGAEGDTC 76. >Salinispora_arenicola_CNY230 MSNQHETYDLVGIGFGPSNLSLAIALKEYEANGQENGISTLFFERQSSFG WHRNMLLPSTTMQISFLKDLVTFRNPTSGFSFISYLHASGRLPQFVNNQD FFPTRQEFHQYLEWAEERMAGRVAYCSEVTSIRLPSGTVPELSDRLRLEV TDAAGRVGRVVEARNVVISTGLVPRMPEGIERDERVWHSSEFLQKYRRMN PGDLRRVAVVGAGQSAAEITRFLHDELPHAEVWVVIPSYGYSVADDTPFA NQIFDPEAVDDYYFGTEQTRDAFWRYHRNTNYSVVDDEVIRDLYRRVYDA EVRGIKRLQILNLTRITGVKRAAAETRVELQVGPDSEVRELDVDALVCAT GYDGMEPTHLLGDLDRLCLRDKAGRHQIERDYRIATAPEMRCGIYLQGGT EHTHGLSSSLLSNIAVRSGEIADSIVSRRARHNSEYALAAGAEGDTC 77. >Salinispora_arenicola_CNY486 MSNQHETYDLVGIGFGPSNLSLAIALKEYEANGQENGISTLFFERQSSFG WHRNMLLPSTTMQISFLKDLVTFRNPTSGFSFISYLHASGRLPQFVNNQD FFPTRQEFHQYLEWAEERMAGRVAYCSEVTSIRLPSGTVPELSDRLRLEV TDAAGRVGRVVEARNVVISTGLVPRMPEGIERDERVWHSSEFLQKYRRMN PGDLRRVAVVGAGQSAAEITRFLHDELPHAEVWVVIPSYGYSVADDTPFA NQIFDPEAVDDYYFGTEQTRDAFWRYHRNTNYSVVDDEVIRDLYRRVYDA EVRGIKRLQILNLTRITGVKRAAAETRVELQVGPDSEVRELDVDALVCAT GYDGMEPTHLLGDLDRLCLRDKAGRHQIERDYRIATAPEMRCGIYLQGGT EHTHGLSSSLLSNIAVRSGEIADSIVSRRARHNSEYALAAGAEGDTC 78. >Salinispora_pacifica_CNY331 MSNQHETYDLVGIGFGPSNLSLAIALKEYEANGQENGISTLFFERQSSFG WHRNMLLPSTTMQISFLKDLVTFRNPTSGFSFISYLHASGRLPQFVNNQD FFPTRQEFHQYLEWAEERMAGRVAYCSEVTSIRLPSGTVPELSDRLRLEV TDAAGRVGRVVEARNVVISTGLVPRMPEGIERDERVWHSSEFLQKYRRMN PGDLRRVAVVGAGQSAAEITRFLHDELPHAEVWVVIPSYGYSVADDTPFA NQIFDPEAVDDYYFGTEQTRDAFWRYHRNTNYSVVDDEVIRDLYRRVYDA EVRGIKRLQILNLTRITGVKRAAAETRVELQVGPDSEVRELDVDALVCAT GYDGMEPTHLLGDLDRLCLRDKAGRHQIERDYRIATAPEMRCGIYLQGGT EHTHGLSSSLLSNIAVRSGEIADSIVSRRARHNSEYALAAGAEGDTC 79. >Streptomyces_aureofaciens_NRRL_2209 VGERQRSGVVAGTGIVDVAGIGFGPSNLALAAAIAEIAGEAPVSARFFEA QPRFGWHRGMLIEGATMQVSYLKDLVTMRNPTSPYSFLCYLQARGRLADF INTKSPYPLRVEFHDYLEWVAESFADLVSYGARVVSVEPVSAEQGVEFLD VHFVAPDGTRQVQRARNLVIAAGIEPRLPAGLPASPRIWHTAKFLPEVDR IARQDPRSFVVLGSGQSAAEAIEHLHARFPRAQVHSVHARYGFSVADDSP FANQVFNPEAVDRFHTAPDDVRQRLIDYHASTNYSVVDADLLHSLFQQAY LEKVAGNPRLNFHNVSRVSEVTETPDGLRIDVESLSSGTSTVIEAQALVC ATGYTRTDPAVFLDGLLPHCPLDDQGRLRLDREHRVVTDESVRCGIYVQG FGEHSHGLSETLLSLSAVRAGEIGDMLVKALSG 80. >Streptomyces_sp._OK885 MGARETEVYDVVGVGFGPSNLSLAVAIQEHNSSTSDRPLTAAFFERQEAF GWHRNMLLPAATMQIPFLKDIATFRNPASRYSFVAYLHASGRLAGFVNNQ TFFPTRREFHRYLEWVAANFTDQVSYGCEVVGLRLSGQGTGAGAPAHLEI EVAGGAGRQRSSVRARNVVVSTGLVPRMPEGVLGDDRVWHSSEFLTRFRG LKPVDLRAVAVVGAGQSAAEITRFVHDAAPHAQVYSVIPSYGYALADDTP FANQVFDPAAVDDYFFGTDRARQAFWDYHKNTNYSVVDDDVIRDLYRRSY DEEVNGARRLHFLNLTRVGEVKRAGDETRVLLMNGERRELEVDLCVFATG YHGMEPAGVLGDLAPYCLRDEAGRLRVERDYRLVTGPELPGGIYLQGGTE HTHGLSSSLLSNIAVRSGEIAESIVSRHRIERELGQVHPAEPAGKIR 81. >Pseudonocardia_sp._AL041005-10 MDTDDMGTYDFVGIGFGPSNLSLAAALRDASSSDASPVRGHFFEAQPSFG WHRNMLLPSAKMQVSFLKDLVTFRNPHSRFSFVSYLHEMNRLPQFANNND FFPTRREFHQYLEWVAGHFADSVTYGARVTGIEPICGGATAGPHDRFRIT IASGKDALATTRVEAYNVVLATGLTPRMPEGSVRDDRVWHSSEFLERFGS CSSASLRRVAVVGAGQSAAEIARFCYDHAPNATISAILPSYGYSIADNTP FANRVFDPGAVDDYYFSDPLGKDRLWESHRNTNYSVVDDEVIRSLFQRQY DDEVRGVERLQIINLARVANIKRSGDETRVTIHSLARDEHFDLDVDVVVC ATGYEAMGADGVLAGLDAFCPRDDRGRHRVERDYRLITTDDLTAGIYLQG GTEHTHGLTSSLLSNLATRSGEIASSLRSSRRVGSAGGDRW PzbB 82. >Mycobacterium_marinum_M MYERPGYSAIEPAAVLDLLTANPLGLVVTIDGARPLATHAPVLFSQGPNGVAQAEVASGD APLVGSLLVGHMNADNPQWRGMQKGGRVLVAFQGPHGYVSPSVYGVTPASPTWNFTAVHI AGTLEPIADPESTFELVCDTARRLEARFGHGWRQEPSLDYFRRIVSGVGAFEIQVESVQT MFKLSQEQPPVLRRRVAEHFESSDSVLHQELADLMRKHVFPKPI 83. >Lentzea_flaviverrucosa_DSM_44664 MFVPAQYREPHGHWITDLVRGHPLAQLVSNGPAGSSPYVTHAPIILDPGHPDPHPDDLHG AVLWGHLNRANPHWAALGDGTEVTAVFTGPGSYVSPTVYERTPAAPTWDFTAVHVRGTLR RVLDAEQTLATVTATVRAFEADHGTGWSMESSLDYFDQLLPGVGAFRLAVTGVDAMFKLS QEQPPEVRLRVRDHFAGSERTHHCLIAEMMDRLPVAEH 84. >Streptomyces_aureofaciens_ATCC_10762 VFTPKLYQVDGDDWPLRIIERHPLAVLVSNGDPVPNATHVPVIAPPDAAPEDALSGMRLW AHLTRANPHWQQLAAAGGGPAKLVFHGPNGYVTPSLYSADMVAPTWNYVAVHLEGTVELA GDDETLAIVHTTAQTLEDRFGDGMALAPSLEYHRQIVGAVGGLFFTVTKVDVMFKLSQEK DPEVQQRVLDRFAASGSGLHREVADTMRALRLGGSAG 85. >Streptomyces_diastatochromogenes_NRRL_B-1698 VYIPDLYRTDDKEWPVRILEENPLGLLTTHASSSAPPFATHLPVIIPSGSRDALLQDEKW RGATLLGHMNRANPHWQSLADGTPARIVFQGPGAYVSPSVYHTDPAAPTWDFTAVHVQGT LWPVRDEAETLAIVTATATELERKFGTGWCPHSSTEYFRQLLAGVGAFELRVDTMDAMFK LSQEKSHEIRNGVVDWFVQGQHGRSRELASLMAEFYKDDRGTGA 86. >Streptomyces_sp._DvalAA-43 MFVPSHYREPDGSWMIDLIRANPMAIMAINGSSADGPFATHLPVIPDPAATGRRSADLSG ATLLGHMNRANPQWAALESGGVALLIFTGPHGYVSPTVYEMAPAAPTWNFTSVHVHGMVE KIDSTEETLGVVKSTVTALETDFGTDWDMSGSVDYFRKIVPAVGAFRFTVSGAEGMFKLS QEQPAEVRDRVQTSFSCREQGRYRETAELMGRLPG 87. >Collimonas_fungivorans_Ter6 MYVPEYYRVDENTARELVYRHPLALLVCNGNNGLPWATHLPAIFPPETRKLLDQGESIIG KTMYGHMNRINPHWNALQAGSALLIFQGPNSYVSPTVYEVTPAAPTWNFTSTHLRGTLRP IDERDQILEIVRWTVATFEKEFCTNWDLTESIPYFERIVHGVGAFAFEVESFDSMFKLSQ EQPAAIQERVVNSFASSSHCPHKEIADLMQRTNSKNKK 88. >Streptomyces_reticuli_TUE45 VYERPLYREDRDGVVLAFLHHHPLALVVTAHEGVPVATHAPVLFRHGPDGADAEAVAAGT VPLAGSTLIGHMNVENPQWRRMRSGDQALIVFQGPHGYVSPTVYDVTPAAPTWNFTAVHV TGTVEPTAEPADVLDIVSDTARRLEGRFGRGWDQESSLDYFRQIAPGVGAFTLRVESVQT MFKLSQEKPTPMRRRVAEQFEASESGTHRALAGMMRAHGLTDADEERETAG 89. >Streptomyces_scabiei_NCPPB_4086 MFVPDPYREPDGSWMTELIRLNPFALLVSNGPADADPYATHLPVLRDPEWTGEWTEDLAG GRLVGHMNRENPHWTALETGTPVLITFTGPHAYVSPIVYDITPAAPTWDFTSVHVHGVFH KIEAAAPGEDTLEVCKDTVKAYERDFGAAKAWDMSRSIDYFATILPAVGAFRVEITGAEG MFKLSQEQDQEIRERVQKDFALRDSTQYRETADLMDRMEKTGTVQGCPVHH 90. >Kutzneria_albida_DSM_43870 MFVPSHYREPDVSWMVDLMRQNPLALLASNGNPADGPFATHLPVITDPAWDGPPAEKLAG WPLLGHMNRANPQWTALENGATVLLTFTGPHAYVSPTVYEISPAAPTWNFTSVHAHGVVE KIESIEETLEVVQATVKVFEKFFGDSWDMTESLGYFRKIVPAVGAFRIRVTRADGMFKLS QEQKPEVRKRVVTSFSERGCGRHAQTAALMTQLP 91. >Streptomyces_albus_ZpM MFVPPEYRPDDPEWLIEVIRSHPLACLVTNGPDGPRASHVPVIPDPEQFPSGMPAREGEV AGRRLFGHMNRLNPHWAALQGGAQALLVFQGPNGYVSPTVYEYTPAAPTWDFTAVHVRGW LEPVGDRESSLQIITETVAAYERDLGTGWDMTESLGYFRQLLPGVGAFRLAIDTVDGMFK LSQEQSPEVRERVACEFAARAEARGTALAEHIQRTK 92. >Rhodococcus_fascians_02-815 MYVPRIYKASDRTWLRRVVAQYPFAALISNGPKAPYATHLPVICAPCAPSESEDLEGSTL FGHMNRANPHWDSLVDGADAQLIFTGPHGYVTPSVYQRDSVAPTWNYVSVHLRGKLQPVA DFEETLKVVQLTVSTYEQKFGSGWEMDSSLDHYRRIGPAVGAFSFEVESADGMFKLSQEQ NLETRRRVADHFSANHAGRGKELASFMREYSHGDYNNF 93. >Streptomyces_neyagawaensis_NRRL_B-3092 MFVPDPYREPDGSWMTELIRLNPFALLVSNGPADADPYATHLPVIRDPEWTGAWTENLAG GRLIGHMNRENPHWTALENGTPVLITFTGPHAYVSPTVYDITPAAPTWDFTSVHVHGVFE KIEAAAPGEDSLEVCKDTVKAYERDFGAAKAWDMSRSIDYFATILPAVGAFRVEITGAEG MFKLSQEQDEEIRERVREDFALRDSSQYRETAELMDRMEKTGTIKGCPVHH 94. >Kutzneria_buriramensis_DSM_45791 MFVPHHYHEPNESWMTDLIRENPLAELVSNGNGPAGPFATHVPVIPDPHDPDRPPGEIVG ATLWGHMNRSNPHWAALESETPVVIVFTGPHAYVSPTLYQRTPAAPTWNFTAVHARGLLR RVDAEAAGDETLETVMATVRAFEARFGAGWAMSESVEYFRRIVPAVGAFRVTVSHVDGMF KLSQEQDADVRARVRESFAERESSNHKAIAAMMGRLADAE 95. >Streptomyces_yanglinensis_CGMCC_4.2023 MFVPSQYREPDVSWMVDLMRDNPLALMASNGTAADGPYATHLPVITDPGWEGPPAADLAG MLLLGHMNRANPHWSALEDGQTILLTFTGPHAYVSPTVYDITPAAPTWNFTSVHVRGTVE KIATTEETLEVVKSTVRAYEKEFGDSWDMNASLDYFRKIVPGVGAFHVRVTRAEAMFKLS QEQSPEVRDRVVRSFAGRGCTRHAQAADLMTRLP 96. >Streptomyces_griseochromogenes_ATCC_14511 MFVPSHYREPDVSWMVDLMRGNPLALMASNGTPADGPFATHLPVITDPQWEGSPTADLAG MPLLGHMNRANPHWAALETGSAILLTFTGPHAYVSPTVYDVTPAAPTWNFTSVHVHGVVE KIESTEETLDVVQATVQAFEGEFGDSWDMSESVDYFRKIVTGVGAFRVRVTKAEGMFKLS QEQRPEIRERVVQSFAGRECTRHVQTADLMNRLP 97. >Frankia_sp._Avcl.1 MFVPCHYRAPNVSMMVDLMRENPLALMVSNGAPGAVPFATHLPVITDPCWDGQAGPDLGG MVLLGHLNRANPHWXALETGSMILLTFTGPHAYVSPTVYGLTPAAPTWDFTSVHVHGVVE KLTTTEETLEVVRATVLAFEQEFGDGWDMTDSLGYFRRIVPRVGAFRLRVTGAQGMFKLS QEQTPEIRERVARSFAAHGSTRHAQTAELISRLPH 98. >Streptomyces_incarnatus_NRRL_8089 MFVPSFYREPDSAWMVDLIRGNPLALAVTNGSPEDGPFATHLPVIFDPETSGDWSGELPG ATLLGHMNRANPHWAALETGSVLLLTFTGPHSYVSPTVYETTPAAPTWNFTAVHVRGVVE KISSTEETLGVVQSTVRAYEGAFGDGWDMSESLDYFRKIVPAVGAFRFTVTGAEGMFKLS QEQPGEVRERVRDAFGQSGCAYRREVAGLMSRLP 99. >Streptomyces_sp._MUSC136T MFVPPQYREPDGSWMVDLMRRNPLALCVTNGDAADGPYATHLPVIRDPGMTGEWAEDLSG GTLLGHMNLQNPHWAALRDGQSVLLVFTGPHAYVSPTVYEKSPAAPTWDFTAVHVHGTVE KLTSAQDTLDVVKSTVRAFESDLGTGWDMTESEAYFDQLLPGVGAFRVEVTGAEGMFKLS QEQQPHVRDRVHDAFAERPCGRHRETAELMARLP 100. >Streptomyces_albulus_PD-1 MFVPPEYRPDDPEWLIEVIRSHPLACLVTNGPDGPRASHVPVIPDPEQFPSGMPAREGEV AGRRLFGHMNRLNPHWAALQGGAQALLVFQGPNGYVSPTVYEYTPAAPTWDFTAVHVRGW LEPVGDRESSLQIITETVAAYERDLGTGWDMTESLGYFRQLLPGVGAFRLAIDTVDGMFK LSQEQSPEVRERVACEFAARAEARGTALAEHIQRTK 101. >Streptomyces_tsukubaensis_NRRL_18488 MFVPSMYRAPDSSWMVNLIRENPLALAVANGSPENGPFATHLPVVFDPETSADPAGELPG TTLLGHMNRANPHWAALETGSVLLLTFTGPNSYVSPSVYGVTPAAPTWNFTAVHVRGVVE KISSLEESLDVVQSTVRAFEGAFGNGWDMTESLGYFRRIAPAVGAFRLTVTGAEGMFKLS QEQPGDVRRRVRESFGQSACRYRRETAGLMSRLP 102. >Streptomyces_himastatinicus_ATCC_53653_hmtC MFVPSHYREPDSSWMVDIIRGNPLALMMSNGAAGEPPFATHLPVIPDPAMTGDWSERLSE ATLLGHMNRDNPQWQALEDGAVVRIAFSGPHAYVSPTLYGVTPAAPTWNFTSVHVRGVVE RIPSTEETLEVVKSTVRAFEADFGEGWDMAASIDYFRKIVPGVGAFRIMVRNVDGMFKLS QEQQPEVRDRVRKSFAGRECGRHQETAAYMSRLP 103. >Streptomyces_flaveolus_DSM_9954_sfaC MYERPLYREDCDGVVLAFLRHNPLAMVVTSHDDVPVATHAPVLFRHGPDGADAEAVAAGT VPLAGSTLIGHMNVENPQWRRMRSGDRALIVFQGPHGYVSPTVYGVTPAAPTWDFIAVHV NGTVEPTADPAAVLDIVSDTARRLESGFGRGWDQESSLDYFRQIAPGVGAFTLRVDSVQT MFKLSQEKPAPMRRRVVEQFEASESGTHRALASVMRDRGLTEADEERETAG 104. >Streptomyces_auranticaus_JA_4570 MFVPSQYRQPDSSWMLDLIHGNPLALFVSNGSPEAGPFATHLPVIQDPEWTGEWSDDLSG GRLLGHMNRANPHWKALESGTVNLLTFTGPHGYVSPTVYRTTPAAPTWNFTSVHVHGVVE KIDGIENTLEVVKATVRAYEGAFGAGWDMTESLDYFRKIVPAVGAFQFRVTGAEGMFKLS QEQPDDVQERVRESFGGRECTRHQAAAQLMDKLR 105. >Streptomyces_sp._RJA2928_padO MFVPQHYRTDDRRWPVRIVQDNPLALLMSTRDGRAPFASHVPVIVLPRQREELERTGRWQ GAVLHGHMNRANPHWKSLADGQPAGLVFQGPAGYVSPAVYNTSPAVPTWNFTAVHVQGRL KLVADEEATLGVVSATARQLEERFGARWTVEPSVDHFRQILPGVGAFELRVEECDSMFKL SQEKEHEVRHAVMDWCARSPRGRSNDLAAVMRDYYPPTTTWPS 106. >Frankia_alni_str._ACN14A MFVPCHYRAPNVSMMVDLMRENPLALMVSNGAPGAVPFATHLPVITDPCWDGQAGPDLGG MVLLGHLNRANPHWAALETGSMILLTFTGPHAYVSPTVYGLTPAAPTWDFTSVHVHGVVE KLTTTEETLEVVRATVLAFEQEFGDGWDMTDSLGYFRRIVPRVGAFRLRVTGAQGMFKLS QEQTPEIRERVARSFAAHGSTRHAQTAELISRLPH 107. >Actinosynnema_mirum_DSM_43827 MHVPPMYRADDEDRARQVVHDYPLATLVSNGPRVPHATHLPVVAAPGAPQVGGLAGSTLW GHLNRANAHWRALAGGVPAVLVFTGPHAYITPAIYRTTPAVPTWDFVSVHLHGRVEPIDG EAGTLEVVKRTAELFESAFGAGWAAEPSHGHFARIVSGVGAFRFHVESVDSMFKLSQEKD RDVRVRIIASLREASGPAAELGRIMHEHGLGGRGAEGA 108. >Kutzneria_sp._744_orf4 MFVPGPYHAPEDRWLVDLVRGHPLAQLASNGAGGAAPHITHVPIIVDPELDGPVDRLVGI TLWGHMNRANPHWAALGGAANVVATFAGPNAYVSPAVYRTAPAAPTWNFTSVQVRGELRK VESADDTLATVRATVAALESRFGAGWDMTGSLDYFRRILPGVGAFRLRVAEADGMFKLSQ EQQPAIRRRVRHSFGGCEATRAVAGLMDRLPTE 109. >Kibdelosporangium_sp._MJ126-NF4 MHVPPMYEAPDPAWIPALIRAHPLATLVTAPDGIPAASHVPMIIRRTPDDERLTLVGHMN RMNPQFKAIGDGCPALLVFTGPHGYVSPTVYGFTPAAPTWNFAVVHASGTLSPLPAGPDT LEVIIDTVTALEGQLGNGWQMRDSLEYFDQLLPGVGAFSVQVDRVEAMYKLSQEQEPTTR ETVAAAFEARSSDLAAMMRVCLDVERSTLGNRVG 110. >Mycobacterium_xenopi_RIVM700367 MLSLLPFRAQAIAQEIAASRHRDAVTVRQRPVGDYPPKRYLETDPDRLRAVIERYRFATL ISARATDEPVVTQLPLTLDTSRGSHGVLFGHMDLANPHAELLDGRPVLALFHGPNGYIPP HQSNQLPTWNSITVEVRGRARILRDKDAVVDGLRGIAAAADPSPGGFRLTREAASDERLF PFLVGFEIDIDEMVGRFKLSQDRDDRDRWLAARTLAHGLEQDDRDLIASIVELPLDRDDD PIPLRRARTSGT 111. >Streptomyces_mirabilis_YR139 MFVPSFYREPDSSWMVDLIRGNPLALAAANGSPEEGPFATHLPVIFDPETSGDWSGELPG ATLLGHMNRANPHWAALATGSVLLLTFTGPHSYVSPTVYEVTPAAPTWNFTAVHVRGVVE KIDSIEETLGVVQSIVRAFEGAFGDGWDMTESLGYFRKIVPDVGAFRFTVTGAEGMFKLS QEQPGEVRERVRESFGHSACAYKRETAGLMSRLP 112. >Streptomyces_scabrisporus_DSM_41855 MFVPRHYREPDSSWMVDLIRANPLALAVMNGDPSAGPFATHLPVIPDPQMTPSWSDDLSG ATLLGHMNRANPHWKALETGTVLLLTFTGPHGYVSPTVYEVTPAAPTWNFTSVHVRGVVE RIDSLEETLGVVRATALAFESEFGAGWDQTESVDYFRKIVPGVGAFRVTVTGAEGMFKLS QEQPAEVRERVRQSFSTRACSLQRETAELMTRLP 113. >Streptomyces_sp._TAA040 VFVPTHYREPDGSWMADLMRENPLALAVTDGGAGDGPFATHLPVVPDPGTTGDWPNGLKG ATLLGHMNRANPHWRALETGGVVLLAFTGPHAYVSPTVYEVTPAAPTWNFTSVHVRGVVD RIDSPEETLDVVRTTALVYEARFGAGWDQAASLDYFRRIVPAVGAFRIAVTSAEGMFKLS QEQPAEVRERVHRSFSGRECGRHRDTAALMERLPRTGAEPPVGR 114. >Actinoalloteichus_cyanogriseus_DSM_43889 MFVPHQYRAADTRPLVELIRSFPLATLVSHADGALFATHVPVLLAADADAGRDVPDPADL TILGHLNRLNPHRDALAGGGACLLTFTGPHSYVSPAHYGRDTAAPTWNFTSVHVHGHLTP LDSTEDTRHVVRSTALLYERRFGAGWDMTGSLDYFEQLLPGVSAFRVDVGTVEGMFKLGQ EQPGHARQGVLAAFTSPGAPPHQRAVAELMRRFPPDAAGGVPGCPAQSAARMSPPADAIR GEH 115. >Streptomyces_sp._HNS054 MFVPNFYREPDASWMVDLVRGNPLALAVSNGCPEDGPFATHLPVIFDPARYGDLPGELAG ATLLGHMNRANPHWPALQTGGILLLTFTGPHSYVSPTAYGTTPAAPTWNFTAVHARGVVE KIDSTEETLDVVKATVRAYEGEFGDGWDMTESLGYFRKIVPAVGAFRLTVTRAEGMFKLS QEQPAEVRERVRESFEQSACRYKRETAGLMSRLP 116. >Streptomyces_sp._AW19M42 MYVPDHYQGSPEAALTVVRAGPLATLVTGADPWPLATHLPVVVPADVEAALEHGPVDLRG HRLIGHLNRANPHWRQLSAGEQPSLLIFRGPHGYISPVVYESTPAAPTWNFTAVHVHGTI RPLPAGKETLDVIHRTVEVLEGGFGHGWDMRGSLEYFEKIVPHVGAFEFQVAEVDGMFKL SQELDEETRERTTHHFATSAHGTHRELACEMARLSTAAETKDGASEGASGSSSKRGTA 117. >Salinispora_pacifica_DSM_45549 MFVPSPYREPDGSWTVDLMRRNPLALLVTSSDKTDVPYATHLPVIFDPCMPEEDYSDPAR FVLLGHMNRANPHWKALATGMPTLVVFSGSHAYVSPTVYDKSPAAPTWNFTAAHARGVLE KIESAEETLGVIGSTVRAFEADFGTDWDMTQSVGYFRKILPGVGAFRIAVSSIDSMFKLS QEQPPEVRDRVGCAFAESASTRHREVAGLMNRLAVPKQVTV 118. >Salinispora_pacifica_CNT150 MFVPSPYREPDGSWTVDLMRRNPLALLVTSSDKTDVPYATHLPVIFDPCM PEEDYSDPARFVLLGHMNRANPHWKALATGMPTLVVFSGSHAYVSPTVYD KSPAAPTWNFTAAHARGVLEKIESAEETLGVIGSTVRAFEADFGTDWDMT QSVGYFRKILPGVGAFRIAVSSIDSMFKLSQEQPPEVRDRVGCAFAESAS TRHREVAGLMNRLAVPKQVTV 119. >Salinispora_tropica_CNB536 MFVPSPYREPDGSWTVDLMRRNPLALLVTSSDKTDIPYATHLPVIFDPRMPEEDYSDPAR FVLLGHMNRANPHWKALATGMPTLVVFSGSHAYVSPTVYDKSPAAPTWNFTAAHARGVLE KIESAEETLGVIGSTVRAFEADFGADWDMAQSVGYFRKILPGVGAFRIAVSSIDSMFKLS QEQSPEVRDRVGCAFAESASTRHREVADLMNRLAVPKQVTV 120. >Salinispora_arenicola_CNH996B MFVPSPYREPDGSWTVDLMRRNPLALLVTSSDKTDVPYATHLPVIFDPCM PEEDYSDPARFVLLGHMNRANPHWKALATGMPTLVVFSGSHAYVSPTVYD KSPAAPTWNFTAAHARGVLEKIESAEEALGVIGSTVRAFEADFGTDWDMT QSVGYFRKILPGVGAFRIAVSSIDSMFKLSQEQPPEVRDRVGCAFAESAS TRHREVAGLMNRLAVPKRVIV 121. >Salinispora_arenicola_CNH996 MFVPSPYREPDGSWTVDLMRRNPLALLVTSSDKTDVPYATHLPVIFDPCMPEEDYSDPAR FVLLGHMNRANPHWKALATGMPTLVVFSGSHAYVSPTVYDKSPAAPTWNFTAAHARGVLE KIESAEEALGVIGSTVRAFEADFGTDWDMTQSVGYFRKILPGVGAFRIAVSSIDSMFKLS QEQPPEVRDRVGCAFAESASTRHREVAGLMNRLAVPKRVTV 122. >Salinispora_tropica_CNY012 MFVPSPYREPDGSWTVDLMRRNPLALLVTSSDKTDIPYATHLPVIFDPRMPEEDYSDPAR FVLLGHMNRANPHWKALATGMPTLVVFSGSHAYVSPTVYDKSPAAPTWNFTAAHARGVLE KIESAEETLGVIGSTVRAFEADFGTDWDMAQSVGYFRKILPGVGAFRIAVSSIDSMFKLS QEQSPEVRDRVGCAFAESASTRHREVADLMNRLAVPKQVTV 123. >Salinispora_tropica_CNT261 MFVPSPYREPDGSWTVDLMRRNPLALLVTSSDKTDIPYATHLPVIFDPRMPEEDYSDPAR FVLLGHMNRANPHWKALATGMPTLVVFSGSHAYVSPTVYDKSPAAPTWNFTAAHARGVLE KIESAEETLGVIGSTVRAFEADFGTDWDMAQSVGYFRKILPGVGAFRIAVSSIDSMFKLS QEQSPEVRDRVGCAFAESASTRHREVADLMNRLAVPKQVTV 124. >Salinispora_tropica_CNH898 MFVPSPYREPDGSWTVDLMRRNPLALLVTSSDKTDIPYATHLPVIFDPRMPEEDYSDPAR FVLLGHMNRANPHWKALVTGMPTLVVFSGSHAYVSPTVYDKSPAAPTWNFTAAHARGVLE KIESAEETLGVIGSTVRAFEADFGTDWDMAQSVGYFRKILPGVGAFRIAVSSIDSMFKLS QEQSPEVRDRVGCAFAESASTRHREVADLMNRLAVPKQVTV 125. >Streptomyces_sp._PsTaAH-137 MFVPSFYREPDSSWMVDLIRGNPLALAVANGPAEDGPFATHLPVIFDPETSADVSGELPG VTLLGHMNRANPHWSALQDGGVLLLTFTGPHSYVSPTVYEKSPAAPTWNFTSVHVRGVVE KISSIEETLEVVQATVRAFEGAFGDGWDMTGSLDYFRKIVPAVGAFRFTVTGAEGMFKLS QEQPGEVRERVRESFGQSACTYKRETAGLMNRLAQTEDVTVSSGA 126. >Salinispora_arenicola_CNS296 MLVPHMYEAPSAAQVDAVITGHPMAVLVTNGPDVPHATHLPVIRTVDTEQTGPGSVLLGH MNRTNPHWSALTSGTPGKLIFTGPNTYVCPVLYQTEPAAPTWDFVVVHVSGRVMPLDAGE PTLAVVQRTAATLEGAFGAGWDHTGSIDYFRSIVGGVGAFEFVVEQVESMFKLSQEKDHT VRQRLIDDFTSAPRNGSAQVGQLMSDLNLGVAP 127. >Salinispora_arenicola_CNS299 MLVPHMYEAPSAAQVDAVITGHPMAVLVTNGPDVPHATHLPVIRTVDTEQTGPGSVLLGH MNRTNPHWSALTSGTPGKLIFTGPNTYVCPVLYQTEPAAPTWDFVVVHVSGRVMPLDAGE PTLAVVQRTAATLEGAFGAGWDHTGSIDYFRSIVGGVGAFEFVVEQVESMFKLSQEKDHT VRQRLIDDFTSAPRNGSAQVGQLMSDLNLGVAP 128. >Salinispora_pacifica_CNY363 MLVPHMYEAPSAAQVDAVITGHPMAVLVTNGPDVPHATHLPVIRTVDTEQTGPGSVLLGH MNRTNPHWSALTSGTPGKLIFTGPNTYVCPVLYQTEPAAPTWDFVVVHVSGRVMPLDAGE PTLAVVQRTAATLEGAFGAGWDHTGSIDYFRSIVGGVGAFEFVVEQVESMFKLSQEKDHT VRQRLIDDFTSAPRNGSTQVGQLMSDLNLGVAP 129. >Actinomadura_atramentaria_DSM_43919 VFVPPQYRPRGRSWTLETVRSNPLAMLVTRGERALPWITHLPVITHPERPPAELPGATLL GHMNAANPHWAAVASGGPGTLVFTGPHGYVSPTVYELPVAAPTWDFVAVHVHGTLRPLDT PEDARRVVRWTVEAYEGTHGTGWDPEGSLDYFDKILPGVRAFEFHVESVDGMYKLSQEQE PETRRRVVRSFAASGRGAHAELSALIDRFGDPGPGAPATGCPAAREAGDGAR 130. >Streptomyces_drozdowiczii_SCSIO_10141 MFVPPMYRTENEGRLRQVMERYPLAMLVTNGEPTPYATHLPVIFDQNGAPGTDGPVGATL LGHLNRNNPHWRTLTDGLAAKLVFTGPHSYITPTLYETTPAAPTWNFVTVHLEGTLHPVT DLEETLGVLQATVETFESAFGNKWEMDSSLDYFRHIGPAVGAFRFVVTSADGMFKLSQEK TPEIQHRIADRLIGTETGTRHELGALMAELTLGDRDGV 131. >Streptomyces_sp._RSD-27 MVDLVRGHPMALAVANGSPEDGPFATHLPVIFDPVTSGQWTGELPGATLLGHMNRANPHW AALETGGVLLLTFTGPHSYVSPTVYAKSPAAPTWNFTSVHVRGVVEKIDSIEETLEVVQS TVRAFEGAFGDGWDMTGSLDYFRKIVPDVGAFRLTVTGAEGMFKLSQEQPGEVRERVRES FGQSACTYRRETAGLMG RLP 132. >Streptomyces_sp._YR375 MVDLLRNNPLALMVSNGDAAAAPFATHLPVIPDPAMTDEWSADLSGATLLGHMNRGNPHW KALETGDVVLLTFTGPHAYVSPTVYEVTPAAPTWNFTSVHVRGVVEKIDSAEETLEVVQS TVRAFEADFGDDWDMTESLGYFRRIVPAVGAFRLTVSGAEGMFKLSQEQKPEVRERVQKA FSGRECGRHRETASFMSRLP 133. >Actinoalloteichus_spitiensis_RMV-1378 MFVPDQYRAADNRPLVELIRSFPLATLVSHAEGTLFATHVPVLLAADADAGRDVPEPADL TILGHLDRRNPHRAALAAGGPCLLTFTGPHSYVSPAHYGRETAAPTWNFTAVHVHGRLTP LDGAEDTRHVVRSTALLYERRFGAGWDTTGSLDYFEQLLPGVSAFRVDVSTVEGMFKLGQ EQPGYARQGVVAAFTSPGAPPHQRAVAELMRRFAPDSPDDGGPGCPVRAPAKPEPATRGE R 134. >Streptomyces_sp._Ncost-T6T-1 MVDLMRSNPLALMVSNGSPEASPFATHLPVIFDPGDAADLAEDLARLPLLGHMNRANPHW SALQDDAVVLLSFTGPHAYVSPTVYDVTPAAPTWNFTSVHVHGVVEKFDSTEETLEVVQA TVRAFEEKFGNNWDMTDSIDYFRKIVHDVGAFRIRVTKAEGMFKLSQEQEPEIRDRVVQS FTGRGCTRHAQTATLMSRLP 135. >Streptomyces_sp._PBH53 VYERPLYREDRDGVVLAFLHHHPLALVVTAHEGVPVATHAPVLFRHGPDGADAEAVAAGT VPLAGSTLIGHMNVENPQWRRMRSGDRALIVFQGPHGYVSPTVYDVTPAAPTWNFTAVHV TGTVEPTAEPADVLDIVSDTARRLEGRFGRGWDQESSLDYFRQIAPGVGAFTLRVESVQT MFKLSQEKPTPMRRRVAEQFEASESGTHRALAGMMRAHGLTDADEERETAG 136. >Salinispora_arenicola_CNS-991_DSM_45545 MLVPHMYEAPSAAQVDAVITGHPMAVLVTNGPDVPHATHLPVIRTVDTEQTGPGSVLLGH MNRTNPHWSALTSGTPGKLIFTGPNTYVCPVLYQTEPAAPTWDFVVVHVSGRVMPLDAGE PTLAVVQRTAATLEGAFGAGWDHTGSIDYFRSIVGGVGAFEFVVEQVESMFKLSQEKDHT VRQRLIDDFTSAPRNGSAQVGQLMSDLNLGVAP 137. >Streptomyces_sp._MNU77 MFVPRIYQVDGEHWPSEIIDRHPLALLTTNGDDVPHATHVPVIRPPHDEQLVGSELLVHM NRANPHWAALSDHDAAKLVFQGPDGYVTPSVYHVEPAVPTWDFVTVHLTGTLRISEDVDE VLSIVTATARTLERRFGAGFDVDRAADHHARIASGVGAIRFRVTKAEAMFKFSQEKDAEI RDRVMQWFEDSDIGEYADLGRLMRQFLDRPDITAPAAAG 138. >Micromonospora_halophytica_DSM_43171 MFVPRSFAVEDAGPVVELMRSNPLACFVLGGESPSVSHLPVVFADDDERDDLAGITLLTH MNRQNPLWGSLSDGARVLVVFQGPHGYVSPTVYGVSPAAPTWNFTVVHAHGVVRLLGAGE PALRVVKRTVQVLEGRFGAGWDMTGSLGYFERIVHAVGALEIHVDAVQSMFKLSQDQPVE LQSKVAAAFAGSGRGTHRELAEQMYTHLRLKADVDGF 139. >Streptacidiphilus_carbonis_NBRC_100919 MFVPPPYRPPDGSWTAELIRSNPLAILASNGSTADGPFATHLPVIPDPGT PDLLSAELTGAVLLGHMNRANPHWAALAEGGTSLLTFTGPHAYVSPTVYG VTPAAPTWNFTSVHARGTIERIESSEETLEVVKATVRAFEERFGAEWDMS ESISYFRQILPGVGGFRFTVTGTDGMFKLSQEQAPEIRCRVQRSFTGREC SRH RETAALMGSLP 140. >Streptomyces_sp._MnatMP-M27 MFVPQHYRTDDRRWPVRIVQDNPLALLMSTRDGRAPFASHVPVIVLPRQR EELERTGRWQGAVLHGHMNRANPHWKSLADGQPAGLVFQGPAGYVSPAVY NTSPAVPTWNFTAVHVQGRLKLVADEEATLGVVSATARQLEERFGARWTV EPSVDHFRQILPGVGAFELRVEECDSMFKLSQEKEHEVRHAVMDWCARSP RGRSNDLAAVMRDYYPPTTAWPS 141. >Pseudonocardia_sp._EC080625-04 MFVPEQYREQDSNWMLDIVRSNPLALMASDGTPEGCGPAATHLPCIPDPS APHDWSDGPRGAVLLGHMNRANPQWRHLHDGQIVLLVFTGPHAYVSPAVY DTTPAAPTWDFTAVHVHGVVTKLEPHKAERTTLDVVTDTVTALEGRFGAG WDMTDSIEYFHRLLPGVGAFRVRVGSAEGMFKLSQEQPSDIRDRVRCHFA AAQHGRSSEIAHLMTTLDGH 142. >Pseudonocardia_sp._HH130629-09 MFVPEQYREQDSNWMLDIVRSNPLALMASDGTPEGCGPAATHLPCIPDPS APHDWSDGPRGAVLLGHMNRANPQWRHLHDGQIVLLVFTGPHAYVSPAVY DTTPAAPTWDFTAVHVHGVVTKLEPHKAERTTLDVVTDTVTALEGRFGAG WDMTDSIEYFHRLLPGVGAFRVRVGSAEGMFKLSQEQPSDIRDRVRCHFA AAQHGRSSEIAHLMTTLDGH 143. >Streptomyces_paryulus_2297 MFVPSFYREPSNSWMVDLIRGNPLALAVANGQPDEGPFATHLPVIFDPDH PLDRDDDLTGATLLGHMNRANPHWGSLETGGVLLLTFTGPHSYVSPTVYE VTPAAPTWNFTAVHVRGVVEKLDSTDETLAVVQSTVRAFEGEFGNGWDMT DSLGYFRKIAPGVGAFRFTVTGAEGMFKLSQEQPGEVRDRVRESFGQSGC VHKRGTAGLMSRLP 144. >Streptomyces_sp._OK885 MFVPDPYREPNTTWMVDLIRRNPLALLTTNGPAECGPFATHLPVIQDPGM TAEWSADLSGSLLLGHMNAQNPHWSALRDGDSVLLAFTGPHAYVSPTVYQ KIPAAPTWNFTSVHVHGVIEKIESEEETLTVVRSTVRAFEEEFGTDWNME GSVDYFRKILPGVGAFRITVSRADGMFKLSQEQEPQIRDRVRQSFAQRKC SLHRETADLMGRLP 145. >Streptomyces_sp._CFMR7 MYVPSIYQAEDRAWLRHVVERYPLATVITNGPQAPYATHVPVIPAPDTTS WNDGPEGATLLGHMNRANSHWGSLTDGTHAQLVFTGPNGYVSPTVYETSP AAPTWNFVSVHLRGRLRPISDFEETLEVVRLTVEAYEKNFGDGWEMDSSL EYFRNIGPAVGGFRFDVESADGMFKLSQEKHPETRRRIADRFGGRRSGRA TELAFFMRQFTSADHHAS 146. >Streptomyces_sp._DvalAA-19 MYVPSIYQAEDRAWLRHVVERYPLATVITNGPQAPYATHVPVIPAPDTTS WNDGPEGATLLGHMNRANSHWGSLTDGTHAQLVFTGPNGYVSPTIYETSP AAPTWNFVSVHLRGRLRPISDFEETLEVVRLTVEAYEKNFGDGWEMDSSL EYFRNIGPAVGGFRFDVESADGMFKLSQEKHPETRRRIADRFGGRRSGRA TELAFFMRQFTSADRHAS 147. >Rhodococcus_fascians_A3b MYVPRIYKASDRTWLRRVVAQYPFAALISNGPKAPYATHLPVICAPCAPS ESEDLEGSTLFGHMNRANPHWDSLVDGADAQLIFTGPHGYVTPSVYQRDS VAPTWNYVSVHLRGKLQPVADFEETLKVVQLTVSTYEQKFGSGWEMDSSL DHYRRIGPAVGAFSFEVESADGMFKLSQEQNLETRRRVADHFSANHAGRG KELASFMREYSHGDYNNF 148. >Rhodococcus_fascians_A73a MYVPRIYKASDRTWLRRVVAQYPFAALISNGPKAPYATHLPVICAPCAPS ESEDLEGSTLFGHMNRANPHWDSLVDGADAQLIFTGPHGYVTPSVYQRDS VAPTWNYVSVHLRGKLQPVADFEETLKVVQLTVSTYEQKFGSGWEMDSSL DHYRRIGPAVGAFSFEVESADGMFKLSQEQNLETRRRVADHFSANHAGRG KELASFMREYSHGDYNNF 149. >Rhodococcus_fascians_A76 MYVPRIYKASDRTWLRRVVAQYPFAALISNGPKAPYATHLPVICAPCAPS ESEDLEGSTLFGHMNRANPHWDSLVDGADAQLIFTGPHGYVTPSVYQRDS VAPTWNYVSVHLRGKLQPVADFEETLKVVQLTVSTYEQKFGSGWEMDSSL DHYRRIGPAVGAFSFEVESADGMFKLSQEQNLETRRRVADHFSANHAGRG KELASFMREYSHGDYNNF 150. >Rhodococcus_fascians_A78 MYVPRIYKASDRTWLRRVVAQYPFAALISNGPKAPYATHLPVICAPCAPS ESEDLEGSTLFGHMNRANPHWDSLVDGADAQLIFTGPHGYVTPSVYQRDS VAPTWNYVSVHLRGKLQPVADFEETLKVVQLTVSTYEQKFGSGWEMDSSL DHYRRIGPAVGAFSFEVESADGMFKLSQEQNLETRRRVADHFSANHAGRG KELASFMREYSHGDYNNF 151. >Rhodococcus_fascians_D188 MYVPRIYKASDRTWLRRVVAQYPFAALISNGPKAPYATHLPVICAPCAPS ESEDLEGSTLFGHMNRANPHWDSLVDGADAQLIFTGPHGYVTPSVYQRDS VAPTWNYVSVHLRGKLQPVADFEETLKVVQLTVSTYEQKFGSGWEMDSSL DHYRRIGPAVGAFSFEVESADGMFKLSQEQNLETRRRVADHFSANHAGRG KELASFMREYSHGDYNNF 152. >Rhodococcus_fascians_02-816c MYVPRIYKASDRTWLRRVVAQYPFAALISNGPKAPYATHLPVICAPCAPS ESEDLEGSTLFGHMNRANPHWDSLVDGADAQLIFTGPHGYVTPSVYQRDS VAPTWNYVSVHLRGKLQPVADFEETLKVVQLTVSTYEQKFGSGWEMDSSL DHYRRIGPAVGAFSFEVESADGMFKLSQEQNLETRRRVADHFSANHAGRG KELASFMREYSHGDYNNF 153. >Rhodococcus_fascians_05-339-1 MYVPRIYKASDRTWLRRVVAQYPFAALISNGPKAPYATHLPVICAPCAPS ESEDLEGSTLFGHMNRANPHWDSLVDGADAQLIFTGPHGYVTPSVYQRDS VAPTWNYVSVHLRGKLQPVADFEETLKVVQLIVSTYEQKFGSGWEMDSSL DHYRRIGPAVGAFSFEVESADGMFKLSQEQNLETRRRVADHFSANHAGRG KELASFMREYSHGDYNNF 154. >Rhodococcus_fascians_LMG_3605 MYVPRIYKASDRTWLRRVVAQYPFAALISNGPKAPYATHLPVICAPCAPS ESEDLEGSTLFGHMNRANPHWDSLVDGADAQLIFTGPHGYVTPSVYQRDS VAPTWNYVSVHLRGKLQPVADFEETLKVVQLTVSTYEQKFGSGWEMDSSL DHYRRIGPAVGAFSFEVESADGMFKLSQEQNLETRRRVADHFSANHAGRG KELASFMREYSHGDYNNF 155. >Rhodococcus_fascians_LMG_3616 MYVPRIYKASDRTWLRRVVAQYPFAALISNGPKAPYATHLPVICAPCAPS ESEDLEGSTLFGHMNRANPHWDSLVDGADAQLIFTGPHGYVTPSVYQRDS VAPTWNYVSVHLRGKLQPVADFEETLKVVQLTVSTYEQKFGSGWEMDSSL DHYRRIGPAVGAFSFEVESADGMFKLSQEQNLETRRRVADHFSANHAGRG KELASFMREYSHGDYNNF 156. >Rhodococcus_fascians_LMG_3623 MYVPRIYKASDRTWLRRVVAQYPFAALISNGPKAPYATHLPVICAPCAPS ESEDLEGSTLFGHMNRANPHWDSLVDGADAQLIFTGPHGYVTPSVYQRDS VAPTWNYVSVHLRGKLQPVADFEETLKVVQLTVSTYEQKFGSGWEMDSSL DHYRRIGPAVGAFSFEVESADGMFKLSQEQNLETRRRVADHFSANHAGRG KELASFMREYSHGDYNNF 157. >Rhodococcus_fascians_A22b MYVPRIYKASDRTWLRRVVAQYPFAALISNGPKAPYATHLPVICAPCAPS ESEDLEGSTLFGHMNRANPHWDSLVDGADAQLIFTGPHGYVTPSVYQRDS VAPTWNYVSVHLRGKLQPVADFEETLKVVQLTVSTYEQKFGSGWEMDSSL DHYRRIGPAVGAFSFEVESADGMFKLSQEQNLETRRRVADHFSANHAGRG KELASFMREYSHGDYNNF 158. >Streptomyces_sp._CNT360 MYVPQHFAVDETEPVVELIRANPLAVFVTTQGGVPVASHIPVVFASEDEA EQADDLVGVTLFGHLNVQNPQYGVLADGDRVLVVFQGSHGYISPTVYDTV PAAPTWNFSAVHVTGTVRLLGPGEPALKVVRRIVTALERRFGAGWDMTES LPYFERIVPGVGAFEIAVEAVDSIFKLSQDQPAELRDKAECAFRNSDAGV HRELAAQMRRHNGAACSHQERTARDGD 159. >Salinispora_arenicola_CN5848 MLVPHMYEAPSAAQVDAVITGHPMAVLVTNGPDVPHATHLPVIRTVDTEQ TGPGSVLLGHMNRTNPHWSALTSGTPGKLIFTGPNTYVCPVLYQTEPAAP TWDFVVVHVSGRVMPLDAGEPTLAVVQRTAATLEGAFGAGWDHTGSIDYF RSIVGGVGAFEFVVEQVESMFKLSQEKDHTVRQRLIDDFTSAPRNGSAQV GQLMSDLNLGVAP 160. >Salinispora_arenicola_CNY231 MLVPHMYEAPSAAQVDAVITGHPMAVLVTNGPDVPHATHLPVIRTVDTEQ TGPGSVLLGHMNRTNPHWSALTSGTPGKLIFTGPNTYVCPVLYQTEPAAP TWDFVVVHVSGRVMPLDAGEPTLAVVQRTAATLEGAFGAGWDHTGSIDYF RSIVGGVGAFEFVVEQVESMFKLSQEKDHTVRQRLIDDFTSAPRNGSAQV GQLMSDLNLGVAP 161. >Salinispora_arenicola_CNY280 MLVPHMYEAPSAAQVDAVITGHPMAVLVTNGPDVPHATHLPVIRTVDTEQ TGPGSVLLGHMNRTNPHWSALTSGTPGKLIFTGPNTYVCPVLYQTEPAAP TWDFVVVHVSGRVMPLDAGEPTLAVVQRTAATLEGAFGAGWDHTGSIDYF RSIVGGVGAFEFVVEQVESMFKLSQEKDHTVRQRLIDDFTSAPRNGSAQV GQLMSDLNLGVAP 162. >Salinispora_arenicola_CNT005 MLVPHMYEAPSAAQVDAVITGHPMAVLVTNGPDVPHATHLPVIRTVDTEQ TGPGSVLLGHMNRTNPHWSALTSGTPGKLIFTGPNTYVCPVLYQTEPAAP TWDFVVVHVSGRVMPLDAGEPTLAVVQRTAATLEGAFGAGWDHTGSIDYF RSIVGGVGAFEFVVEQVESMFKLSQEKDHTVRQRLIDDFTSAPRNGSAQV GQLMSDLNLGVAP 163. >Salinispora_arenicola_CNY230 MLVPHMYEAPSAAQVDAVITGHPMAVLVTNGPDVPHATHLPVIRTVDTEQ TGPGSVLLGHMNRTNPHWSALTSGTPGKLIFTGPNTYVCPVLYQTEPAAP TWDFVVVHVSGRVMPLDAGEPTLAVVQRTAATLEGAFGAGWDHTGSIDYF RSIVGGVGAFEFVVEQVESMFKLSQEKDHTVRQRLIDDFTSAPRNGSTQV GQLMSDLNLGVAP 164. >Salinispora_arenicola_CNY486 MLVPHMYEAPSAAQVDAVITGHPMAVLVTNGPDVPHATHLPVIRTVDTEQ TGPGSVLLGHMNRTNPHWSALTSGTPGKLIFTGPNTYVCPVLYQTEPAAP TWDFVVVHVSGRVMPLDAGEPTLAVVQRTAATLEGAFGAGWDHTGSIDYF RSIVGGVGAFEFVVEQVESMFKLSQEKDHTVRQRLIDDFTSAPRNGSTQV GQLMSDLNLGVAP 165. >Salinispora_pacifica_CNY331 MLVPHMYEAPSAAQVDAVITGHPMAVLVTNGPDVPHATHLPVIRTVDTEQ TGPGSVLLGHMNRTNPHWSALTSGTPGKLIFTGPNTYVCPVLYQTEPAAP TWDFVVVHVSGRVMPLDAGEPTLAVVQRTAATLEGAFGAGWDHTGSIDYF RSIVGGVGAFEFVVEQVESMFKLSQEKDHTVRQRLIDDFTSAPRNGSTQV GQLMSDLNLGVAP 166. >Streptomyces_aureofaciens_NRRL_2209 VFTPKLYQVDGDDWPLRIIERHPLAVLVSNGDPVPNATHVPVIAPPDAAP EDALSGMRLWAHLTRANPHWQQLAAAGGGPAKLVFHGPNGYVTPSLYSAD MVAPTWNYVAVHLEGTVELAGDDETLAIVHTTAQTLEDRFGDGMALAPSL EYHRQIVGAVGGLFFTVTKVDVMFKLSQEKDPEVQQRVLDRFAASGSGLH REVADTMRALRLGGSAG PzbAB 167. >Streptomyces_sp._CFMR_7 VRNAHATHPDDDPVGTTTERPYDLLGIGFGPSNLALAVCAREQKLPLSCL FVERQDTVAWHPGMLIDGARMQISFLKDLVSLRNPSSPYSFLQYTKAKGR LERFVNLNESRPTRIEYDDYLKWVAQDFADQVRFGSQVDRVTPVQGPDGG DLSLFRVETQDVATGRHSVHYARNVVHAGGGRPPARTAGVAEVSSVVHSS EFLTRFPDQFKDHDGAYRFVVVGGGQSAGEISEYLLDHYDRAEVHVVVSG YTLLPTDNSPFVNEQFYSGNADAFYRMRPEQRAAVSGRLRAANYGVVRED LLERLFNTDYLDQVKGRKRLHIHPFSRLSEVRENGDALAVTLRQHLDEGP EEPLRCDGVVLATGYDRSLDPAVFGDVLPHLTAGEGEGVGGVALSRHYRA RTSPELRAGLYLQGFGEAQFGLGDTLLSLLPFRSQEIVEDIADRVPVAGV GGCPVMSPYGSGVVSTSPHGPARSAVYPPKWYLEHDREKLYGLMERFRFA TLISARSGDQPFATHLPLILDRSRGANGVLFGHLDRGNEHADLIDGRHML AVFHGPNAYMPPGVFESDPLPTWNSMSVHVRGRVRVVRDRDALVHGLIGI AERSQPDNRLAADDPRIDRIIGSIVGFEFEVEELVGRFKLSQDRDETDRR HAAVALARATERGERDFIEYVVGLSLITEDDPRDLAGRPLSPLAIGGVHE 168. >Micromonospora_tulbaghiae_DSM_45142 MRNDPAPDARSSEPGSEQNPYDLIGVGFGPSNLALAIAAEELDGERTCLF FERSPSLQWHPGMLLEGSRMQISFLKDLVSLRNPASPYTFLQYAKAKDRL ERFVNLSEFRPTRLEYQDYLRWVAEFFAGQVRYHTEVTRVSPVRRPGEDV HRLFRVEARDIRTGETTVHHAANVVHAAGGRPRLPPGGVCASPAVIHSSD FLPHFPERFADRSRPYEFAVAGDGQSAGEVALYLMRTYPESRVHLFLSGQ ALRATDNSPFVNEQFFESSANAFSARPRDERTALRAELRNTNYGVVEAGT LDDLYRTVYDDEVRGRHRLIVHPATRVVAVREGDEGPLVAILDRRSGAEG EIRCDGVVLATGYVRALDESIFSELTPFLRTESDKLLLSGYRVRTTAEVA GGFYVQGYGEQHFGLGDTLLSLLPFRSRQIFTDICRRTPPPRQAVAVSDA SAYPPPHYLEHDPEKLYAVMERFNFATVISARAAEDPVVTHVPLTLDRSR GAHGVLFGHLDRANPHAQLIDGKQVTVVFHGPNTYLSPYALETDALPTWN SMNVHVGGRGRLLADRAALVTGLSGICEKSDPGVDSYRLDPDDPRIDRLV DYVVGFEIEIQALVGRFKLSQELDDRNRRLAASALMATARRDESEVIGKV FGMSPVNGRQNGSSALWSAHSR 169. >Amycolatopsis_alba_DSM_44262 MRNDAPPNPLTAELGAEGNPYDLIGVGFGPSNLALAIAAEELDSERNCLF FERSSRLRWHPGMLIDGSRMQISFLKDLVSLRNLASPYTFLQYTKAKGRL EQFVNLNDFRPTRLEYQDYLEWVAESFSGQVRYNSEVTRVTPVRRTGEDA HRLFRVEARDVVTGQTTVRYAANVVHAAGGRPRLPDGGVCDSPAVVHSSD FLPRFPGHFADRSRPYEFGVAGDGQSAGEIAAYLLSRYPASRVHLLLSGS ALRAADSNPFVNEQFFEGRANHFHARTKPDRTGLLAELRNTNYAVVEPGF LDDLYRLVYDDEVRGTRRLIVHPGTKVTAVGADGASLRVAVTDRRGGDEE MRCDGVVLATGYVRALDESMFADLLPFLREESGDLVLSPDYRVGTTAELE GGFYVQGYGESSFGLGDTLLSLLPFRAKQIFTDICKQTPPPVRTRRPVEV SKASAYPPPHYVETDPKKIYAVMERFSFATLISARGAEDPVVTHLPLTLD RARGAHGVLFGHLDRANPHVQLIDGHQLTVLFHGPNAYLSPQVFETSVLP TWNSMNVHVRGRGRLLPDRAALLAGLSGICVKSDPGDDSYRLDLDDPRID RMIEHIVGFEIEIHELVGRFKLSQELDDQNRMLAASALSATARRGELELI EEVVGLNVVQG 170. >Mycobacterium_sp._IS-1556 MTSMPPGEGHDSDLDFIGIGFGPSNLALAVAADEIVPDRKGLFFERSGTF QWHPGMLLDGTKMQISFLKDLATLRNPASRYTFLQYAKARGRLEQFVNLH EFHPSRLEYNDYLRWVAEFFTDRVCYNTIVTAVVPVGHSPSSNGHLTRFR VHVRDMATGAESCFFTANVIFGGGGVPRLLGARADASAVLHSSAFLPNFT NRFNESQKPYRFAVIGNGQSAAEIVDYLLNHYPGATIHLFISDCTLRATD HSPFINEHFFSTSAADFYNHPPAQRVALRSALRSTNYGVVDADLLQKLYQ ITYLDEVKGCRRLLLHRESRLSQIEEIDDQVVASFEDRFSGDSSEFHFDG AVLATGYERVLDAEVFRHVLPHVLWDESGAISLTRSCRVNIVPAVTARLF LQGYGEAWFGIGDTLLSLLPFRAQAIAQEIGNAPSGAPIRRKQRVHGEYP PKRYLETDPDRLHDVINRYRFATLVSASGVDEPVVTQLPLTLDTSRGSLG VLFGHMDFANPHTELLDGRRVLVLFHGPNGYISPHVYESAQLPTWNSITV EVRGRARILRDKDAVVNGLRGIAAAADPTPGGFRLTREAASDQRLFPLLV GFEIDIDDMRGRFKLSQERDDRDRWHAAHALANGVEQDDRDLISSIVGLP LDVDEEPKPQQQAQIHQYGNAPADTAYRRVDG 171. >Streptomyces_sp._Root55 MSSEAGAVFPCANGRPAAEVAPGPSRGSHPADPYDLIGVGFGPSNMALAI AVEELDPGRSCLFLERNTGVRWHPGMLIEGARMQISYLKDLVSLRNLASP YTFLSYLKAKGRLEKFINVGASRPTRLEYQDYLSWVAEDFGHVVRYESEV VAVVPVAGPGSETLDLLRVRVRDAGSAEFHDLYARNVVHAGGGTPRRGAP GQICDASSVIHSSTFLDAFPARFPDHDAALDLGVVGDGQSAAEITSHVLK GYPNARVHLFVPGYALRATDNNPFANEQFYQRNAGEFYASGARRRTILRT ELRNTNYGAVEAGHLDELYDITYADEVRGAPRLVVHRASHVSRVVEDGER LSVEVRDRTDGPDRTMVCDGLVLATGYTRELHPAVFGELTPLLSRDDSGE LLVTADCRVRTDERVTAGFYVQGYAESAYGIGDTLLSLLPFRSQQIVDDI RGRLPAGRPVAVEESAPYPPSHYVETDLDRIRSLMERFNFATVISVARDA RVLVTHVPLVVERDRGGEHGMLIGHLDRSNPQVELLRDRPVTVVFHGPDA YLSPDVLKTDRLPTWNSMSVHVRGHARLFSGRDELMRVFNGLCEQAEGES GSYWLRPDDTRIEQLRGQVVGFEVDIHELTGRFKLSQELDEANRELAAAD MARGTSAERQAFIERAFDLQPRPDVLGPPGGPGVGGCPVGGARAAGGTTA VADNERETAR 172. >Streptomyces_sp._2AW MLDLLGIGFGPSNVALAAAMAEGGKPPRALFLEAKERFGWHPGMLLDGAR MQISFLKDLVTLRNPESPYSFLAYLKAKGRLEEFANLREFYPSRIEFQDY LRWVAGHFEHQAVFGARVASVSPDFGIDGMARSFTVRAELADSGEYVTYQ ARNVVYAPGGTPNRVAGVAPRDERVIHTAEFLERFPKSFPDHSADLSFAV VGGGQSAAEIIEYILAKYPLSRVHAILPGYSFRPADDSPYSNEVFFSAEV DDHFTAHDQAARLAEARSTNYGVVDLDLIEDLYRMGYEDQVRGNVPRLTF CRSSRLLSADAGPSGIEVTVGGPEGSRSLNLDGLVLATGYHRELDPEMFR DVIPHLQRNESGNFLVSRAYRADSVPELTAGIYFQGLTELSHGIGDTLLS LLSFRSAEIAEDVRKRSEVPSADEVEYPPARHIEPYRAAILETLQRFPLA TLISSDDESEVFATHLPLILDRERGEQGVLFGHLDVGNPQVPNLNGRRVL AVFHGPNSYISPRTYTTDQLPTWNYVAVHVRGHVRVLENQDQVVSGLASI SEKADRSDGAYRLDENDSRIEKLIGGIVGFELDIESLTGRFKLSQDRSDE DRKRAMAVLREGAGDEHHDFVARIHQQ 173. >Streptomyces_sp._SolWspMP-5a-2 MPKKGGAVTPRAQGLPSGEAGPAPRRGTDPADPLDLIGIGFGPSNLALAI AAEELDPAADRLFLERNAGVHWHPGMLLEGARMQISYLKDLVSLRNLASP YTFLSYLKAKGRLEKFINIGVTRPTRLEYQDYLTWVAGHFADVVRYRSEV VSVTPVSGPGSTALDLLHVRVRDTATGTPYSLYARNVVHAGGGTPRRGTP DRICDTPSVIHSSRFLPAFPRRFPDHDAALDLGVVGDGQSAAEIAAHMLT HYPDATVHLFVPGYALRATDNNPFVNEQFYRHNADAFYADEPHRRALLRT ELRNTNYGAVEAGYLDTLYDITYADEVRGAPRLLVHRGCDVTRITEDGPR LDVLVRDRTGGPDRTVRCDGVVLATGYTRALDPAVFAGLDPLLRRDESGA LLVSADCRVDAEAPLTAGFYVQGYAEGAYGIGDTLLSLLPFRSQRIIDDL RARRPEDLPSGGPYPPDHYVEKDLERVRAVMERFNFATVISADRDARVLV THVPLVVERDRGGEHGTLIGHLDRSNPQVELLRDRPVTVVFHGPNSYLSP DVLTTDKLPTWNSMSVHVRGHARLFSGRDELMRVFNGLCEQAEPGPGSYR LRPDDERIDQLLGHVVGFEVDIQEVTGRFKLSQDLDEDNRALAAADMQRD LGEERRTFVADVFDLAPRPDGPEAGPRACGCPLGGPPAGTGAALAEEAGQ TVR 174. >Streptomyces_sp._ScaeMP-e83 VRNAHATHPDDDPVGTTTERPYDLLGIGFGPSNLALAVCAREQKLPLSCL FVERQDTVAWHPGMLIDGARMQISFLKDLVSLRDPSSPYSFLRYTKAKGR LERFVNLNESRPTRIEYDDYLKWVAQDFADQVRFGSQVDRVTPVQGPDGG DLSLFRVETEDVATGRRSVHYARNVVHAGGGRPPTRTAGVAEVPSVVHSS EFLTRFPGQFKDHDGAYRFVVVGGGQSAGEISEYLLDHYDRAEVHVVVPG YTLLPTDNSPFVNEQFYSGNADAFYRMRPEQRAAVSGRLRAANYGVVRED LLERLFNTDYLDQVKGRKRLHIHSFSRLSEVREDGEALAVTLQPRLDEGP EESLRCDGVVLATGYDRSLDPAVFGDVLPHLTPGEGEGAAGVVLSRHYRA RTSPELRAGLYLQGFGEAQFGLGDTLLSLLPFRSQEIVEDIADRVPAAGV GGCPVMSPYGSGVVSTSPHGPVPSAVYPPKWYLEHDREKLYGLMERFRFA TLISARSGDEPFATHLPLILDRSRGANGVLFGHLDRGNEHAELIDGRHML AVFHGPNAYMPPGVFESDPLPTWNSMSVHVRGRVRAVRDQDALVRGLIGI AERSQPDNRLAADDPRIDRIIGSIVGFEFEVEELVGRFKLSQDRDETDRR HAAVALARATERGERDFIEYVVGLSLITEDDPRDLAGRPLSPSP 175. >Mycobacterium_sp._GA-0227b MTSMPPGEGHDSDLDFIGIGFGPSNLALAVAADEIVPDRKGLFFERSGTF QWHPGMLLDGTKMQISFLKDLATLRNPASRYTFLQYAKARGRLEQFVNLH EFHPSRLEYNDYLRWVAEFFTDRVCYNTIVTAVVPVGHSPSSNGHLTRFR VHVRDMATGAESCFFTANVIFGGGGVPRLLGARADASAVLHSSAFLPNFT NRFNESQKPYRFAVIGNGQSAAEIVDYLLNHYPGATIHLFISDCTLRATD HSPFINEHFFSTSAADFYNHPPAQRVALRSALRSTNYGVVDADLLQKLYQ ITYLDEVKGCRRLLLHRESRLSQIEEIDDQVVASFEDRFSGDSSEFHFDG AVLATGYERVLDAEVFRHVLPHVLWDESGAISLTRSCRVNIVPAVTARLF LQGYGEAWFGIGDTLLSLLPFRAQAIAQEIGNAPSGAPIRRKQRVHGEYP PKRYLETDPDRLHDVINRYRFATLVSASGVDEPVVTQLPLTLDTSRGSLG VLFGHMDFANPHTELLDGRRVLVLFHGPNGYISPHVYESAQLPTWNSITV EVRGRARILRDKDAVVNGLRGIAAAADPTPGGFRLTREAASDQRLFPLLV GFEIDIDDMRGRFKLSQERDDRDRWHAAHALANGVEQDDRDLISSIVGLP LDVDEEPKPQQQAQIHQYGNAPADTAYRRVDG 176. >Mycobacterium_sp._GA-1999 MTSMPPGEGHDSDLDFIGIGFGPSNLALAVAADEIVPDRKGLFFERSGTF QWHPGMLLDGTKMQISFLKDLATLRNPASRYTFLQYAKARGRLEQFVNLH EFHPSRLEYNDYLRWVAEFFTDRVCYNTIVTAVVPVGHSPSSNGHLTRFR VHVRDMATGAESCFFTANVIFGGGGVPRLLGARADASAVLHSSAFLPNFT NRFNESQKPYRFAVIGNGQSAAEIVDYLLNHYPGATIHLFISDCTLRATD HSPFINEHFFSTSAADFYNHPPAQRVALRSALRSTNYGVVDADLLQKLYQ ITYLDEVKGCRRLLLHRESRLSQIEEIDDQVVASFEDRFSGDSSEFHFDG AVLATGYERVLDAEVFRHVLPHVLWDESGAISLTRSCRVNIVPAVTARLF LQGYGEAWFGIGDTLLSLLPFRAQAIAQEIGNAPSGAPIRRKQRVHGEYP PKRYLETDPDRLHDVINRYRFATLVSASGVDEPVVTQLPLTLDTSRGSLG VLFGHMDFANPHTELLDGRRVLVLFHGPNGYISPHVYESAQLPTWNSITV EVRGRARILRDKDAVVNGLRGIAAAADPTPGGFRLTREAASDQRLFPLLV GFEIDIDDMRGRFKLSQERDDRDRWHAAHALANGVEQDDRDLISSIVGLP LDVDEEPKPQQQAQIHQYGNAPADTAYRRVDG Plasmids: 177. SfaB (PzbA) expression    1 tatggctgcc gcgcggcacc aggccgctgc tgtgatgatg atgatgatgg ctgctgccca   61 tggtatatct ccttcttaaa gttaaacaaa attatttcta gaggggaatt gttatccgct  121 cacaattccc ctatagtgag tcgtattaat ttcgcgggat cgagatctcg atcctctacg  181 ccggacgcat cgtggccggc atcaccggcg ccacaggtgc ggttgctggc gcctatatcg  241 ccgacatcac cgatggggaa gatcgggctc gccacttcgg gctcatgagc gcttgtttcg  301 gcgtgggtat ggtggcaggc cccgtggccg ggggactgtt gggcgccatc tccttgcatg  361 caccattcct tgcggcggcg gtgctcaacg gcctcaacct actactgggc tgcttcctaa  421 tgcaggagtc gcataaggga gagcgtcgag atcccggaca ccatcgaatg gcgcaaaacc  481 tttcgcggta tggcatgata gcgcccggaa gagagtcaat tcagggtggt gaatgtgaaa  541 ccagtaacgt tatacgatgt cgcagagtat gccggtgtct cttatcagac cgtttcccgc  601 gtggtgaacc aggccagcca cgtttctgcg aaaacgcggg aaaaagtgga agcggcgatg  661 gcggagctga attacattcc caaccgcgtg gcacaacaac tggcgggcaa acagtcgttg  721 ctgattggcg ttgccacctc cagtctggcc ctgcacgcgc cgtcgcaaat tgtcgcggcg  781 attaaatctc gcgccgatca actgggtgcc agcgtggtgg tgtcgatggt agaacgaagc  841 ggcgtcgaag cctgtaaagc ggcggtgcac aatcttctcg cgcaacgcgt cagtgggctg  901 atcattaact atccgctgga tgaccaggat gccattgctg tggaagctgc ctgcactaat  961 gttccggcgt tatttcttga tgtctctgac cagacaccca tcaacagtat tattttctcc 1021 catgaagacg gtacgcgact gggcgtggag catctggtcg cattgggtca ccagcaaatc 1081 gcgctgttag cgggcccatt aagttctgtc tcggcgcgtc tgcgtctggc tggctggcat 1141 aaatatctca ctcgcaatca aattcagccg atagcggaac gggaaggcga ctggagtgcc 1201 atgtccggtt ttcaacaaac catgcaaatg ctgaatgagg gcatcgttcc cactgcgatg 1261 ctggttgcca acgatcagat ggcgctgggc gcaatgcgcg ccattaccga gtccgggctg 1321 cgcgttggtg cggatatctc ggtagtggga tacgacgata ccgaagacag ctcatgttat 1381 atcccgccgt taaccaccat caaacaggat tttcgcctgc tggggcaaac cagcgtggac 1441 cgcttgctgc aactctctca gggccaggcg gtgaagggca atcagctgtt gcccgtctca 1501 ctggtgaaaa gaaaaaccac cctggcgccc aatacgcaaa ccgcctctcc ccgcgcgttg 1561 gccgattcat taatgcagct ggcacgacag gtttcccgac tggaaagcgg gcagtgagcg 1621 caacgcaatt aatgtaagtt agctcactca ttaggcaccg ggatctcgac cgatgccctt 1681 gagagccttc aacccagtca gctccttccg gtgggcgcgg ggcatgacta tcgtcgccgc 1741 acttatgact gtcttcttta tcatgcaact cgtaggacag gtgccggcag cgctctgggt 1801 cattttcggc gaggaccgct ttcgctggag cgcgacgatg atcggcctgt cgcttgcggt 1861 attcggaatc ttgcacgccc tcgctcaagc cttcgtcact ggtcccgcca ccaaacgttt 1921 cggcgagaag caggccatta tcgccggcat ggcggccgac gcgctgggct acgtcttgct 1981 ggcgttcgcg acgcgaggct ggatggcctt ccccattatg attcttctcg cttccggcgg 2041 catcgggatg cccgcgttgc aggccatgct gtccaggcag gtagatgacg accatcaggg 2101 acagcttcaa ggatcgctcg cggctcttac cagcctaact tcgatcactg gaccgctgat 2161 cgtcacggcg atttatgccg cctcggcgag cacatggaac gggttggcat ggattgtagg 2221 cgccgcccta taccttgtct gcctccccgc gttgcgtcgc ggtgcatgga gccgggccac 2281 ctcgacctga atggaagccg gcggcacctc gctaacggat tcaccactcc aagaattgga 2341 gccaatcaat tcttgcggag aactgtgaat gcgcaaacca acccttggca gaacatatcc 2401 atcgcgtccg ccatctccag cagccgcacg cggcgcatct cgggcagcgt tgggtcctgg 2461 ccacgggtgc gcatgatcgt gctcctgtcg ttgaggaccc ggctaggctg gcggggttgc 2521 cttactggtt agcagaatga atcaccgata cgcgagcgaa cgtgaagcga ctgctgctgc 2581 aaaacgtctg cgacctgagc aacaacatga atggtcttcg gtttccgtgt ttcgtaaagt 2641 ctggaaacgc ggaagtcagc gccctgcacc attatgttcc ggatctgcat cgcaggatgc 2701 tgctggctac cctgtggaac acctacatct gtattaacga agcgctggca ttgaccctga 2761 gtgatttttc tctggtcccg ccgcatccat accgccagtt gtttaccctc acaacgttcc 2821 agtaaccggg catgttcatc atcagtaacc cgtatcgtga gcatcctctc tcgtttcatc 2881 ggtatcatta cccccatgaa cagaaatccc ccttacacgg aggcatcagt gaccaaacag 2941 gaaaaaaccg cccttaacat ggcccgcttt atcagaagcc agacattaac gcttctggag 3001 aaactcaacg agctggacgc ggatgaacag gcagacatct gtgaatcgct tcacgaccac 3061 gctgatgagc tttaccgcag ctgcctcgcg cgtttcggtg atgacggtga aaacctctga 3121 cacatgcagc tcccggagac ggtcacagct tgtctgtaag cggatgccgg gagcagacaa 3181 gcccgtcagg gcgcgtcagc gggtgttggc gggtgtcggg gcgcagccat gacccagtca 3241 cgtagcgata gcggagtgta tactggctta actatgcggc atcagagcag attgtactga 3301 gagtgcacca tatatgcggt gtgaaatacc gcacagatgc gtaaggagaa aataccgcat 3361 caggcgctct tccgcttcct cgctcactga ctcgctgcgc tcggtcgttc ggctgcggcg 3421 agcggtatca gctcactcaa aggcggtaat acggttatcc acagaatcag gggataacgc 3481 aggaaagaac atgtgagcaa aaggccagca aaaggccagg aaccgtaaaa aggccgcgtt 3541 gctggcgttt ttccataggc tccgcccccc tgacgagcat cacaaaaatc gacgctcaag 3601 tcagaggtgg cgaaacccga caggactata aagataccag gcgtttcccc ctggaagctc 3661 cctcgtgcgc tctcctgttc cgaccctgcc gcttaccgga tacctgtccg cctttctccc 3721 ttcgggaagc gtggcgcttt ctcatagctc acgctgtagg tatctcagtt cggtgtaggt 3781 cgttcgctcc aagctgggct gtgtgcacga accccccgtt cagcccgacc gctgcgcctt 3841 atccggtaac tatcgtcttg agtccaaccc ggtaagacac gacttatcgc cactggcagc 3901 agccactggt aacaggatta gcagagcgag gtatgtaggc ggtgctacag agttcttgaa 3961 gtggtggcct aactacggct acactagaag gacagtattt ggtatctgcg ctctgctgaa 4021 gccagttacc ttcggaaaaa gagttggtag ctcttgatcc ggcaaacaaa ccaccgctgg 4081 tagcggtggt ttttttgttt gcaagcagca gattacgcgc agaaaaaaag gatctcaaga 4141 agatcctttg atcttttcta cggggtctga cgctcagtgg aacgaaaact cacgttaagg 4201 gattttggtc atgagattat caaaaaggat cttcacctag atccttttaa attaaaaatg 4261 aagttttaaa tcaatctaaa gtatatatga gtaaacttgg tctgacagtt accaatgctt 4321 aatcagtgag gcacctatct cagcgatctg tctatttcgt tcatccatag ttgcctgact 4381 ccccgtcgtg tagataacta cgatacggga gggcttacca tctggcccca gtgctgcaat 4441 gataccgcga gacccacgct caccggctcc agatttatca gcaataaacc agccagccgg 4501 aagggccgag cgcagaagtg gtcctgcaac tttatccgcc tccatccagt ctattaattg 4561 ttgccgggaa gctagagtaa gtagttcgcc agttaatagt ttgcgcaacg ttgttgccat 4621 tgctgcaggc atcgtggtgt cacgctcgtc gtttggtatg gcttcattca gctccggttc 4681 ccaacgatca aggcgagtta catgatcccc catgttgtgc aaaaaagcgg ttagctcctt 4741 cggtcctccg atcgttgtca gaagtaagtt ggccgcagtg ttatcactca tggttatggc 4801 agcactgcat aattctctta ctgtcatgcc atccgtaaga tgcttttctg tgactggtga 4861 gtactcaacc aagtcattct gagaatagtg tatgcggcga ccgagttgct cttgcccggc 4921 gtcaacacgg gataataccg cgccacatag cagaacttta aaagtgctca tcattggaaa 4981 acgttcttcg gggcgaaaac tctcaaggat cttaccgctg ttgagatcca gttcgatgta 5041 acccactcgt gcacccaact gatcttcagc atcttttact ttcaccagcg tttctgggtg 5101 agcaaaaaca ggaaggcaaa atgccgcaaa aaagggaata agggcgacac ggaaatgttg 5161 aatactcata ctcttccttt ttcaatatta ttgaagcatt tatcagggtt attgtctcat 5221 gagcggatac atatttgaat gtatttagaa aaataaacaa ataggggttc cgcgcacatt 5281 tccccgaaaa gtgccacctg acgtctaaga aaccattatt atcatgacat taacctataa 5341 aaataggcgt atcacgaggc cctttcgtct tcaagaattc tcatgtttga cagcttatca 5401 tcgataagct ttaatgcggt agtttatcac agttaaattg ctaacgcagt caggcaccgt 5461 gtatgaaatc taacaatgcg ctcatcgtca tcctcggcac cgtcaccctg gatgctgtag 5521 gcataggctt ggttatgccg gtactgccgg gcctcttgcg ggatatccgg atatagttcc 5581 tcctttcagc aaaaaacccc tcaagacccg tttagaggcc ccaaggggtt atgctagtta 5641 ttgctcagcg gtggcagcag ccaactcagc ttcctttcgg gctttgttag cagccggatc 5701 ctcagcccct gttccccgct gctgccttgc ttccggtgga gcggtccggg tcgcaccggc 5761 cgccggtgat cgaccgggcg atctcgcccg cgcggaccgc caccatggac agcagggtgg 5821 aggcgatgcc gtgggtcgcc tcggtggcgc cctggacgta gatgccgcac cggaaatccc 5881 cggtggtgcc gagccggtag tcgcggccga tcagcaactc ccccgcctcg tcccggcgga 5941 gggcgccgga gacgccgccg agcagttcgg ccgggtcggt ggagtcgtac ccggtggcgt 6001 acacgaccag gtcggcgtcc aggtcggtgt gttcgcccgt gggcaggaac tccacgcgta 6061 cggcggcgga ttcctggcgc ggttcgacgg acaccaggcg ggaggcgttc atcacccgca 6121 gccgcggggc gccggacacc ttctgctcgt actggcggcg gtagaggccc tggaggacgt 6181 cctcgtcgac gacggcgtag ttggtgccgc cgtggtagcg catgatggcc tgcttgacct 6241 cgggcggggc gaagtagaag tcgtccacgg cggccgggtc gaagacgcgg ttggcgaacg 6301 ggctggagtc ggcgacgctg tagccgtagc gggcgaacac cgcgcacacc tcggcctgcg 6361 ggtagcggtc catgaggtgc gcggcgacct cggccgcgct ctggccggcg ccgaccacga 6421 cggcccggcg gggcgggcgt tcgtcgaacg cgggcagccg gtgcagcaac tgggagctgt 6481 gccagacgcg ttcgccggtc tccgcgccct cgggcagccg ggggcgcagg ccggaggcga 6541 ggacgaggtt tctggtccgg gcgaccaccc ggtccccggc gagcacgtcg agcgcgacga 6601 cctcaccggc ttcggtcacc ggccgcacac cggtggcctc cacgccgtac tcgaccaggt 6661 ggttcagccg gtcggcggcc cactggaggt agtcgtggta ctcgatccgg gagggcagca 6721 gggtgtgctg gttgatgaag tcgaccagcc ggtccttctc ctggagatag gacaggaatc 6781 cgaaatcact ggtgggattg cgcatcgtgg cgatgtcctt gagaaaggac acctggagcg 6841 aggagccccc caggagcatc ccccgatgcc agccgaattc cttctgcttc tccaggaaaa 6901 gggccttccc ggcggcttcg gattcatgga gcgccaccgc cagggcgaga ttcgcggcac 6961 cgaatccgat tccggtgacg tccagtactt ctgattccgg gctctgctgc gcagtggatg 7021 attgctctgc gagccgggtc a 178. SfaB (PzbA) in vivo expression    1 gtaggagggc gtggatatgt cctgcgggta aactatagtc gttgagagga ggagtctgac   61 tcctgttgat agatccagta atgacctcag aactccatct ggatttgttc agaacgctcg  121 gttgccgccg ggcgtttttt attggtgaga ataggtcttg acggctggcg agaggtgcgg  181 ggaggatctg accgacgcgg tccacacgtg gcaccgcgat gctgttgtgg gcacaatcgt  241 gccggttggt aggatccggt taattaagca gtaccagatc tgactgagtg accaaaggag  301 gcggacatat gacccggctc gcagagcaat catccactgc gcagcagagc ccggaatcag  361 aagtactgga cgtcaccgga atcggattcg gtgccgcgaa tctcgccctg gcggtggcgc  421 tccatgaatc cgaagccgcc gggaaggccc ttttcctgga gaagcagaag gaattcggct  481 ggcatcgggg gatgctcctg gggggctcct cgctccaggt gtcctttctc aaggacatcg  541 ccacgatgcg caatcccacc agtgatttcg gattcctgtc ctatctccag gagaaggacc  601 ggctggtcga cttcatcaac cagcacaccc tgctgccctc ccggatcgag taccacgact  661 acctccagtg ggccgccgac cggctgaacc acctggtcga gtacggcgtg gaggccaccg  721 gtgtgcggcc ggtgaccgaa gccggtgagg tcgtcgcgct cgacgtgctc gccggggacc  781 gggtggtcgc ccggaccaga aacctcgtcc tcgcctccgg cctgcgcccc cggctgcccg  841 agggcgcgga gaccggcgaa cgcgtctggc acagctccca gttgctgcac cggctgcccg  901 cgttcgacga acgcccgccc cgccgggccg tcgtggtcgg cgccggccag agcgcggccg  961 aggtcgccgc gcacctcatg gaccgctacc cgcaggccga ggtgtgcgcg gtgttcgccc 1021 gctacggcta cagcgtcgcc gactccagcc cgttcgccaa ccgcgtcttc gacccggccg 1081 ccgtggacga cttctacttc gccccgcccg aggtcaagca ggccatcatg cgctaccacg 1141 gcggcaccaa ctacgccgtc gtcgacgagg acgtcctcca gggcctctac cgccgccagt 1201 acgagcagaa ggtgtccggc gccccgcggc tgcgggtgat gaacgcctcc cgcctggtgt 1261 ccgtcgaacc gcgccaggaa tccgccgccg tacgcgtgga gttcctgccc acgggcgaac 1321 acaccgacct ggacgccgac ctggtcgtgt acgccaccgg gtacgactcc accgacccgg 1381 ccgaactgct cggcggcgtc tccggcgccc tccgccggga cgaggcgggg gagttgctga 1441 tcggccgcga ctaccggctc ggcaccaccg gggatttccg gtgcggcatc tacgtccagg 1501 gcgccaccga ggcgacccac ggcatcgcct ccaccctgct gtccatggtg gcggtccgcg 1561 cgggcgagat cgcccggtcg atcaccggcg gccggtgcga cccggaccgc tccaccggaa 1621 gcaaggcagc agcggggaac aggggctgag gatccccggg taccttcgaa aaaaaaaggc 1681 tccaaaagga gcctttaatt gttcctccag accttacttg accggcgctc actgcccgct 1741 ttccagtcgg gaaacctgtc gtgccagctg cattaatgaa tcggccaacg cgcggggaga 1801 ggcggtttgc gtattgggcg ctcttccgct tcctcgctca ctgactcgct gcgctcggtc 1861 gttcggctgc ggcgagcggt atcagctcac tcaaaggcgg taatacggtt atccacagaa 1921 tcaggggata acgcaggaaa gaacatgtga gcaaaaggcc agcaaaaggc caggaaccgt 1981 aaaaaggccg cgttgctggc gtttttccat aggctccgcc cccctgacga gcatcacaaa 2041 aatcgacgct caagtcagag gtggcgaaac ccgacaggac tataaagata ccaggcgttt 2101 ccccctggaa gctccctcgt gcgctctcct gttccgaccc tgccgcttac cggatacctg 2161 tccgcctttc tcccttcggg aagcgtggcg ctttctcata gctcacgctg taggtatctc 2221 agttcggtgt aggtcgttcg ctccaagctg ggctgtgtgc acgaaccccc cgttcagccc 2281 gaccgctgcg ccttatccgg taactatcgt cttgagtcca acccggtaag acacgactta 2341 tcgccactgg cagcagccac tggtaacagg attagcagag cgaggtatgt aggcggtgct 2401 acagagttct tgaagtggtg gcctaactac ggctacacta gaagaacagt atttggtatc 2461 tgcgctctgc tgaagccagt taccttcgga aaaagagttg gtagctcttg atccggcaaa 2521 caaaccaccg ctggtagcgg tggttttttt gtttgcaagc agcagattac gcgcagaaaa 2581 aaaggatctc aagaagatcc tttgatcttt tctacggggt ctgacgctca gtggaacgaa 2641 aactcacgtt aagggatttt ggtcatgaga ttatcaaaaa ggatcttcac ctagatcctt 2701 ttggttcatg tgcagctcca ctgctttaga ctctacatct gtatgaagtc ttcagatcct 2761 ctacgccgga cgcatcgtgg ccggatctaa aaaaaagccc gctcattagg cgggctgaca 2821 gttaccaatg cttaatcagt gaggcaccta tctcagcgat ctgtctattt cgttcatcca 2881 tagttgcctg actccccgtc gtgtagataa ctacgatacg ggagggctta ccatctggcc 2941 ccagtgctgc aatgataccg cgagacccac gctcaccggc tccagattta tcagcaataa 3001 accagccagc cggaagggcc gagcgcagaa gtggtcctgc aactttatcc gcctccatcc 3061 agtctattaa ttgttgccgg gaagctagag taagtagttc gccagttaat agtttgcgca 3121 acgttgttgc cattgctaca ggcatcgtgg tgtcacgctc gtcgtttggt atggcttcat 3181 tcagctccgg ttcccaacga tcaaggcgag ttacatgatc ccccatgttg tgcaaaaaag 3241 cggttagctc cttcggtcct ccgatcgttg tcagaagtaa gttggccgca gtgttatcac 3301 tcatggttat ggcagcactg cataattctc ttactgtcat gccatccgta agatgctttt 3361 ctgtgactgg tgagtactca accaagtcat tctgagaata gtgtatgcgg cgaccgagtt 3421 gctcttgccc ggcgtcaata cgggataata ccgcgccaca tagcagaact ttaaaagtgc 3481 tcatcattgg aaaacgttct tcggggcgaa aactctcaag gatcttaccg ctgttgagat 3541 ccagttcgat gtaacccact cgtgcaccca actgatcttc agcatctttt actttcacca 3601 gcgtttctgg gtgagcaaaa acaggaaggc aaagtgccgc aaaaaaggga ataagggcga 3661 cacggaaatg ttgaatactc atactcttcc tttttcaata ttattgaagc atttatcagg 3721 gttattgtct catgagcgga tacatatttg aatgtattta gaaaaataaa caaatagggg 3781 ttccgcgcac atttccccga aaagtgccac ctggcgcgcc acaaaacagc agggaagcag 3841 cgcttttccg ctgcataacc ctgcttcggg gtcattatag cgattttttc ggtatatcca 3901 tcctttttcg cacgatatac aggattttgc caaagggttc gtgtagactt tccttggtgt 3961 atccaacggc gtcagccggg caggataggt gaagtaggcc cacccgcgag cgggtgttcc 4021 ttcttcactg tcccttattc gcacctggcg gtgctcaacg ggaatcctgc tctgcgaggc 4081 tggccggcta ccgccggcgt aacagatgag ggcaagcgga tggctgatga aaccaagcca 4141 accaggaagg gcagcccacc tatcaaggtg tactgccttc cagacgaacg aagagcgatt 4201 gaggaaaagg cggcggcggc cggcatgagc ctgtcggcct acctgctggc cgtcggccag 4261 ggctacaaaa tcacgggcgt cgtggactat gagcacgtcg gcgcgcctct agtatgcagg 4321 agtggggagg cacgatggcc gctttggtcg acctcaacga gacgatgaag ccgtggaacg 4381 acaccacccc ggcggccctg ctggaccaca cccggcacta caccttcgac gtctgatcat 4441 cactgacgaa tcgaggtcga ggaaccgagc gtccgaggaa cagaggcgct tatcggttgg 4501 ccgcgagatt cctgtcgatc ctctcgtgca gcgcgattcc gagggaaacg gaaacgttga 4561 gagactcggt ctggctcatc atggggatgg aaaccgaggc ggaagacgcc tcctcgaaca 4621 ggtcggaagg cccacccttt tcgctgccga acagcaaggc cagccgatcc ggattgtccc 4681 cgagttcctt cacggaaatg tcgccatccg ccttgagcgt catcagctgc ataccgctgt 4741 cccgaatgaa ggcgatggcc tcctcgcgac cggagagaac gacgggaagg gagaagacgt 4801 aacctcggct ggccctttgg agacgccggt ccgcgatgct ggtgatgtca ctgtcgacca 4861 ggatgatccc cgacgctccg agcgcgagcg acgtgcgtac tatcgcgccg atgttcccga 4921 cgatcttcac cccgtcgaga acgacgacgt ccccacgccg gctcgcgata tcgccgaacc 4981 tggccgggcg agggacgcgg gcgatgccga atgtcttggc cttccgctcc cccttgaaca 5041 actggttgac gatcgaggag tcgatgaggc ggaccggtat gttctgccgc ccgcacagat 5101 ccagcaactc agatggaaaa ggactgctgt cgctgccgta gacctcgatg aactccaccc 5161 cggccgcgat gctgtgcatg aggggctcga cgtcctcgat caacgttgtc tttatgttgg 5221 atcgcgacgg cttggtgaca tcgatgatcc gctgcaccgc gggatcggac ggatttgcga 5281 tggtgtccaa ctcagtcatg gtcgtcctac cggctgctgt gttcagtgac gcgattcctg 5341 gggtgtgaca ccctacgcga cgatggcgga tggctgccct gaccggcaat caccaacgca 5401 aggggaagac tacgccttcc actagaccgg tcgacctgca ggcctgctgg cgccggacgg 5461 ggcttcagac gtttcgggtg ctgggttgtt gtctctggac agtgatccat gggaaactac 5521 tcagcaccac caatgttccc aaaagaaagc gcaggtcagc gcccatgagc caatatctag 5581 gcatgtcgcc cttcatcgct cccgaggtcc ctgagcacct tctcgacact gttcgcgtct 5641 tcctgtacgc gcgtcagtct aagggccggt ccgacggctc agacgtgtcg accgaagcac 5701 agctcgcggc cggtcgtgcg ttggtcgcgt ctcgcaacgc ccaggggggt gcgcgctggg 5761 tcgtggcagg tgagttcgtg gacgtcgggc gctccggctg ggacccgaac gtgacccgtg 5821 ccgacttcga gcgcatgatg ggcgaagtcc gcgccggcga aggtgacgtt gtcgttgtga 5881 atgagctttc ccggctcact cgcaagggcg cccatgacgc gctcgaaatc gacaacgaat 5941 tgaagaagca cggcgtgcgc ttcatgtcgg ttcttgagcc gttccttgac acgtctaccc 6001 ctatcggcgt cgccattttc gcgctgatcg ctgcccttgc gaaacaggac agtgacctga 6061 aggcggagcg cctgaagggt gcgaaagacg agattgccgc gctgggtggc gttcactcgt 6121 cttccgcccc gttcggaatg cgcgccgtgc gcaagaaggt cgataatctc gtgatctccg 6181 ttcttgagcc ggacgaagac aacccggatc acgtcgagct agttgagcgc atggcgaaaa 6241 tgtcgttcga gggcgtgtcc gacaacgcca ttgcaacgac cttcgagaag gaaaagatcc 6301 cgtcgcccgg aatggctgag agacgcgcca cggaaaagcg tcttgcgtcc atcaaggcac 6361 gtcgcctgaa cggcgctgaa aagccgatca tgtggcgcgc tcaaacggtc cgatggattc 6421 tcaaccatcc cgcaatcggc ggtttcgcat tcgagcgtgt gaagcacggt aaggcgcaca 6481 tcaacgtcat acggcgcgac cccggcggca agccgctaac gccccacacg ggcattctca 6541 gcggctcgaa gtggcttgag cttcaagaga agcgttccgg gaagaatctc agcgaccgga 6601 agcctggggc cgaagtcgaa ccgacgcttc tgagcgggtg gcgtttcctg gggtgccgaa 6661 tctgcggcgg ctcaatgggt cagtcccagg gtggccgtaa gcgcaacggc gaccttgccg 6721 aaggcaatta catgtgcgcc aacccgaagg ggcacggcgg cttgtcggtc aagcgcagcg 6781 aactggacga gttcgttgct tcgagggtgt gggcacggct ccgcacagcc gacatggaag 6841 atgaacacga tcaggcatgg attgccgccg ctgcggagcg cttcgccctt cagcacgacc 6901 tagcgggggt ggccgatgag cggcgcgaac aacaggcgca cctagacaac gtgcggcgct 6961 ccatcaagga ccttcaggcg gaccgtaagg ccggtctgta cgtcgggcgt gaagagctgg 7021 aaacgtggcg ctcaacggtg ctgcaatacc ggtcctacga agcggagtgc acgacccgac 7081 tcgctgagct tgacgagaag atgaacggca gcacccgcgt tccgtctgag tggttcagcg 7141 gcgaagaccc gacggccgaa gggggcatct gggcaagctg ggacgtgtac gagcgtcggg 7201 agttcctgag cttcttcctt gactccgtca tggtcgaccg ggggcgccac cctgagacga 7261 agaaatacat ccccctgaag gaccgtgtga cgctcaagtg ggcggagctg ctgaaggagg 7321 aagacgaagc gagcgaagcc actgagcggg agcttgcggc gctgtaggta caatcataat 7381 gaggctagac tacagacgcg aagaatctcg tgctttcagc ttcgat 179. SfaC (PzbB) expression    1 tatgtacgaa cgtccgctgt accgggagga ttgcgacggc gtcgtcctgg cgtttctgcg   61 acacaaccca ctggcaatgg tcgtcacctc gcacgacgac gtcccggtgg ccacccacgc  121 gccggtgctg ttccggcacg gacccgacgg cgccgacgcc gaggccgtcg ccgcgggcac  181 cgtcccgctc gccggctcca ccctgatcgg ccacatgaac gtcgagaacc cgcagtggcg  241 ccggatgcgc tccggcgacc gggcgctcat cgtcttccag ggcccgcacg gctatgtctc  301 gccgacggtc tacggggtca cgcccgcggc ccccacctgg gacttcatcg ccgtccacgt  361 gaacggcaca gtggagccca ccgccgaccc cgccgccgtg ctggacatcg tctccgacac  421 cgcccggcgg ctggagtccg gcttcgggcg cggctgggac caggagtcct ccctcgacta  481 cttccgccag atcgcgcccg gcgtgggcgc cttcaccctg cgggtcgatt ccgtgcagac  541 gatgttcaag ctcagccagg agaagcccgc cccgatgcgg cggcgcgtgg tcgagcagtt  601 cgaagcaagc gagtccggca cccaccgcgc cctggccagc gtgatgcgcg accgcggact  661 caccgaagcc gacgaggagc gggagacagc cggatgagga tccggctgct aacaaagccc  721 gaaaggaagc tgagttggct gctgccaccg ctgagcaata actagcataa ccccttgggg  781 cctctaaacg ggtcttgagg ggttttttgc tgaaaggagg aactatatcc ggatatcccg  841 caagaggccc ggcagtaccg gcataaccaa gcctatgcct acagcatcca gggtgacggt  901 gccgaggatg acgatgagcg cattgttaga tttcatacac ggtgcctgac tgcgttagca  961 atttaactgt gataaactac cgcattaaag cttatcgatg ataagctgtc aaacatgaga 1021 attcttgaag acgaaagggc ctcgtgatac gcctattttt ataggttaat gtcatgataa 1081 taatggtttc ttagacgtca ggtggcactt ttcggggaaa tgtgcgcgga acccctattt 1141 gtttattttt ctaaatacat tcaaatatgt atccgctcat gagacaataa ccctgataaa 1201 tgcttcaata atattgaaaa aggaagagta tgagtattca acatttccgt gtcgccctta 1261 ttcccttttt tgcggcattt tgccttcctg tttttgctca cccagaaacg ctggtgaaag 1321 taaaagatgc tgaagatcag ttgggtgcac gagtgggtta catcgaactg gatctcaaca 1381 gcggtaagat ccttgagagt tttcgccccg aagaacgttt tccaatgatg agcactttta 1441 aagttctgct atgtggcgcg gtattatccc gtgttgacgc cgggcaagag caactcggtc 1501 gccgcataca ctattctcag aatgacttgg ttgagtactc accagtcaca gaaaagcatc 1561 ttacggatgg catgacagta agagaattat gcagtgctgc cataaccatg agtgataaca 1621 ctgcggccaa cttacttctg acaacgatcg gaggaccgaa ggagctaacc gcttttttgc 1681 acaacatggg ggatcatgta actcgccttg atcgttggga accggagctg aatgaagcca 1741 taccaaacga cgagcgtgac accacgatgc ctgcagcaat ggcaacaacg ttgcgcaaac 1801 tattaactgg cgaactactt actctagctt cccggcaaca attaatagac tggatggagg 1861 cggataaagt tgcaggacca cttctgcgct cggcccttcc ggctggctgg tttattgctg 1921 ataaatctgg agccggtgag cgtgggtctc gcggtatcat tgcagcactg gggccagatg 1981 gtaagccctc ccgtatcgta gttatctaca cgacggggag tcaggcaact atggatgaac 2041 gaaatagaca gatcgctgag ataggtgcct cactgattaa gcattggtaa ctgtcagacc 2101 aagtttactc atatatactt tagattgatt taaaacttca tttttaattt aaaaggatct 2161 aggtgaagat cctttttgat aatctcatga ccaaaatccc ttaacgtgag ttttcgttcc 2221 actgagcgtc agaccccgta gaaaagatca aaggatcttc ttgagatcct ttttttctgc 2281 gcgtaatctg ctgcttgcaa acaaaaaaac caccgctacc agcggtggtt tgtttgccgg 2341 atcaagagct accaactctt tttccgaagg taactggctt cagcagagcg cagataccaa 2401 atactgtcct tctagtgtag ccgtagttag gccaccactt caagaactct gtagcaccgc 2461 ctacatacct cgctctgcta atcctgttac cagtggctgc tgccagtggc gataagtcgt 2521 gtcttaccgg gttggactca agacgatagt taccggataa ggcgcagcgg tcgggctgaa 2581 cggggggttc gtgcacacag cccagcttgg agcgaacgac ctacaccgaa ctgagatacc 2641 tacagcgtga gctatgagaa agcgccacgc ttcccgaagg gagaaaggcg gacaggtatc 2701 cggtaagcgg cagggtcgga acaggagagc gcacgaggga gcttccaggg ggaaacgcct 2761 ggtatcttta tagtcctgtc gggtttcgcc acctctgact tgagcgtcga tttttgtgat 2821 gctcgtcagg ggggcggagc ctatggaaaa acgccagcaa cgcggccttt ttacggttcc 2881 tggccttttg ctggcctttt gctcacatgt tctttcctgc gttatcccct gattctgtgg 2941 ataaccgtat taccgccttt gagtgagctg ataccgctcg ccgcagccga acgaccgagc 3001 gcagcgagtc agtgagcgag gaagcggaag agcgcctgat gcggtatttt ctccttacgc 3061 atctgtgcgg tatttcacac cgcatatatg gtgcactctc agtacaatct gctctgatgc 3121 cgcatagtta agccagtata cactccgcta tcgctacgtg actgggtcat ggctgcgccc 3181 cgacacccgc caacacccgc tgacgcgccc tgacgggctt gtctgctccc ggcatccgct 3241 tacagacaag ctgtgaccgt ctccgggagc tgcatgtgtc agaggttttc accgtcatca 3301 ccgaaacgcg cgaggcagct gcggtaaagc tcatcagcgt ggtcgtgaag cgattcacag 3361 atgtctgcct gttcatccgc gtccagctcg ttgagtttct ccagaagcgt taatgtctgg 3421 cttctgataa agcgggccat gttaagggcg gttttttcct gtttggtcac tgatgcctcc 3481 gtgtaagggg gatttctgtt catgggggta atgataccga tgaaacgaga gaggatgctc 3541 acgatacggg ttactgatga tgaacatgcc cggttactgg aacgttgtga gggtaaacaa 3601 ctggcggtat ggatgcggcg ggaccagaga aaaatcactc agggtcaatg ccagcgcttc 3661 gttaatacag atgtaggtgt tccacagggt agccagcagc atcctgcgat gcagatccgg 3721 aacataatgg tgcagggcgc tgacttccgc gtttccagac tttacgaaac acggaaaccg 3781 aagaccattc atgttgttgc tcaggtcgca gacgttttgc agcagcagtc gcttcacgtt 3841 cgctcgcgta tcggtgattc attctgctaa ccagtaaggc aaccccgcca gcctagccgg 3901 gtcctcaacg acaggagcac gatcatgcgc acccgtggcc aggacccaac gctgcccgag 3961 atgcgccgcg tgcggctgct ggagatggcg gacgcgatgg atatgttctg ccaagggttg 4021 gtttgcgcat tcacagttct ccgcaagaat tgattggctc caattcttgg agtggtgaat 4081 ccgttagcga ggtgccgccg gcttccattc aggtcgaggt ggcccggctc catgcaccgc 4141 gacgcaacgc ggggaggcag acaaggtata gggcggcgcc tacaatccat gccaacccgt 4201 tccatgtgct cgccgaggcg gcataaatcg ccgtgacgat cagcggtcca gtgatcgaag 4261 ttaggctggt aagagccgcg agcgatcctt gaagctgtcc ctgatggtcg tcatctacct 4321 gcctggacag catggcctgc aacgcgggca tcccgatgcc gccggaagcg agaagaatca 4381 taatggggaa ggccatccag cctcgcgtcg cgaacgccag caagacgtag cccagcgcgt 4441 cggccgccat gccggcgata atggcctgct tctcgccgaa acgtttggtg gcgggaccag 4501 tgacgaaggc ttgagcgagg gcgtgcaaga ttccgaatac cgcaagcgac aggccgatca 4561 tcgtcgcgct ccagcgaaag cggtcctcgc cgaaaatgac ccagagcgct gccggcacct 4621 gtcctacgag ttgcatgata aagaagacag tcataagtgc ggcgacgata gtcatgcccc 4681 gcgcccaccg gaaggagctg actgggttga aggctctcaa gggcatcggt cgagatcccg 4741 gtgcctaatg agtgagctaa cttacattaa ttgcgttgcg ctcactgccc gctttccagt 4801 cgggaaacct gtcgtgccag ctgcattaat gaatcggcca acgcgcgggg agaggcggtt 4861 tgcgtattgg gcgccagggt ggtttttctt ttcaccagtg agacgggcaa cagctgattg 4921 cccttcaccg cctggccctg agagagttgc agcaagcggt ccacgctggt ttgccccagc 4981 aggcgaaaat cctgtttgat ggtggttaac ggcgggatat aacatgagct gtcttcggta 5041 tcgtcgtatc ccactaccga gatatccgca ccaacgcgca gcccggactc ggtaatggcg 5101 cgcattgcgc ccagcgccat ctgatcgttg gcaaccagca tcgcagtggg aacgatgccc 5161 tcattcagca tttgcatggt ttgttgaaaa ccggacatgg cactccagtc gccttcccgt 5221 tccgctatcg gctgaatttg attgcgagtg agatatttat gccagccagc cagacgcaga 5281 cgcgccgaga cagaacttaa tgggcccgct aacagcgcga tttgctggtg acccaatgcg 5341 accagatgct ccacgcccag tcgcgtaccg tcttcatggg agaaaataat actgttgatg 5401 ggtgtctggt cagagacatc aagaaataac gccggaacat tagtgcaggc agcttccaca 5461 gcaatggcat cctggtcatc cagcggatag ttaatgatca gcccactgac gcgttgcgcg 5521 agaagattgt gcaccgccgc tttacaggct tcgacgccgc ttcgttctac catcgacacc 5581 accacgctgg cacccagttg atcggcgcga gatttaatcg ccgcgacaat ttgcgacggc 5641 gcgtgcaggg ccagactgga ggtggcaacg ccaatcagca acgactgttt gcccgccagt 5701 tgttgtgcca cgcggttggg aatgtaattc agctccgcca tcgccgcttc cactttttcc 5761 cgcgttttcg cagaaacgtg gctggcctgg ttcaccacgc gggaaacggt ctgataagag 5821 acaccggcat actctgcgac atcgtataac gttactggtt tcacattcac caccctgaat 5881 tgactctctt ccgggcgcta tcatgccata ccgcgaaagg ttttgcgcca ttcgatggtg 5941 tccgggatct cgacgctctc ccttatgcga ctcctgcatt aggaagcagc ccagtagtag 6001 gttgaggccg ttgagcaccg ccgccgcaag gaatggtgca tgcaaggaga tggcgcccaa 6061 cagtcccccg gccacggggc ctgccaccat acccacgccg aaacaagcgc tcatgagccc 6121 gaagtggcga gcccgatctt ccccatcggt gatgtcggcg atataggcgc cagcaaccgc 6181 acctgtggcg ccggtgatgc cggccacgat gcgtccggcg tagaggatcg agatctcgat 6241 cccgcgaaat taatacgact cactataggg gaattgtgag cggataacaa ttcccctcta 6301 gaaataattt tgtttaactt taagaaggag atataccatg ggcagcagcc atcatcatca 6361 tcatcacagc agcggcctgg tgccgcgcgg cagcca 180. SfaC (PzbB) complementation of flaveolus    1 gtaggagggc gtggatatgt cctgcgggta aactatagtc gttgagagga ggagtctgac   61 tcctgttgat agatccagta atgacctcag aactccatct ggatttgttc agaacgctcg  121 gttgccgccg ggcgtttttt attggtgaga ataggtcttg acggctggcg agaggtgcgg  181 ggaggatctg accgacgcgg tccacacgtg gcaccgcgat gctgttgtgg gcacaatcgt  241 gccggttggt aggatccggt taattaagca gtaccagatc tgactgagtg accaaaggag  301 gcggacatat gtacgaacgt ccgctgtacc gggaggattg cgacggcgtc gtcctggcgt  361 ttctgcgaca caacccactg gcaatggtcg tcacctcgca cgacgacgtc ccggtggcca  421 cccacgcgcc ggtgctgttc cggcacggac ccgacggcgc cgacgccgag gccgtcgccg  481 cgggcaccgt cccgctcgcc ggctccaccc tgatcggcca catgaacgtc gagaacccgc  541 agtggcgccg gatgcgctcc ggcgaccggg cgctcatcgt cttccagggc ccgcacggct  601 atgtctcgcc gacggtctac ggggtcacgc ccgcggcccc cacctgggac ttcatcgccg  661 tccacgtgaa cggcacagtg gagcccaccg ccgaccccgc cgccgtgctg gacatcgtct  721 ccgacaccgc ccggcggctg gagtccggct tcgggcgcgg ctgggaccag gagtcctccc  781 tcgactactt ccgccagatc gcgcccggcg tgggcgcctt caccctgcgg gtcgattccg  841 tgcagacgat gttcaagctc agccaggaga agcccgcccc gatgcggcgg cgcgtggtcg  901 agcagttcga agcaagcgag tccggcaccc accgcgccct ggccagcgtg atgcgcgacc  961 gcggactcac cgaagccgac gaggagcggg agacagccgg atgaggatcc ccgggtacct 1021 tcgaaaaaaa aaggctccaa aaggagcctt taattgttcc tccagacctt acttgaccgg 1081 cgctcactgc ccgctttcca gtcgggaaac ctgtcgtgcc agctgcatta atgaatcggc 1141 caacgcgcgg ggagaggcgg tttgcgtatt gggcgctctt ccgcttcctc gctcactgac 1201 tcgctgcgct cggtcgttcg gctgcggcga gcggtatcag ctcactcaaa ggcggtaata 1261 cggttatcca cagaatcagg ggataacgca ggaaagaaca tgtgagcaaa aggccagcaa 1321 aaggccagga accgtaaaaa ggccgcgttg ctggcgtttt tccataggct ccgcccccct 1381 gacgagcatc acaaaaatcg acgctcaagt cagaggtggc gaaacccgac aggactataa 1441 agataccagg cgtttccccc tggaagctcc ctcgtgcgct ctcctgttcc gaccctgccg 1501 cttaccggat acctgtccgc ctttctccct tcgggaagcg tggcgctttc tcatagctca 1561 cgctgtaggt atctcagttc ggtgtaggtc gttcgctcca agctgggctg tgtgcacgaa 1621 ccccccgttc agcccgaccg ctgcgcctta tccggtaact atcgtcttga gtccaacccg 1681 gtaagacacg acttatcgcc actggcagca gccactggta acaggattag cagagcgagg 1741 tatgtaggcg gtgctacaga gttcttgaag tggtggccta actacggcta cactagaaga 1801 acagtatttg gtatctgcgc tctgctgaag ccagttacct tcggaaaaag agttggtagc 1861 tcttgatccg gcaaacaaac caccgctggt agcggtggtt tttttgtttg caagcagcag 1921 attacgcgca gaaaaaaagg atctcaagaa gatcctttga tcttttctac ggggtctgac 1981 gctcagtgga acgaaaactc acgttaaggg attttggtca tgagattatc aaaaaggatc 2041 ttcacctaga tccttttggt tcatgtgcag ctccactgct ttagactcta catctgtatg 2101 aagtcttcag atcctctacg ccggacgcat cgtggccgga tctaaaaaaa agcccgctca 2161 ttaggcgggc tgacagttac caatgcttaa tcagtgaggc acctatctca gcgatctgtc 2221 tatttcgttc atccatagtt gcctgactcc ccgtcgtgta gataactacg atacgggagg 2281 gcttaccatc tggccccagt gctgcaatga taccgcgaga cccacgctca ccggctccag 2341 atttatcagc aataaaccag ccagccggaa gggccgagcg cagaagtggt cctgcaactt 2401 tatccgcctc catccagtct attaattgtt gccgggaagc tagagtaagt agttcgccag 2461 ttaatagttt gcgcaacgtt gttgccattg ctacaggcat cgtggtgtca cgctcgtcgt 2521 ttggtatggc ttcattcagc tccggttccc aacgatcaag gcgagttaca tgatccccca 2581 tgttgtgcaa aaaagcggtt agctccttcg gtcctccgat cgttgtcaga agtaagttgg 2641 ccgcagtgtt atcactcatg gttatggcag cactgcataa ttctcttact gtcatgccat 2701 ccgtaagatg cttttctgtg actggtgagt actcaaccaa gtcattctga gaatagtgta 2761 tgcggcgacc gagttgctct tgcccggcgt caatacggga taataccgcg ccacatagca 2821 gaactttaaa agtgctcatc attggaaaac gttcttcggg gcgaaaactc tcaaggatct 2881 taccgctgtt gagatccagt tcgatgtaac ccactcgtgc acccaactga tcttcagcat 2941 cttttacttt caccagcgtt tctgggtgag caaaaacagg aaggcaaagt gccgcaaaaa 3001 agggaataag ggcgacacgg aaatgttgaa tactcatact cttccttttt caatattatt 3061 gaagcattta tcagggttat tgtctcatga gcggatacat atttgaatgt atttagaaaa 3121 ataaacaaat aggggttccg cgcacatttc cccgaaaagt gccacctggc gcgccacaaa 3181 acagcaggga agcagcgctt ttccgctgca taaccctgct tcggggtcat tatagcgatt 3241 ttttcggtat atccatcctt tttcgcacga tatacaggat tttgccaaag ggttcgtgta 3301 gactttcctt ggtgtatcca acggcgtcag ccgggcagga taggtgaagt aggcccaccc 3361 gcgagcgggt gttccttctt cactgtccct tattcgcacc tggcggtgct caacgggaat 3421 cctgctctgc gaggctggcc ggctaccgcc ggcgtaacag atgagggcaa gcggatggct 3481 gatgaaacca agccaaccag gaagggcagc ccacctatca aggtgtactg ccttccagac 3541 gaacgaagag cgattgagga aaaggcggcg gcggccggca tgagcctgtc ggcctacctg 3601 ctggccgtcg gccagggcta caaaatcacg ggcgtcgtgg actatgagca cgtcggcgcg 3661 cctctagtat gcaggagtgg ggaggcacga tggccgcttt ggtcgacctc aacgagacga 3721 tgaagccgtg gaacgacacc accccggcgg ccctgctgga ccacacccgg cactacacct 3781 tcgacgtctg atcatcactg acgaatcgag gtcgaggaac cgagcgtccg aggaacagag 3841 gcgcttatcg gttggccgcg agattcctgt cgatcctctc gtgcagcgcg attccgaggg 3901 aaacggaaac gttgagagac tcggtctggc tcatcatggg gatggaaacc gaggcggaag 3961 acgcctcctc gaacaggtcg gaaggcccac ccttttcgct gccgaacagc aaggccagcc 4021 gatccggatt gtccccgagt tccttcacgg aaatgtcgcc atccgccttg agcgtcatca 4081 gctgcatacc gctgtcccga atgaaggcga tggcctcctc gcgaccggag agaacgacgg 4141 gaagggagaa gacgtaacct cggctggccc tttggagacg ccggtccgcg atgctggtga 4201 tgtcactgtc gaccaggatg atccccgacg ctccgagcgc gagcgacgtg cgtactatcg 4261 cgccgatgtt cccgacgatc ttcaccccgt cgagaacgac gacgtcccca cgccggctcg 4321 cgatatcgcc gaacctggcc gggcgaggga cgcgggcgat gccgaatgtc ttggccttcc 4381 gctccccctt gaacaactgg ttgacgatcg aggagtcgat gaggcggacc ggtatgttct 4441 gccgcccgca cagatccagc aactcagatg gaaaaggact gctgtcgctg ccgtagacct 4501 cgatgaactc caccccggcc gcgatgctgt gcatgagggg ctcgacgtcc tcgatcaacg 4561 ttgtctttat gttggatcgc gacggcttgg tgacatcgat gatccgctgc accgcgggat 4621 cggacggatt tgcgatggtg tccaactcag tcatggtcgt cctaccggct gctgtgttca 4681 gtgacgcgat tcctggggtg tgacacccta cgcgacgatg gcggatggct gccctgaccg 4741 gcaatcacca acgcaagggg aagactacgc cttccactag accggtcgac ctgcaggcct 4801 gctggcgccg gacggggctt cagacgtttc gggtgctggg ttgttgtctc tggacagtga 4861 tccatgggaa actactcagc accaccaatg ttcccaaaag aaagcgcagg tcagcgccca 4921 tgagccaata tctaggcatg tcgcccttca tcgctcccga ggtccctgag caccttctcg 4981 acactgttcg cgtcttcctg tacgcgcgtc agtctaaggg ccggtccgac ggctcagacg 5041 tgtcgaccga agcacagctc gcggccggtc gtgcgttggt cgcgtctcgc aacgcccagg 5101 ggggtgcgcg ctgggtcgtg gcaggtgagt tcgtggacgt cgggcgctcc ggctgggacc 5161 cgaacgtgac ccgtgccgac ttcgagcgca tgatgggcga agtccgcgcc ggcgaaggtg 5221 acgttgtcgt tgtgaatgag ctttcccggc tcactcgcaa gggcgcccat gacgcgctcg 5281 aaatcgacaa cgaattgaag aagcacggcg tgcgcttcat gtcggttctt gagccgttcc 5341 ttgacacgtc tacccctatc ggcgtcgcca ttttcgcgct gatcgctgcc cttgcgaaac 5401 aggacagtga cctgaaggcg gagcgcctga agggtgcgaa agacgagatt gccgcgctgg 5461 gtggcgttca ctcgtcttcc gccccgttcg gaatgcgcgc cgtgcgcaag aaggtcgata 5521 atctcgtgat ctccgttctt gagccggacg aagacaaccc ggatcacgtc gagctagttg 5581 agcgcatggc gaaaatgtcg ttcgagggcg tgtccgacaa cgccattgca acgaccttcg 5641 agaaggaaaa gatcccgtcg cccggaatgg ctgagagacg cgccacggaa aagcgtcttg 5701 cgtccatcaa ggcacgtcgc ctgaacggcg ctgaaaagcc gatcatgtgg cgcgctcaaa 5761 cggtccgatg gattctcaac catcccgcaa tcggcggttt cgcattcgag cgtgtgaagc 5821 acggtaaggc gcacatcaac gtcatacggc gcgaccccgg cggcaagccg ctaacgcccc 5881 acacgggcat tctcagcggc tcgaagtggc ttgagcttca agagaagcgt tccgggaaga 5941 atctcagcga ccggaagcct ggggccgaag tcgaaccgac gcttctgagc gggtggcgtt 6001 tcctggggtg ccgaatctgc ggcggctcaa tgggtcagtc ccagggtggc cgtaagcgca 6061 acggcgacct tgccgaaggc aattacatgt gcgccaaccc gaaggggcac ggcggcttgt 6121 cggtcaagcg cagcgaactg gacgagttcg ttgcttcgag ggtgtgggca cggctccgca 6181 cagccgacat ggaagatgaa cacgatcagg catggattgc cgccgctgcg gagcgcttcg 6241 cccttcagca cgacctagcg ggggtggccg atgagcggcg cgaacaacag gcgcacctag 6301 acaacgtgcg gcgctccatc aaggaccttc aggcggaccg taaggccggt ctgtacgtcg 6361 ggcgtgaaga gctggaaacg tggcgctcaa cggtgctgca ataccggtcc tacgaagcgg 6421 agtgcacgac ccgactcgct gagcttgacg agaagatgaa cggcagcacc cgcgttccgt 6481 ctgagtggtt cagcggcgaa gacccgacgg ccgaaggggg catctgggca agctgggacg 6541 tgtacgagcg tcgggagttc ctgagcttct tccttgactc cgtcatggtc gaccgggggc 6601 gccaccctga gacgaagaaa tacatccccc tgaaggaccg tgtgacgctc aagtgggcgg 6661 agctgctgaa ggaggaagac gaagcgagcg aagccactga gcgggagctt gcggcgctgt 6721 aggtacaatc ataatgaggc tagactacag acgcgaagaa tctcgtgctt tcagcttcga 6781 t 181. SfaC (PzbB) in vivo expression    1 atctacgtct gtcgagaagt ttctgatcga aaagttcgac agcgtctccg acctgatgca   61 gctctcgcag ggcgaagaat ctcgtgcttt cagcttcgat gtaggagggc gtggatatgt  121 cctgcgggta aactatagtc gttgagagga ggagtctgac tcctgttgat agatccagta  181 atgacctcag aactccatct ggatttgttc agaacgctcg gttgccgccg ggcgtttttt  241 attggtgaga ataggtcttg acggctggcg agaggtgcgg ggaggatctg accgacgcgg  301 tccacacgtg gcaccgcgat gctgttgtgg gcacaatcgt gccggttggt aggatccggt  361 taattaagca gtaccagatc tgactgagtg accaaaggag gcggacatat gtacgaacgt  421 ccgctgtacc gggaggattg cgacggcgtc gtcctggcgt ttctgcgaca caacccactg  481 gcaatggtcg tcacctcgca cgacgacgtc ccggtggcca cccacgcgcc ggtgctgttc  541 cggcacggac ccgacggcgc cgacgccgag gccgtcgccg cgggcaccgt cccgctcgcc  601 ggctccaccc tgatcggcca catgaacgtc gagaacccgc agtggcgccg gatgcgctcc  661 ggcgaccggg cgctcatcgt cttccagggc ccgcacggct atgtctcgcc gacggtctac  721 ggggtcacgc ccgcggcccc cacctgggac ttcatcgccg tccacgtgaa cggcacagtg  781 gagcccaccg ccgaccccgc cgccgtgctg gacatcgtct ccgacaccgc ccggcggctg  841 gagtccggct tcgggcgcgg ctgggaccag gagtcctccc tcgactactt ccgccagatc  901 gcgcccggcg tgggcgcctt caccctgcgg gtcgattccg tgcagacgat gttcaagctc  961 agccaggaga agcccgcccc gatgcggcgg cgcgtggtcg agcagttcga agcaagcgag 1021 tccggcaccc accgcgccct ggccagcgtg atgcgcgacc gcggactcac cgaagccgac 1081 gaggagcggg agacagccgg atgaggatcc ccgggtacct tcgaaaaaaa aaggctccaa 1141 aaggagcctt taattgttcc tccagacctt acttgaccgg cgctcactgc ccgctttcca 1201 gtcgggaaac ctgtcgtgcc agctgcatta atgaatcggc caacgcgcgg ggagaggcgg 1261 tttgcgtatt gggcgctctt ccgcttcctc gctcactgac tcgctgcgct cggtcgttcg 1321 gctgcggcga gcggtatcag ctcactcaaa ggcggtaata cggttatcca cagaatcagg 1381 ggataacgca ggaaagaaca tgtgagcaaa aggccagcaa aaggccagga accgtaaaaa 1441 ggccgcgttg ctggcgtttt tccataggct ccgcccccct gacgagcatc acaaaaatcg 1501 acgctcaagt cagaggtggc gaaacccgac aggactataa agataccagg cgtttccccc 1561 tggaagctcc ctcgtgcgct ctcctgttcc gaccctgccg cttaccggat acctgtccgc 1621 ctttctccct tcgggaagcg tggcgctttc tcatagctca cgctgtaggt atctcagttc 1681 ggtgtaggtc gttcgctcca agctgggctg tgtgcacgaa ccccccgttc agcccgaccg 1741 ctgcgcctta tccggtaact atcgtcttga gtccaacccg gtaagacacg acttatcgcc 1801 actggcagca gccactggta acaggattag cagagcgagg tatgtaggcg gtgctacaga 1861 gttcttgaag tggtggccta actacggcta cactagaaga acagtatttg gtatctgcgc 1921 tctgctgaag ccagttacct tcggaaaaag agttggtagc tcttgatccg gcaaacaaac 1981 caccgctggt agcggtggtt tttttgtttg caagcagcag attacgcgca gaaaaaaagg 2041 atctcaagaa gatcctttga tcttttctac ggggtctgac gctcagtgga acgaaaactc 2101 acgttaaggg attttggtca tgagattatc aaaaaggatc ttcacctaga tccttttggt 2161 tcatgtgcag ctccatcagc aaaaggggat gataagttta tcaccaccga ctatttgcaa 2221 cagtgccgtt gatcgtgcta tgatcgactg atgtcatcag cggtggagtg caatgtcgtg 2281 caatacgaat ggcgaaaagc cgagctcatc ggtcagcttc tcaaccttgg ggttaccccc 2341 ggcggtgtgc tgctggtcca cagctccttc cgtagcgtcc ggcccctcga agatgggcca 2401 cttggactga tcgaggccct gcgtgctgcg ctgggtccgg gagggacgct cgtcatgccc 2461 tcgtggtcag gtctggacga cgagccgttc gatcctgcca cgtcgcccgt tacaccggac 2521 cttggagttg tctctgacac attctggcgc ctgccaaatg taaagcgcag cgcccatcca 2581 tttgcctttg cggcagcggg gccacaggca gagcagatca tctctgatcc attgcccctg 2641 ccacctcact cgcctgcaag cccggtcgcc cgtgtccatg aactcgatgg gcaggtactt 2701 ctcctcggcg tgggacacga tgccaacacg acgctgcatc ttgccgagtt gatggcaaag 2761 gttccctatg gggtgccgag acactgcacc attcttcagg atggcaagtt ggtacgcgtc 2821 gattatctcg agaatgacca ctgctgtgag cgctttgcct tggcggacag gtggctcaag 2881 gagaagagcc ttcagaagga aggtccagtc ggtcatgcct ttgctcggtt gatccgctcc 2941 cgcgacattg tggcgacagc cctgggtcaa ctgggccgag atccgttgat cttcctgcat 3001 ccgccagagg cgggatgcga agaatgcgat gccgctcgcc agtcgattgg ctgagctcat 3061 gagcggagaa cgagatgacg ttggaggggc aaggtcgcgc tgattgctgg ggcaacacgt 3121 ggagcggatc ggggattgtc tttcttcagc tcgctgatga tatgctgacg ctcaatgccg 3181 tttggcctcc gactaacgaa aatcccgcat ttggacggct gatccgattg gcacggcgga 3241 cggcgaatgg cggagcagac gctcgtccgg gggcaatgag atatgaaaaa gcctgaactc 3301 accgcgacgt atcgggccct ggccagctag ctagagtcga cctgcaggtc cccggggatc 3361 ggtcttgcct tgctcgtcgg tgatgtactt caccagctcc gcgaagtcgc tcttcttgat 3421 ggagcgcatg gggacgtgct tggcaatcac gcgcaccccc cggccgtttt agcggctaaa 3481 aaagtcatgg ctctgccctc gggcggacca cgcccatcat gaccttgcca agctcgtcct 3541 gcttctcttc gatcttcgcc agcagggcga ggatcgtggc atcaccgaac cgcgccgtgc 3601 gcgggtcgtc ggtgagccag agtttcagca ggccgcccag gcggcccagg tcgccattga 3661 tgcgggccag ctcgcggacg tgctcatagt ccacgacgcc cgtgattttg tagccctggc 3721 cgacggccag caggtaggcc gacaggctca tgccggccgc cgccgccttt tcctcaatcg 3781 ctcttcgttc gtctggaagg cagtacacct tgataggtgg gctgcccttc ctggttggct 3841 tggtttcatc agccatccgc ttgccctcat ctgttacgcc ggcggtagcc ggccagcctc 3901 gcagagcagg attcccgttg agcaccgcca ggtgcgaata agggacagtg aagaaggaac 3961 acccgctcgc gggtgggcct acttcaccta tcctgcccgg ctgacgccgt tggatacacc 4021 aaggaaagtc tacacgaacc ctttggcaaa atcctgtata tcgtgcgaaa aaggatggat 4081 ataccgaaaa aatcgctata atgaccccga agcagggtta tgcagcggaa aagatccgtc 4141 gacctgcagg catgcaagct ctagcgattc cagacgtccc gaaggcgtgg cgcggcttcc 4201 ccgtgccgga gcaatcgccc tgggtgggtt acacgacgcc cctctatggc ccgtactgac 4261 ggacacaccg aagccccggc ggcaaccctc agcggatgcc ccggggcttc acgttttccc 4321 aggtcagaag cggttttcgg gagtagtgcc ccaactgggg taacctttga gttctctcag 4381 ttgggggcgt agggtcgccg acatgacaca aggggttgtg accggggtgg acacgtacgc 4441 gggtgcttac gaccgtcagt cgcgcgagcg cgaaaattcg agcgcagcaa gcccagcgac 4501 acagcgtagc gccaacgaag acaaggcggc cgaccttcag cgcgaagtcg agcgcgacgg 4561 gggccggttc aggttcgtcg ggcatttcag cgaagcgccg ggcacgtcgg cgttcgggac 4621 ggcggagcgc ccggagttcg aacgcatcct gaacgaatgc cgcgccgggc ggctcaacat 4681 gatcattgtc tatgacgtgt cgcgcttctc gcgcctgaag gtcatggacg cgattccgat 4741 tgtctcggaa ttgctcgccc tgggcgtgac gattgtttcc actcaggaag gcgtcttccg 4801 gcagggaaac gtcatggacc tgattcacct gattatgcgg ctcgacgcgt cgcacaaaga 4861 atcttcgctg aagtcggcga agattctcga cacgaagaac cttcagcgcg aattgggcgg 4921 gtacgtcggc gggaaggcgc cttacggctt cgagcttgtt tcggagacga aggagatcac 4981 gcgcaacggc cgaatggtca atgtcgtcat caacaagctt gcgcactcga ccactcccct 5041 taccggaccc ttcgagttcg agcccgacgt aatccggtgg tggtggcgtg agatcaagac 5101 gcacaaacac cttcccttca agccgggcag tcaagccgcc attcacccgg gcagcatcac 5161 ggggctttgt aagcgcatgg acgctgacgc cgtgccgacc cggggcgaga cgattgggaa 5221 gaagaccgct tcaagcgcct gggacccggc aaccgttatg cgaatccttc gggacccgcg 5281 tattgcgggc ttcgccgctg aggtgatcta caagaagaag ccggacggca cgccgaccac 5341 gaagattgag ggttaccgca ttcagcgcga cccgatcacg ctccggccgg tcgagcttga 5401 ttgcggaccg atcatcgagc ccgctgagtg gtatgagctt caggcgtggt tggacggcag 5461 ggggcgcggc aaggggcttt cccgggggca agccattctg tccgccatgg acaagctgta 5521 ctgcgagtgt ggcgccgtca tgacttcgaa gcgcggggaa gaatcgatca aggactctta 5581 ccgctgccgt cgccggaagg tggtcgaccc gtccgcacct gggcagcacg aaggcacgtg 5641 caacgtcagc atggcggcac tcgacaagtt cgttgcggaa cgcatcttca acaagatcag 5701 gcacgccgaa ggcgacgaag agacgttggc gcttctgtgg gaagccgccc gacgcttcgg 5761 caagctcact gaggcgcctg agaagagcgg cgaacgggcg aaccttgttg cggagcgcgc 5821 cgacgccctg aacgcccttg aagagctgta cgaagaccgc gcggcaggcg cgtacgacgg 5881 acccgttggc aggaagcact tccggaagca acaggcagcg ctgacgctcc ggcagcaagg 5941 ggcggaagag cggcttgccg aacttgaagc cgccgaagcc ccgaagcttc cccttgacca 6001 atggttcccc gaagacgccg acgctgaccc gaccggccct aagtcgtggt gggggcgcgc 6061 gtcagtagac gacaagcgcg tgttcgtcgg gctcttcgta gacaagatcg ttgtcacgaa 6121 gtcgactacg ggcagggggc agggaacgcc catcgagaag cgcgcttcga tcacgtgggc 6181 gaagccgccg accgacgacg acgaagacga cgcccaggac ggcacggaag acgtagcggc 6241 gtagcgagac acccgggaag cctg 

What is claimed is:
 1. A method for preparing a piperazic acid (Piz)-containing product comprising: (i) providing N⁵—OH-Ornithine or derivative thereof; (ii) providing a suitable enzyme comprising a N⁵—OH Ornithine cyclase/dehydratase; and (iii) optionally, buffer salts, a NADPH cofactor, Fe⁺² salts, and a catalytic Flavin Adenine Dinucleotide (FAD) cofactor.
 2. The method of claim 1 further comprising: (i) providing an ornithine or a derivative thereof; and (ii) providing a suitable enzyme comprising an ornithine N⁵ hydroxylase.
 3. The method of claim 1, wherein (i) the N⁵—OH-Ornithine or derivative thereof is an enantiopure L-Ornithine or derivative thereof; (ii) the enzyme comprising N⁵—OH Ornithine cyclase/dehydratase is a L-N⁵—OH Ornithine cyclase/dehydratase or a PzbB enzyme; or (iii) the enzyme comprising ornithine N⁵ hydroxylase is an L-ornithine N⁵—OHase or a PzbA enzyme.
 4. The method of claim 1, wherein the method is carried out in the absence of O₂, substantially no O₂, or in the presence of low O₂.
 5. The method of claim 2 wherein the method comprises a coupled enzyme assay.
 6. The method of claim 1, wherein the piperazic acid (Piz)-containing product comprises a compound of formula:

wherein: R⁵ is a hydrogen, an alkyl, a piperazic acid, an acetyl, or a carboxyl protecting group; each R¹ and R² are independently selected from hydrogen or an amino protecting group, wherein R¹ and R² may be taken together to form a fused bicyclic or tricyclic amino protecting group; and each R³ and R⁴ are independently selected from a hydrogen, a halo (optionally, a chloro, a fluoro, a bromo, or a iodo), or a hydroxyl.
 7. The method of claim 1, wherein R¹ and R² are not simultaneously hydrogen.
 8. The method of claim 1, wherein the piperazic acid (Piz)-containing product is used as a starting material in a synthetic method of making a bioactive Piz-containing composition selected from the group consisting of: (i) an antibacterial agent, an antibiotic agent, an antitumor agent, an antiviral agent, an immunomodulatory agent, or an anti-inflammatory agent; (ii) a molecular probe, anticancer drug, or drug lead; (iii) a metalloprotease inhibitor, a caspase inhibitor, an angiotensin converting enzyme (ACE) inhibitor, an inflammatory peptide C5a antagonist, an oxytocin receptor antagonist, or a matylastin type-IV collagenase inhibitor; (iv) a dehydropiperazic acid; a chloropiperazic acid; a hydroxypiperazic acid; a monamycin, an aurantimycin, an antrimycin, an azinothricin, a luzopeptin, a kettapeptin, a quinoxapeptin, a lydiamycin, a piperazimycin, or a sangamide; or (v) sanglifehrin A, pandanamide A, azinothricin, Sch392583, luzopeptin A, kutzernide 2, piperazic acid, L-piperazic acid, antrimycin, kettapeptin, GE3, A83586C, chloptosin, himastatin, luzopeptin, quinoxapeptin, lydiamycin, piperazimycin, sanglifehrin, sangamide NVP018, sangamide NVP019, sanglifehrin, Sch 382583; chloptosin, himastatin, verucopeptin, luzopeptin A, L-156,602, aurantimycin A, or L-156,373.
 9. A transgenic microorganism comprising an artificial DNA construct comprising, as operably associated components in the 5′ to 3′ direction of transcription: (I) (a) a promoter functional in the microorganism; (b) (i) a first polynucleotide comprising a nucleotide sequence encoding a first polypeptide having a L-Ornithine N⁵ hydroxylase activity; (ii) a second polynucleotide comprising a nucleotide sequence encoding a second polypeptide having a L-Ornithine N⁵ cyclase activity or L-Ornithine N⁵ dehydratase activity; or (iii) a third polynucleotide comprising a nucleotide sequence encoding a third polypeptide having a L-Ornithine N⁵ hydroxylase activity and a L-Ornithine N⁵ cyclase activity or L-Ornithine N⁵ dehydratase activity; and (c) a transcriptional termination sequence; or (II) (a) a promoter functional in the microorganism; (b) (i) a first polynucleotide comprising a nucleotide sequence encoding a first polypeptide having PzbA activity; (ii) a second polynucleotide comprising a nucleotide sequence encoding a second polypeptide having PzbB activity; or (iii) a third polynucleotide comprising a nucleotide sequence encoding a first polypeptide having PzbA activity and PzbB activity; and (c) a transcriptional termination sequence; wherein, the transgenic microorganism accumulates increased levels of a piperazic acid (Piz)-containing product, optionally L-Piz, compared to a microorganism not comprising the DNA construct.
 10. The transgenic microorganism of claim 9, wherein the microorganism comprises: (a) (i) a nucleotide sequence encoding a polypeptide selected from SEQ ID NO: 1-SEQ ID NO: 81 or SEQ ID NO: 167-SEQ ID NO: 176 or a sequence at least 25% identical thereto having L-Ornithine N⁵ hydroxylase activity; and (ii) a nucleotide sequence encoding a polypeptide selected from SEQ ID NO: 82-SEQ ID NO: 166 or SEQ ID NO: 167-SEQ ID NO: 176 or a sequence at least 25% identical thereto having L-Ornithine N⁵ cyclase activity and L-Ornithine N⁵ dehydratase activity; or (b) a nucleotide sequence encoding a polypeptide selected from SEQ ID NO: 167-SEQ ID NO: 176 or a sequence at least 25% identical thereto having L-Ornithine N⁵ hydroxylase activity, L-Ornithine N⁵ cyclase activity, and L-Ornithine N⁵ dehydratase activity.
 11. The transgenic microorganism of claim 9 comprising: (i) a PzbA ortholog with at least about 25% identity to SEQ ID NO: 1-SEQ ID NO: 81 or SEQ ID NO: 167-SEQ ID NO: 176 and has PzbA activity to produce a piperazic acid (Piz)-containing product; (ii) a PzbB ortholog with at least about 25% identity to SEQ ID NO: 82-SEQ ID NO: 166 or SEQ ID NO: 167-SEQ ID NO: 176 and has PzbB activity to produce a piperazic acid (Piz)-containing product; or (iii) a PzbAB ortholog with at least about 25% identity to or SEQ ID NO: 167-SEQ ID NO: 176 and has PzbA and PzbB activity to produce a piperazic acid (Piz)-containing product.
 12. The transgenic microorganism of claim 9, wherein the microorganism is an Actinobacteria selected from the group consisting of Streptomyces, Corynebacterium, Kutzneria, and Actinomadura; is a heterologous population of microorganisms; is an Actinobacteria (optionally, an actinomycete); or is selected from the group consisting of Streptomyces lividans or Corynebacterium glutamicum, optionally carrying one or more copies of a native or non-native pzbA and optionally carrying one or more copies of pzbB.
 13. The transgenic microorganism of claim 9, wherein the transgenic microorganism overproduces L-Ornithine; the pzbA or the pzbB are cloned from a sanglifehrin biosynthetic locus of Streptomyces flaveolus; or a piperazic acid (Piz)-containing product accumulates within the microorganism.
 14. A method for producing a piperazic acid (Piz)-containing product comprising: (i) providing a transgenic microorganism capable of accumulating a piperazic acid (Piz)-containing product; (ii) cultivating the microorganism; and (iii) isolating accumulated piperazic acid (Piz)-containing product.
 15. The method of claim 14, comprising: providing a transgenic microorganism and providing a feedstock, wherein the transgenic microorganism comprises at least one copy of pzbA and at least one copy of pzbB under a constitutive promoter; and the at least one pzbA is optionally a native copy.
 16. The method of claim 14, wherein the transgenic microorganism is (i) a heterologous population of microorganisms; (ii) an Actinobacteria (optionally, an actinomycete); or (ii) selected from the group consisting of Streptomyces lividans or Corynebacterium glutamicum, optionally carrying one or more copies of a native or non-native pzbA and optionally carrying one or more copies of pzbB.
 17. The method of claim 14, wherein pzbA or pzbB are cloned from a sanglifehrin biosynthetic locus of Streptomyces flaveolus; or a piperazic acid (Piz)-containing product accumulates within the microorganism.
 18. The method of claim 14, wherein the method is carried out in the absence of O₂, substantially no O₂, or in the presence of low O₂.
 19. The method of claim 14, wherein the piperazic acid (Piz)-containing product comprises a compound of formula:

wherein: R⁵ is a hydrogen, an alkyl, a piperazic acid, an acetyl, or a carboxyl protecting group; each R¹ and R² are independently selected from hydrogen or an amino protecting group, wherein R¹ and R² may be taken together to form a fused bicyclic or tricyclic amino protecting group; and each R³ and R⁴ are independently selected from a hydrogen, a halo (optionally, a chloro, a fluoro, a bromo, or a iodo), or hydroxyl.
 20. The method of claim 14, wherein R¹ and R² are not simultaneously hydrogen. 